Involvement	O
of	O
the	O
endocannabinoid	O
system	O
in	O
the	O
physiological	O
response	O
to	O
transient	O
common	O
carotid	O
artery	O
occlusion	O
and	O
reperfusion	O
.	O

The	O
transient	O
global	O
cerebral	O
hypoperfusion	O
/	O
reperfusion	O
achieved	O
by	O
induction	O
of	O
Bilateral	O
Common	O
Carotid	O
Artery	O
Occlusion	O
followed	O
by	O
Reperfusion	O
(	O
BCCAO	O
/	O
R	O
)	O
may	O
trigger	O
a	O
physiological	O
response	O
in	O
an	O
attempt	O
to	O
preserve	O
tissue	O
and	O
function	O
integrity	O
.	O

There	O
are	O
several	O
candidate	O
molecules	O
among	O
which	O
the	O
endocannabinoid	O
system	O
(	O
ECS	O
)	O
and/or	O
peroxisome-proliferator	O
activated	O
receptor-alpha	O
(	O
PPAR-alpha	O
)	O
may	O
play	O
a	O
role	O
in	O
modulating	O
oxidative	O
stress	O
and	O
inflammation	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
are	O
to	O
evaluate	O
whether	O
the	O
ECS	O
,	O
the	O
enzyme	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
and	O
PPAR-alpha	O
are	O
involved	O
during	O
BCCAO	O
/	O
R	O
in	O
rat	O
brain	O
,	O
and	O
to	O
identify	O
possible	O
markers	O
of	O
the	O
ongoing	O
BCCAO	O
/	O
R	O
-	O
induced	O
challenge	O
in	O
plasma	O
.	O

Adult	O
Wistar	O
rats	O
underwent	O
BCCAO	O
/	O
R	O
with	O
30	O
min	O
hypoperfusion	O
followed	O
by	O
60	O
min	O
reperfusion	O
.	O

The	O
frontal	O
and	O
temporal	O
-	O
occipital	O
cortices	O
and	O
plasma	O
were	O
analyzed	O
by	O
high	O
performance	O
liquid	O
chromatography-mass	O
spectrometry	O
(	O
HPLC-MS	O
)	O
to	O
determine	O
concentrations	O
of	O
endocannabinoids	O
(	O
eCBs	O
)	O
and	O
related	O
molecules	O
behaving	O
as	O
ligands	O
of	O
PPAR-alpha	O
,	O
and	O
of	O
oxidative-stress	O
markers	O
such	O
as	O
lipoperoxides	O
,	O
while	O
Western	O
Blot	O
and	O
immunohistochemistry	B-P
were	O
used	O
to	O
study	O
protein	O
expression	O
of	O
cannabinoid	O
receptors	O
,	O
COX-2	O
and	O
PPAR-alpha	O
.	O

Unpaired	O
Student	O
's	O
t-test	O
was	O
used	O
to	O
evaluate	O
statistical	O
differences	O
between	O
groups	O
.	O

The	O
acute	O
BCCAO	O
/	O
R	O
procedure	O
is	O
followed	O
by	O
increased	O
brain	O
tissue	O
levels	O
of	O
the	O
eCBs	O
2-arachidonoylglycerol	O
and	O
anandamide	O
,	O
palmitoylethanolamide	O
,	O
an	O
avid	O
ligand	O
of	O
PPAR-alpha	O
,	O
lipoperoxides	O
,	O
type	O
1	O
(	O
CB1	O
)	O
and	O
type	O
2	O
(	O
CB2	O
)	O
cannabinoid	O
receptors	O
,	O
and	O
COX-2	O
,	O
and	O
decreased	O
brain	O
tissue	O
concentrations	O
of	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
,	O
one	O
of	O
the	O
major	O
targets	O
of	O
lipid	O
peroxidation	O
.	O

In	O
plasma	O
,	O
increased	O
levels	O
of	O
anandamide	O
and	O
lipoperoxides	O
were	O
observed	O
.	O

The	O
BCCAO	O
/	O
R	O
stimulated	O
early	O
molecular	O
changes	O
that	O
can	O
be	O
easily	O
traced	O
in	O
brain	O
tissue	O
and	O
plasma	O
,	O
and	O
that	O
are	O
indicative	O
of	O
the	O
tissue	O
physiological	O
response	O
to	O
the	O
reperfusion	O
-	O
induced	O
oxidative	O
stress	O
and	O
inflammation	O
.	O

The	O
observed	O
variations	O
suggest	O
that	O
the	O
positive	O
modulation	O
of	O
the	O
ECS	O
and	O
the	O
increase	O
of	O
proinflammatory	O
substances	O
are	O
directly	O
correlated	O
events	O
.	O

Increase	O
of	O
plasmatic	O
levels	O
of	O
anandamide	O
and	O
lipoperoxides	O
further	O
suggests	O
that	O
dysregulation	O
of	O
these	O
molecules	O
may	O
be	O
taken	O
as	O
an	O
indicator	O
of	O
an	O
ongoing	O
hypoperfusion	O
/	O
reperfusion	O
challenge	O
.	O

Multifunctional	O
theranostic	O
Pluronic	O
mixed	O
micelles	O
improve	O
targeted	O
photoactivity	O
of	O
Verteporfin	O
in	O
cancer	O
cells	O
.	O

Nanotechnology	O
development	O
provides	O
new	O
strategies	O
to	O
treat	O
cancer	O
by	O
integration	O
of	O
different	O
treatment	O
modalities	O
in	O
a	O
single	O
multifunctional	O
nanoparticle	O
.	O

In	O
this	O
scenario	O
,	O
we	O
applied	O
the	O
multifunctional	O
Pluronic	O
P123	O
/	O
F127	O
mixed	O
micelles	O
for	O
Verteporfin	O
-mediated	O
photodynamic	O
therapy	O
in	O
PC3	O
and	O
MCF-7	O
cancer	O
cells	O
.	O

Micelles	O
functionalization	O
aimed	O
the	O
targeted	O
delivery	O
by	O
the	O
insertion	O
of	O
biotin	O
moiety	O
on	O
micelle	O
surface	O
and	O
fluorescence	B-P
image	I-P
-based	O
through	O
rhodamine-B	O
dye	O
conjugation	O
in	O
the	O
polymer	O
chains	O
.	O

Multifunctional	O
Pluronics	O
formed	O
spherical	O
nanoparticulated	O
micelles	O
that	O
efficiently	O
encapsulated	O
the	O
photosensitizer	O
Verteporfin	O
maintaining	O
its	O
favorable	O
photophysical	O
properties	O
.	O

Lyophilized	O
formulations	O
were	O
stable	O
at	O
least	O
for	O
6	O
months	O
and	O
readily	O
reconstituted	O
in	O
aqueous	O
media	O
.	O

The	O
multifunctional	O
micelles	O
were	O
stable	O
in	O
protein	O
-rich	O
media	O
due	O
to	O
the	O
dual	O
Pluronic	O
mixed	O
micelles	O
characteristic	O
:	O
high	O
drug	O
loading	O
capacity	O
provided	O
by	O
its	O
micellar	O
core	O
and	O
high	O
kinetic	O
stability	O
due	O
its	O
biocompatible	O
shell	O
.	O

Biotin	O
surface	O
functionalized	O
micelles	O
showed	O
higher	O
internalization	O
rates	O
due	O
biotin	O
-mediated	O
endocytosis	O
,	O
as	O
demonstrated	O
by	O
competitive	O
cellular	O
uptake	O
studies	O
.	O

Rhodamine	O
B	O
-tagged	O
micelles	O
allowed	O
monitoring	O
cellular	O
uptake	O
and	O
intracellular	O
distribution	O
of	O
the	O
formulations	O
.	O

Confocal	O
microscopy	O
studies	O
demonstrated	O
a	O
larger	O
intracellular	O
distribution	O
of	O
the	O
formulation	O
and	O
photosensitizer	O
,	O
which	O
could	O
drive	O
Verteporfin	O
to	O
act	O
on	O
multiple	O
cell	O
sites	O
.	O

Formulations	O
were	O
not	O
toxic	O
in	O
the	O
dark	O
condition	O
,	O
but	O
showed	O
high	O
Verteporfin	O
-induced	O
phototoxicity	O
against	O
both	O
cancer	O
cell	O
lines	O
at	O
low	O
drug	O
and	O
light	O
doses	O
.	O

These	O
results	O
point	O
Verteporfin	O
-loaded	O
multifunctional	O
micelles	O
as	O
a	O
promising	O
tool	O
to	O
further	O
developments	O
in	O
photodynamic	O
therapy	O
of	O
cancer	O
.	O

Stressful	O
life	O
events	O
and	O
leucocyte	O
telomere	O
length	O
:	O
Do	O
lifestyle	O
factors	O
,	O
somatic	O
and	O
mental	O
health	O
,	O
or	O
low	O
grade	O
inflammation	O
mediate	O
this	O
relationship	O
?	O

Results	O
from	O
a	O
cohort	O
of	O
Danish	O
men	O
born	O
in	O
1953	O
.	O

Exposure	O
to	O
psychosocial	O
stress	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
a	O
number	O
of	O
somatic	O
and	O
mental	O
disorders	O
with	O
relation	O
to	O
immune	O
system	O
functioning	O
.	O

We	O
aimed	O
to	O
explore	O
whether	O
stressful	O
events	O
in	O
early	O
and	O
recent	O
life	O
was	O
associated	O
with	O
leucocyte	O
telomere	O
length	O
(	O
TL	O
)	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	O
burden	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
occurring	O
during	O
the	O
life	O
course	O
.	O

We	O
specifically	O
aimed	O
to	O
address	O
whether	O
childhood	O
constitutes	O
a	O
sensitive	O
period	O
and	O
how	O
much	O
of	O
the	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	O
is	O
mediated	O
through	O
somatic	O
and	O
mental	O
health	O
,	O
lifestyle	O
,	O
and	O
markers	O
of	O
low-grade	O
inflammation	O
.	O

A	O
cohort	O
of	O
Danish	O
men	O
born	O
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	O
in	O
the	O
Metropolit	O
Cohort	O
.	O

These	O
men	O
underwent	O
a	O
health	O
examination	O
including	O
blood	B-P
sampling	I-P
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	O
PCR-based	O
measurement	O
of	O
TL	O
.	O

The	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	O
was	O
analysed	O
using	O
structural	O
equation	O
modelling	O
,	O
which	O
also	O
provided	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
the	O
total	O
effect	O
mediated	O
by	O
somatic	O
and	O
mental	O
health	O
(	O
cardiovascular	O
disease	O
,	O
body	O
mass	O
and	O
depressive	O
mood	O
)	O
,	O
lifestyle	O
factors	O
,	O
and	O
low	O
grade	O
inflammation	O
(	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
interleukin	O
(	O
IL	O
)	O
-6	O
and	O
IL-10	O
)	O
.	O

Total	O
number	O
of	O
stressful	O
events	O
experienced	O
during	O
the	O
life	O
course	O
was	O
not	O
associated	O
with	O
TL	O
.	O

In	O
terms	O
of	O
sensitive	O
periods	O
,	O
we	O
found	O
that	O
number	O
of	O
stressful	O
events	O
in	O
childhood	O
was	O
associated	O
with	O
shorter	O
TL	O
(	O
βper	O
number	O
stressful	O
events	O
in	O
childhood	O
=-0.02	O
(	O
SE=-0.02	O
)	O
;	O
P=0.05	O
)	O
.	O

This	O
relation	O
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	O
(	O
β=-0.16	O
;	O
P	O
<	O
0.000	O
)	O
.	O

Thirty	O
percent	O
of	O
the	O
total	O
effect	O
of	O
stressful	O
events	O
in	O
childhood	O
on	O
TL	O
was	O
mediated	O
by	O
the	O
included	O
variables	O
,	O
with	O
the	O
largest	O
proportion	O
being	O
mediated	O
through	O
depressive	O
mood	O
(	O
16	O
%	O
)	O
and	O
CRP	O
(	O
9	O
%	O
)	O
.	O

This	O
study	O
suggests	O
that	O
stressful	O
events	O
in	O
childhood	O
are	O
associated	O
with	O
shorter	O
TL	O
in	O
middle-aged	O
men	O
and	O
that	O
part	O
of	O
this	O
relation	O
is	O
explained	O
by	O
depressive	O
mood	O
and	O
low	O
grade	O
inflammation	O
.	O

Opportunistic	O
screening	O
for	O
osteoporosis	O
by	O
routine	O
CT	B-P
in	O
Southern	O
Europe	O
.	O

Feasibility	O
evaluation	O
of	O
early	B-P
detection	I-P
of	O
osteoporosis	O
in	O
oncologic	O
patients	O
by	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
on	O
abdominal	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scans	I-P
performed	O
for	O
other	O
clinical	O
indications	O
,	O
by	O
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
as	O
reference	O
.	O

Abdominal	B-P
CT	I-P
images	O
can	O
identify	O
patients	O
with	O
osteoporosis	O
BMD	O
without	O
additional	O
radiation	O
exposure	O
or	O
cost	O
.	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
evaluate	O
the	O
feasibility	O
of	O
early	B-P
detection	I-P
of	O
osteoporosis	O
by	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
on	O
abdominal	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scans	I-P
performed	O
in	O
oncologic	O
patients	O
,	O
comparing	O
calibrated	O
and	O
uncalibrated	O
measurements	O
by	O
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
as	O
reference	O
.	O

We	O
also	O
performed	O
an	O
external	O
validation	O
of	O
a	O
threshold	O
of	O
160	O
Hounsfield	O
units	O
(	O
HU	O
)	O
,	O
proposed	O
as	O
highly	O
sensitive	O
.	O

Cohort	O
comprised	O
CT	B-P
-	O
DXA	B-P
pairs	O
within	O
a	O
6-month	O
period	O
performed	O
for	O
any	O
indication	O
on	O
326	O
consecutive	O
adults	O
,	O
aged	O
62.4	O
±	O
12.38	O
years	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
.	O

CT	B-P
attenuation	O
of	O
trabecular	O
bone	O
in	O
HU	O
was	O
measured	O
at	O
the	O
axial	O
cross	O
sections	O
of	O
L1	O
,	O
L2	O
,	O
L3	O
,	O
and	O
L4	O
vertebrae	O
.	O

Vertebral	O
compression	O
fractures	O
were	O
assessed	O
by	O
sagittal	B-P
reconstruction	I-P
view	O
.	O

Diagnostic	O
performance	O
measures	O
and	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
)	O
for	O
diagnosing	O
osteoporosis	O
were	O
calculated	O
.	O

BMD	O
values	O
were	O
statistical	O
significantly	O
lower	O
at	O
any	O
vertebral	O
level	O
from	O
L1	O
to	O
L4	O
for	O
patients	O
with	O
osteoporosis	O
defined	O
by	O
DXA	B-P
(	O
p	O
<	O
0.001	O
)	O
.	O

Calibrated	O
and	O
uncalibrated	O
BMD	O
values	O
were	O
significantly	O
correlated	O
(	O
R	O
(	O
2	O
)	O
=	O
0.833	O
,	O
p	O
<	O
0.01	O
)	O
.	O

An	O
uncalibrated	O
L1	O
CT	B-P
attenuation	O
threshold	O
of	O
160	O
HU	O
was	O
more	O
than	O
90	O
%	O
sensitive	O
,	O
and	O
a	O
threshold	O
of	O
73	O
HU	O
was	O
more	O
than	O
90	O
%	O
specific	O
for	O
distinguishing	O
osteoporosis	O
BMD	O
.	O

Fifty-nine	O
percent	O
of	O
patients	O
with	O
vertebral	O
compression	O
fracture	O
had	O
non	O
-	O
osteoporotic	O
DXA	O
T-scores	O
.	O

Abdominal	B-P
CT	I-P
images	O
obtained	O
for	O
other	O
reasons	O
can	O
identify	O
patients	O
with	O
osteoporosis	O
BMD	O
without	O
additional	O
radiation	O
exposure	O
or	O
cost	O
.	O

Uncalibrated	O
values	O
at	O
L1	O
can	O
detect	O
more	O
osteoporosis	O
patients	O
with	O
spinal	O
compression	O
fractures	O
than	O
DXA	B-P
in	O
oncologic	O
patients	O
.	O

Study	O
of	O
the	O
Microfocus	O
X-Ray	O
Tube	O
Based	O
on	O
a	O
Point-Like	O
Target	O
Used	O
for	O
Micro-Computed	B-P
Tomography	I-P
.	O

For	O
a	O
micro-Computed	B-P
Tomography	I-P
(	I-P
Micro-CT	I-P
)	I-P
system	I-P
,	O
the	O
microfocus	O
X-ray	O
tube	O
is	O
an	O
essential	O
component	O
because	O
the	O
spatial	O
resolution	O
of	O
CT	B-P
images	O
,	O
in	O
theory	O
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	O
and	O
stability	O
of	O
the	O
X-ray	B-P
focal	O
spot	O
of	O
the	O
microfocus	O
X-ray	O
tube	O
.	O

However	O
,	O
many	O
factors	O
,	O
including	O
voltage	O
fluctuations	O
,	O
mechanical	O
vibrations	O
,	O
and	O
temperature	O
changes	O
,	O
can	O
cause	O
the	O
size	O
and	O
the	O
stability	O
of	O
the	O
X-ray	B-P
focal	O
spot	O
to	O
degrade	O
.	O

A	O
new	O
microfocus	O
X-ray	O
tube	O
based	O
on	O
a	O
point-like	O
micro-target	O
in	O
which	O
the	O
X-ray	B-P
target	O
is	O
irradiated	O
with	O
an	O
unfocused	O
electron	O
beam	O
was	O
investigated	O
.	O

EGS4	O
Monte	O
Carlo	O
simulation	O
code	O
was	O
employed	O
for	O
the	O
calculation	O
of	O
the	O
X-ray	B-P
intensity	O
produced	O
from	O
the	O
point-like	O
micro-target	O
and	O
the	O
substrate	O
.	O

The	O
effects	O
of	O
several	O
arrangements	O
of	O
the	O
target	O
material	O
,	O
target	O
and	O
beam	O
size	O
were	O
studied	O
.	O

The	O
simulation	O
results	O
demonstrated	O
that	O
if	O
the	O
intensity	O
of	O
X-rays	B-P
generated	O
at	O
the	O
point-like	O
target	O
is	O
greater	O
than	O
half	O
of	O
the	O
X-ray	B-P
intensity	O
produced	O
on	O
the	O
substrate	O
,	O
the	O
X-ray	B-P
focal	O
spot	O
is	O
determined	O
in	O
part	O
by	O
the	O
point-like	O
target	O
rather	O
than	O
by	O
the	O
electron	O
beam	O
in	O
the	O
conventional	O
X-ray	O
tube	O
.	O

In	O
theory	O
,	O
since	O
it	O
is	O
able	O
to	O
reduce	O
those	O
unfavorable	O
effects	O
such	O
as	O
the	O
electron	O
beam	O
trajectory	O
swinging	O
and	O
the	O
beam	O
size	O
changing	O
for	O
the	O
microfocus	O
X-ray	O
tube	O
,	O
it	O
could	O
alleviate	O
CT	B-P
image	O
artifacts	O
caused	O
by	O
the	O
X-ray	B-P
focal	O
spot	O
shift	O
and	O
size	O
change	O
.	O

Grade	O
Group	O
Underestimation	O
in	O
Prostate	B-P
Biopsy	I-P
:	O
Predictive	O
Factors	O
and	O
Outcomes	O
in	O
Candidates	O
for	O
Active	O
Surveillance	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	O
for	O
underestimating	O
the	O
prostate	O
cancer	O
(	O
PCa	O
)	O
grade	O
group	O
(	O
GG	O
)	O
from	O
prostate	B-P
biopsies	I-P
in	O
a	O
large	O
monocentric	O
cohort	O
of	O
patients	O
treated	O
by	O
minimally	O
invasive	O
radical	O
prostatectomy	O
(	O
RP	O
)	O
.	O

Using	O
a	O
monocentric	O
prospectively	O
maintained	O
database	O
,	O
we	O
included	O
3062	O
patients	O
who	O
underwent	O
minimally	O
invasive	O
RP	O
between	O
2006	O
and	O
2013	O
.	O

We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	O
associated	O
with	O
a	O
GG	O
upgrade	O
from	O
biopsy	B-P
to	O
RP	O
.	O

Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	O
to	O
predict	O
upgrading	O
for	O
GG1	O
.	O

Biopsy	B-P
GG	O
was	O
upgraded	O
after	O
RP	O
in	O
51.5	O
%	O
of	O
cases	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
RP	O
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	O
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	B-P
and	O
RP	O
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	O
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
PCa	O
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	B-P
digital	I-P
rectal	I-P
examination	I-P
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	O
-specific	O
antigen	O
density	O
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	O
of	O
positive	O
cores	O
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	O
index	O
(	O
P	O
=	O
.037	O
)	O
.	O

A	O
nomogram	O
was	O
generated	O
and	O
validated	O
internally	O
.	O

Biopsy	B-P
grading	O
system	O
is	O
misleading	O
in	O
approximately	O
50	O
%	O
of	O
cases	O
.	O

Upgrading	O
GG	O
from	O
biopsy	B-P
to	O
RP	O
may	O
have	O
consequences	O
on	O
clinical	O
outcomes	O
.	O

A	O
nomogram	O
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
GG1	O
patients	O
at	O
their	O
initial	O
evaluation	O
.	O

Multicenter	B-P
Patch	I-P
Testing	I-P
With	O
Methylchloroisothizoline/Methylisothiazolinone	O
in	O
100	O
and	O
200	O
ppm	O
Within	O
the	O
International	O
Contact	O
Dermatitis	O
Research	O
Group	O
.	O

The	O
preservative	O
methylchloroisothiazolinone/methylisothiazolinone	O
(	O
MCI/MI	O
)	O
is	O
a	O
well-known	O
contact	O
sensitizer	O
.	O

Historically	O
,	O
there	O
have	O
been	O
different	O
opinions	O
on	O
the	O
optimal	O
patch	B-P
test	I-P
concentration	O
of	O
MCI/MI	O
,	O
and	O
both	O
0.01	O
%	O
and	O
0.02	O
%	O
aqueous	O
(	O
aq	O
.	O
)	O

have	O
been	O
proposed	O
.	O

In	O
2011	O
,	O
based	O
on	O
literature	O
reviews	O
,	O
it	O
was	O
recommended	O
that	O
the	O
concentration	O
of	O
0.02	O
%	O
aq	O
.	O

should	O
be	O
used	O
in	O
the	O
international	O
baseline	O
series	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
verify	O
the	O
recommendation	O
from	O
2011	O
by	O
comparing	O
the	O
patch	B-P
test	I-P
results	O
from	O
consecutive	O
patch	B-P
testing	I-P
with	O
MCI/MI	O
0.01	O
%	O
and	O
0.02	O
%	O
in	O
clinics	O
representing	O
countries	O
around	O
the	O
world	O
.	O

Two	O
thousand	O
seven	O
hundred	O
three	O
consecutive	O
patients	O
with	O
dermatitis	O
in	O
8	O
dermatology	O
clinics	O
representing	O
8	O
countries	O
were	O
patch	B-P
tested	I-P
with	O
MCI/MI	O
0.01	O
%	O
aq	O
.	O

and	O
,	O
in	O
parallel	O
with	O
MCI/MI	O
0.02	O
%	O
aq.	O
,	O
provisionally	O
included	O
in	O
the	O
baseline	O
series	O
.	O

Contact	O
allergy	O
to	O
MCI/MI	O
at	O
0.01	O
%	O
and	O
0.02	O
%	O
was	O
found	O
in	O
3.7	O
%	O
and	O
5.6	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Methylchloroisothiazolinone/MI	O
0.02	O
%	O
aq	O
.	O

(	O
dose	O
,	O
6	O
μg/cm	O
)	O
diagnoses	O
significantly	O
more	O
contact	O
allergy	O
than	O
0.01	O
%	O
(	O
dose	O
,	O
3	O
μg/cm	O
)	O
,	O
without	O
resulting	O
in	O
more	O
adverse	O
reactions	O
.	O

Methylchloroisothiazolinone/MI	O
at	O
0.02	O
%	O
aq	O
.	O

should	O
therefore	O
be	O
continuously	O
used	O
in	O
the	O
international	O
baseline	O
series	O
.	O

A	O
Recombinant	O
Human	O
Anti-Platelet	O
scFv	O
Antibody	O
Produced	O
in	O
Pichia	O
pastoris	O
for	O
Atheroma	O
Targeting	O
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	O
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	O
disease	O
,	O
cerebrovascular	O
disease	O
and	O
peripheral	O
arterial	O
disease	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single-chain	O
variable	O
fragment	O
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αIIbβ3	O
antibody	O
(	O
HuAb	O
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

The	O
DNA	O
sequence	O
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	O
scFv	O
previously	O
obtained	O
from	O
a	O
phage-display	O
selection	O
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	O
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	O
.	O

The	O
recombinant	O
protein	O
was	O
expressed	O
at	O
high	O
yields	O
in	O
Pichia	O
pastoris	O
(	O
30	O
mg/L	O
culture	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	O
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	O
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	O
scFv	O
fragments	O
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	B-P
of	O
atherosclerotic	O
plaques	O
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	O
of	O
instability	O
.	O

Dynamic	O
Cross-Entropy	O
.	O

Complexity	O
measures	O
for	O
time	O
series	O
have	O
been	O
used	O
in	O
many	O
applications	O
to	O
quantify	O
the	O
regularity	O
of	O
one	O
dimensional	O
time	O
series	O
,	O
however	O
many	O
dynamical	O
systems	O
are	O
spatially	O
distributed	O
multidimensional	O
systems	O
.	O

We	O
introduced	O
Dynamic	O
Cross-Entropy	O
(	O
DCE	O
)	O
a	O
novel	O
multidimensional	O
complexity	O
measure	O
that	O
quantifies	O
the	O
degree	O
of	O
regularity	O
of	O
EEG	B-P
signals	O
in	O
selected	O
frequency	O
bands	O
.	O

Time	O
series	O
generated	O
by	O
discrete	O
logistic	O
equations	O
with	O
varying	O
control	O
parameter	O
r	O
are	O
used	O
to	O
test	O
DCE	O
measures	O
.	O

Sliding	O
window	O
DCE	O
analyses	O
are	O
able	O
to	O
reveal	O
specific	O
period	O
doubling	O
bifurcations	O
that	O
lead	O
to	O
chaos	O
.	O

A	O
similar	O
behavior	O
can	O
be	O
observed	O
in	O
seizures	O
triggered	O
by	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Sample	O
entropy	O
data	O
show	O
the	O
level	O
of	O
signal	O
complexity	O
in	O
different	O
phases	O
of	O
the	O
ictal	O
ECT	O
.	O

The	O
transition	O
to	O
irregular	O
activity	O
is	O
preceded	O
by	O
the	O
occurrence	O
of	O
cyclic	O
regular	O
behavior	O
.	O

A	O
significant	O
increase	O
of	O
DCE	O
values	O
in	O
successive	O
order	O
from	O
high	O
frequencies	O
in	O
gamma	O
to	O
low	O
frequencies	O
in	O
delta	O
band	O
reveals	O
several	O
phase	O
transitions	O
into	O
less	O
ordered	O
states	O
,	O
possible	O
chaos	O
in	O
the	O
human	O
brain	O
.	O

To	O
our	O
knowledge	O
there	O
are	O
no	O
reliable	O
techniques	O
able	O
to	O
reveal	O
the	O
transition	O
to	O
chaos	O
in	O
case	O
of	O
multidimensional	O
times	O
series	O
.	O

In	O
addition	O
,	O
DCE	O
based	O
on	O
sample	O
entropy	O
appears	O
to	O
be	O
robust	O
to	O
EEG	O
artifacts	O
compared	O
to	O
DCE	O
based	O
on	O
Shannon	O
entropy	O
.	O

The	O
applied	O
technique	O
may	O
offer	O
new	O
approaches	O
to	O
better	O
understand	O
nonlinear	O
brain	O
activity	O
.	O

Variation	O
in	O
the	O
Intensity	O
of	O
Selection	O
on	O
Codon	O
Bias	O
over	O
Time	O
Causes	O
Contrasting	O
Patterns	O
of	O
Base	O
Composition	O
Evolution	O
in	O
Drosophila	O
.	O

Four-fold	O
degenerate	O
coding	O
sites	O
form	O
a	O
major	O
component	O
of	O
the	O
genome	O
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	O
and	O
demography	O
,	O
so	O
that	O
understanding	O
their	O
evolution	O
is	O
important	O
.	O

Despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	O
composition	O
changes	O
at	O
these	O
sites	O
in	O
Drosophila	O
remain	O
unanswered	O
.	O

To	O
shed	O
further	O
light	O
on	O
this	O
issue	O
,	O
we	O
obtained	O
a	O
new	O
whole-genome	O
polymorphism	O
data	O
set	O
from	O
D.	O
simulans	O
.	O

We	O
analyzed	O
samples	O
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
D.	O
simulans	O
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	O
data	O
set	O
from	O
an	O
African	O
population	O
of	O
D.	O
melanogaster	O
.	O

By	O
using	O
D.	O
yakuba	O
as	O
an	O
outgroup	O
,	O
we	O
found	O
clear	O
evidence	O
for	O
selection	O
on	O
4-fold	O
sites	O
along	O
both	O
lineages	O
over	O
a	O
substantial	O
period	O
,	O
with	O
the	O
intensity	O
of	O
selection	O
increasing	O
with	O
GC	O
content	O
.	O

Based	O
on	O
an	O
explicit	O
model	O
of	O
base	O
composition	O
evolution	O
,	O
we	O
suggest	O
that	O
the	O
observed	O
AT-	O
biased	O
substitution	O
pattern	O
in	O
both	O
lineages	O
is	O
probably	O
due	O
to	O
an	O
ancestral	O
reduction	O
in	O
selection	O
intensity	O
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	O
of	O
an	O
increase	O
in	O
mutational	O
bias	O
towards	O
AT	O
alone	O
.	O

By	O
using	O
two	O
polymorphism-based	B-P
methods	I-P
for	O
estimating	O
selection	O
coefficients	O
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	O
intensity	O
on	O
codon	O
usage	O
has	O
been	O
rather	O
stable	O
in	O
D.	O
simulans	O
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long-term	O
estimates	O
in	O
D.	O
melanogaster	O
are	O
much	O
higher	O
than	O
the	O
short-term	O
ones	O
,	O
indicating	O
a	O
continuing	O
decline	O
in	O
selection	O
intensity	O
,	O
to	O
such	O
an	O
extent	O
that	O
the	O
short-term	O
estimates	O
suggest	O
that	O
selection	O
is	O
only	O
active	O
in	O
the	O
most	O
GC	O
-rich	O
parts	O
of	O
the	O
genome	O
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
for	O
complex	O
evolutionary	O
patterns	O
in	O
the	O
putatively	O
neutral	O
short	O
introns	O
,	O
which	O
can	O
not	O
be	O
explained	O
by	O
the	O
standard	O
GC	O
-	O
biased	O
gene	O
conversion	O
model	O
.	O

These	O
results	O
reveal	O
a	O
dynamic	O
picture	O
of	O
base	O
composition	O
evolution	O
.	O

Oral	O
health-related	O
quality	O
of	O
life	O
in	O
the	O
elderly	O
population	O
receiving	O
health	O
care	O
at	O
the	O
public	O
hospital	O
network	O
in	O
Medellín	O
,	O
Colombia	O
,	O
and	O
its	O
related	O
factors	O
.	O

Metrosalud	O
is	O
the	O
largest	O
public	O
hospital	O
network	O
in	O
the	O
city	O
of	O
Medellin	O
and	O
one	O
of	O
the	O
most	O
important	O
in	O
Colombia	O
providing	O
health	O
care	O
to	O
the	O
most	O
vulnerable	O
population	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
Oral	O
HealthRelated	O
Quality	O
of	O
Life	O
(	O
OHRQoL	O
)	O
and	O
its	O
related	O
factors	O
in	O
the	O
elderly	O
population	O
receiving	O
health	O
care	O
at	O
the	O
public	O
hospital	O
network	O
in	O
Medellin	O
(	O
Colombia	O
)	O
.	O

A	O
crosssectional	O
design	O
was	O
used	O
.	O

Men	O
and	O
women	O
≥	O
65	O
years	O
old	O
were	O
considered	O
for	O
this	O
research	O
,	O
selected	O
from	O
first	O
consultation	O
records	O
by	O
the	O
institution	O
's	O
statistical	O
unit	O
for	O
2011	O
,	O
who	O
accepted	O
to	O
participate	O
after	O
being	O
contacted	O
by	O
telephone	O
.	O

Sampling	O
was	O
performed	O
in	O
two	O
stages	O
:	O
simple	O
random	O
sampling	O
for	O
selecting	O
Hospital	O
Units	O
HU	O
and	O
Health	O
Centers	O
HC	O
throughout	O
the	O
hospital	O
network	O
in	O
the	O
city	O
,	O
followed	O
by	O
random	O
quota	O
sampling	O
in	O
proportion	O
to	O
the	O
number	O
of	O
elderly	O
population	O
assigned	O
to	O
each	O
HU	O
and	O
HC	O
.	O

A	O
total	O
342	O
patients	O
(	O
58.2	O
%	O
women	O
)	O
participated	O
in	O
the	O
study	O
.	O

The	O
project	O
involved	O
the	O
use	O
of	O
a	O
structured	O
questionnaire	O
and	O
complete	O
dental	O
examination	O
with	O
information	O
on	O
sociodemographic	O
data	O
,	O
selfperceived	O
health	O
variables	O
(	O
mental	O
,	O
general	O
and	O
oral	O
)	O
,	O
use	O
of	O
oral	O
health	O
services	O
,	O
Oral	O
HealthRelated	O
Quality	O
of	O
Life	O
(	O
OHRQoL	O
as	O
measured	O
with	O
GOHAI	O
index	O
)	O
,	O
temporomandibular	O
joint	O
test	O
,	O
oral	O
mucosa	O
,	O
soft	O
tissue	O
evaluation	O
,	O
periodontal	O
,	O
dental	B-P
and	O
prosthetic	O
examination	O
.	O

Descriptive	O
and	O
bivariate	O
analyses	O
were	O
conducted	O
to	O
determine	O
statistically	O
significant	O
differences	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
,	O
using	O
logistic	O
regression	O
,	O
calculating	O
crude	O
and	O
adjusted	O
odds	O
ratios	O
(	O
OR	O
)	O
with	O
their	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

Impacts	O
were	O
found	O
to	O
be	O
generated	O
by	O
education	O
levels	O
,	O
differences	O
in	O
socioeconomic	O
status	O
and	O
urban	O
or	O
rural	O
housing	O
conditions	O
.	O

The	O
results	O
of	O
this	O
research	O
show	O
low	O
OHRQoL	O
levels	O
in	O
the	O
elderly	O
population	O
receiving	O
health	O
care	O
services	O
at	O
the	O
public	O
hospital	O
network	O
in	O
Medellin	O
.	O

Tissue-engineered	O
cardiac	O
patch	O
seeded	O
with	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
promoted	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
in	O
a	O
rat	O
model	O
.	O

Thousands	O
of	O
babies	O
are	O
born	O
with	O
congenital	O
heart	O
defects	O
that	O
require	O
surgical	O
repair	O
involving	O
a	O
prosthetic	O
implant	O
.	O

Lack	O
of	O
growth	O
in	O
prosthetic	O
grafts	O
is	O
especially	O
detrimental	O
in	O
pediatric	O
surgery	O
.	O

Cell	O
seeded	O
biodegradable	O
tissue	O
engineered	O
grafts	O
are	O
a	O
novel	O
solution	O
to	O
this	O
problem	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
feasibility	O
of	O
seeding	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
(	O
hiPS-CMs	O
)	O
onto	O
a	O
biodegradable	O
cardiac	O
patch	O
.	O

The	O
hiPS-CMs	O
were	O
cultured	O
on	O
a	O
biodegradable	O
patch	O
composed	O
of	O
a	O
polyglycolic	O
acid	O
(	O
PGA	O
)	O
and	O
a	O
50:50	O
poly	O
(	O
l-lactic-co-ε-caprolactone	O
)	O
copolymer	O
(	O
PLCL	O
)	O
for	O
1	O
week	O
.	O

Male	O
athymic	O
rats	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
of	O
10	O
animals	O
each	O
:	O
1.	O
hiPS-CM	O
seeded	O
group	O
,	O
and	O
2	O
.	O

Unseeded	O
group	O
.	O

After	O
culture	O
,	O
the	O
cardiac	O
patch	O
was	O
implanted	O
to	O
repair	O
a	O
defect	O
with	O
a	O
diameter	O
of	O
2	O
mm	O
created	O
in	O
the	O
right	O
ventricular	O
outflow	O
tract	O
(	O
RVOT	O
)	O
wall	O
.	O

Hearts	O
were	O
explanted	O
at	O
4	O
(	O
n	O
=	O
2	O
)	O
,	O
8	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
16	O
(	O
n	O
=	O
6	O
)	O
weeks	O
after	O
patch	O
implantation	O
.	O

Explanted	O
patches	O
were	O
assessed	O
immunohistochemically	B-P
.	O

Seeded	O
patch	O
explants	O
did	O
not	O
stain	O
positive	O
for	O
α-actinin	O
(	O
marker	O
of	O
cardiomyocytes	O
)	O
at	O
the	O
4	O
week	O
time	O
point	O
,	O
suggesting	O
that	O
the	O
cultured	O
hiPS-CMs	O
evacuated	O
the	O
patch	O
in	O
the	O
early	O
phase	O
of	O
tissue	O
remodeling	O
.	O

However	O
,	O
after	O
16	O
weeks	O
implantation	O
,	O
the	O
area	O
fraction	O
of	O
positively	O
stained	O
α-actinin	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
seeded	O
group	O
than	O
in	O
the	O
unseeded	O
group	O
(	O
Seeded	O
group	O
:	O
6.1	O
±	O
2.8	O
%	O
vs.	O
Unseeded	O
group	O
:	O
0.95	O
±	O
0.50	O
%	O
,	O
p	O
=	O
0.004	O
)	O
,	O
suggesting	O
cell	O
seeding	O
promoted	O
regenerative	O
proliferation	O
of	O
host	O
cardiomyocytes	O
.	O

Seeded	O
hiPS-CMs	O
were	O
not	O
present	O
in	O
the	O
patch	O
after	O
4	O
weeks	O
.	O

However	O
,	O
we	O
surmise	O
that	O
they	O
influenced	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
via	O
a	O
paracrine	O
mechanism	O
.	O

Tissue-engineered	O
hiPS-CMs	O
seeded	O
cardiac	O
patches	O
warrant	O
further	O
investigation	O
for	O
use	O
in	O
the	O
repair	O
of	O
congenital	O
heart	O
diseases	O
.	O

Spermatocytic	O
Tumor	O
With	O
Sarcoma	O
:	O
A	O
Rare	O
Testicular	O
Neoplasm	O
.	O

Spermatocytic	O
tumor	O
,	O
formerly	O
known	O
as	O
spermatocytic	O
seminoma	O
,	O
is	O
an	O
uncommon	O
testicular	O
neoplasm	O
which	O
is	O
a	O
distinct	O
clinicopathologic	O
entity	O
from	O
classic	O
seminoma	O
.	O

These	O
tumors	O
are	O
not	O
associated	O
with	O
germ	O
cell	O
neoplasia	O
in	O
situ	O
,	O
other	O
germ	O
cell	O
tumors	O
,	O
or	O
isochromosome	O
12p	O
.	O

Although	O
typically	O
,	O
these	O
tumors	O
have	O
an	O
excellent	O
prognosis	O
occasional	O
cases	O
are	O
associated	O
with	O
sarcoma	O
and	O
have	O
a	O
very	O
poor	O
prognosis	O
.	O

We	O
present	O
a	O
case	O
of	O
spermatocytic	O
tumor	O
with	O
sarcoma	O
showing	O
a	O
chondrosarcomatous	O
component	O
,	O
discuss	O
the	O
pathologic	O
findings	O
and	O
differential	B-P
diagnosis	I-P
and	O
provide	O
follow-up	O
information	O
.	O

Safety	O
of	O
Large	O
-	O
Volume	O
,	O
Same	O
-	O
Day	O
Oral	O
Bowel	O
Preparations	O
During	O
Deep	O
Sedation	O
:	O
A	O
Prospective	O
Observational	O
Study	O
.	O

Colonoscopy	B-P
quality	O
is	O
directly	O
related	O
to	O
the	O
bowel	O
preparation	O
.	O

It	O
is	O
well	O
established	O
that	O
bowel	O
preparations	O
are	O
improved	O
when	O
at	O
least	O
part	O
of	O
the	O
laxative	O
is	O
ingested	O
on	O
the	O
day	O
of	O
the	O
procedure	O
.	O

However	O
,	O
there	O
is	O
concern	O
that	O
this	O
can	O
result	O
in	O
higher	O
gastric	O
residual	O
volumes	O
(	O
GRV	O
)	O
and	O
increase	O
the	O
risk	O
of	O
pulmonary	O
aspiration	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
GRV	O
and	O
gastric	O
pH	O
in	O
patients	O
who	O
received	O
day	O
-	O
before	O
bowel	O
preparation	O
versus	O
those	O
ingesting	O
their	O
laxative	O
on	O
the	O
day	O
of	O
colonoscopy	B-P
under	O
anesthesiologist	O
-	O
directed	O
propofol	O
deep	O
sedation	O
.	O

This	O
is	O
a	O
prospective	O
observational	O
study	O
for	O
patients	O
undergoing	O
same	O
-	O
day	O
upper	O
endoscopy	B-P
and	O
colonoscopy	B-P
.	O

All	O
included	O
patients	O
had	O
large	O
-	O
volume	O
polyethylene	O
glycol	O
lavage	O
preparation	O
and	O
received	O
propofol	O
sedation	O
.	O

Gastric	O
fluid	O
was	O
collected	O
during	O
the	O
upper	O
endoscopy	B-P
for	O
volume	O
and	O
pH	O
measurement	O
.	O

The	O
study	O
included	O
428	O
patients	O
with	O
56	O
%	O
receiving	O
same	O
-	O
day	O
laxative	O
preparation	O
and	O
the	O
remainder	O
evening	O
-	O
before	O
preparation	O
.	O

Mean	O
±	O
SD	O
GRV	O
was	O
18.1	O
±	O
10.2	O
mL	O
,	O
16.3	O
±	O
16.5	O
mL	O
in	O
each	O
of	O
these	O
preparation	O
groups	O
,	O
respectively	O
(	O
P	O
=	O
.69	O
)	O
.	O

GRV	O
≥	O
25	O
mL	O
or	O
higher	O
than	O
expected	O
GRV	O
adjusted	O
by	O
weight	O
(	O
0.4	O
mL/kg	O
)	O
were	O
also	O
not	O
different	O
among	O
the	O
study	O
groups	O
(	O
P	O
=	O
.90	O
and	O
P	O
=	O
.87	O
,	O
respectively	O
)	O
.	O

Evaluating	O
GRV	O
based	O
on	O
time	O
since	O
last	O
ingestion	O
of	O
preparation	O
(	O
3-5	O
,	O
5-7	O
,	O
>	O
7	O
hours	O
)	O
did	O
not	O
result	O
in	O
any	O
differences	O
(	O
P	O
=	O
.56	O
)	O
.	O

Gastric	O
pH	O
was	O
also	O
similar	O
between	O
the	O
bowel	O
preparation	O
groups	O
(	O
P	O
=	O
.23	O
)	O
,	O
with	O
mean	O
±	O
SD	O
of	O
2.5	O
±	O
1.4	O
for	O
evening	O
-	O
before	O
and	O
2.5	O
±	O
1.3	O
for	O
the	O
same	O
-	O
day	O
preparation	O
.	O

There	O
were	O
more	O
inadequate	O
bowel	O
preparations	O
in	O
day	O
before	O
bowel	O
preparations	O
(	O
P	O
=	O
.001	O
)	O
.	O

A	O
large	O
-	O
volume	O
bowel	O
preparation	O
regimen	O
finished	O
on	O
the	O
day	O
of	O
colonoscopy	B-P
as	O
close	O
as	O
3	O
hours	O
before	O
the	O
procedure	O
result	O
s	O
in	O
no	O
increase	O
in	O
GRV	O
or	O
decrease	O
in	O
gastric	O
pH	O
.	O

Metabolic	O
signatures	O
of	O
birthweight	O
in	O
18	O
288	O
adolescents	O
and	O
adults	O
.	O

Lower	O
birthweight	O
is	O
associated	O
with	O
increased	O
susceptibility	O
to	O
cardiometabolic	O
diseases	O
in	O
adulthood	O
,	O
but	O
the	O
underlying	O
molecular	O
pathways	O
are	O
incompletely	O
understood	O
.	O

We	O
examined	O
associations	O
of	O
birthweight	O
with	O
a	O
comprehensive	O
metabolic	O
profile	O
measured	O
in	O
adolescents	O
and	O
adults	O
.	O

High-throughput	B-P
nuclear	O
magnetic	O
resonance	O
metabolomics	O
and	O
biochemical	O
assays	O
were	O
used	O
to	O
quantify	O
87	O
circulating	O
metabolic	O
measures	O
in	O
seven	O
cohorts	O
from	O
Finland	O
and	O
the	O
UK	O
,	O
comprising	O
altogether	O
18	O
288	O
individuals	O
(	O
mean	O
age	O
26	O
years	O
,	O
range	O
15-75	O
)	O
.	O

Metabolic	O
associations	O
with	O
birthweight	O
were	O
assessed	O
by	O
linear	O
regression	O
models	O
adjusted	O
for	O
sex	O
,	O
gestational	O
age	O
and	O
age	O
at	O
blood	B-P
sampling	I-P
.	O

The	O
metabolic	O
associations	O
with	O
birthweight	O
were	O
compared	O
with	O
the	O
corresponding	O
associations	O
with	O
adult	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

Lower	O
birthweight	O
adjusted	O
for	O
gestational	O
age	O
was	O
adversely	O
associated	O
with	O
cardiometabolic	O
biomarkers	O
,	O
including	O
lipoprotein	O
subclasses	O
,	O
fatty	O
acids	O
,	O
amino	O
acids	O
and	O
markers	O
of	O
inflammation	O
and	O
impaired	O
liver	O
function	O
(	O
P	O
<	O
0.0015	O
for	O
46	O
measures	O
)	O
.	O

Associations	O
were	O
consistent	O
across	O
cohorts	O
with	O
different	O
ages	O
at	O
metabolic	O
profiling	O
,	O
but	O
the	O
magnitudes	O
were	O
weak	O
.	O

The	O
pattern	O
of	O
metabolic	O
deviations	O
associated	O
with	O
lower	O
birthweight	O
resembled	O
the	O
metabolic	O
signature	O
of	O
higher	O
adult	O
BMI	O
(	O
R	O
(	O
2	O
)	O
=	O
0.77	O
)	O
assessed	O
at	O
the	O
same	O
time	O
as	O
the	O
metabolic	O
profiling	O
.	O

The	O
resemblance	O
indicated	O
that	O
1	O
kg	O
lower	O
birthweight	O
is	O
associated	O
with	O
similar	O
metabolic	O
aberrations	O
as	O
caused	O
by	O
0.92	O
units	O
higher	O
BMI	O
in	O
adulthood	O
.	O

Lower	O
birthweight	O
adjusted	O
for	O
gestational	O
age	O
is	O
associated	O
with	O
adverse	O
biomarker	O
aberrations	O
across	O
multiple	O
metabolic	O
pathways	O
.	O

Coherent	O
metabolic	O
signatures	O
between	O
lower	O
birthweight	O
and	O
higher	O
adult	O
adiposity	O
suggest	O
that	O
shared	O
molecular	O
pathways	O
may	O
potentially	O
underpin	O
the	O
metabolic	O
deviations	O
.	O

However	O
,	O
the	O
magnitudes	O
of	O
metabolic	O
associations	O
with	O
birthweight	O
are	O
modest	O
in	O
comparison	O
to	O
the	O
effects	O
of	O
adiposity	O
,	O
implying	O
that	O
birthweight	O
is	O
only	O
a	O
weak	O
indicator	O
of	O
the	O
metabolic	O
risk	O
profile	O
in	O
adulthood	O
.	O

Understanding	O
Supportive	O
Care	O
Factors	O
Among	O
African	O
American	O
Breast	O
Cancer	O
Survivors	O
.	O

Comprehensive	O
breast	O
cancer	O
care	O
includes	O
not	O
only	O
diagnosis	O
,	O
staging	B-P
,	O
and	O
treatment	O
of	O
cancer	O
but	O
also	O
assessment	O
and	O
management	O
of	O
the	O
physical	O
,	O
psychological	O
,	O
social	O
,	O
and	O
informational	O
needs	O
,	O
collectively	O
known	O
as	O
supportive	O
care	O
.	O

Several	O
studies	O
have	O
documented	O
the	O
importance	O
of	O
addressing	O
supportive	O
care	O
factors	O
among	O
breast	O
cancer	O
survivors	O
.	O

However	O
,	O
there	O
appears	O
to	O
be	O
a	O
paucity	O
of	O
research	O
concerning	O
African	O
American	O
breast	O
cancer	O
survivors	O
(	O
AABCS	O
)	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
and	O
understand	O
the	O
patient-centered	O
supportive	O
care	O
factors	O
among	O
self-identified	O
AABCS	O
.	O

Using	O
a	O
qualitative	O
descriptive	O
approach	O
,	O
an	O
open-ended	O
question	O
explored	O
supportive	O
care	O
factors	O
that	O
were	O
used	O
by	O
N	O
=	O
155	O
AABCS	O
.	O

Four	O
supportive	O
care	O
factors	O
were	O
identified	O
:	O
faith	O
,	O
supportive	O
structures	O
,	O
optimism	O
,	O
and	O
access	O
to	O
information	O
.	O

An	O
understanding	O
of	O
these	O
factors	O
might	O
facilitate	O
discussion	O
between	O
survivors	O
and	O
the	O
health	O
care	O
team	O
.	O

The	O
resultant	O
effect	O
could	O
also	O
inform	O
and	O
promote	O
the	O
delivery	O
of	O
culturally	O
specific	O
health	O
care	O
to	O
address	O
the	O
supportive	O
care	O
needs	O
among	O
these	O
women	O
.	O

Spatial	O
Mnemonic	O
Encoding	O
:	O
Theta	O
Power	O
Decreases	O
and	O
Medial	O
Temporal	O
Lobe	O
BOLD	B-P
Increases	O
Co-Occur	O
during	O
the	O
Usage	O
of	O
the	O
Method	O
of	O
Loci	O
.	O

The	O
method	O
of	O
loci	O
is	O
one	O
,	O
if	O
not	O
the	O
most	O
,	O
efficient	O
mnemonic	O
encoding	O
strategy	O
.	O

This	O
spatial	O
mnemonic	O
combines	O
the	O
core	O
cognitive	O
processes	O
commonly	O
linked	O
to	O
medial	O
temporal	O
lobe	O
(	O
MTL	O
)	O
activity	O
:	O
spatial	O
and	O
associative	O
memory	O
processes	O
.	O

During	O
such	O
processes	O
,	O
fMRI	B-P
studies	O
consistently	O
demonstrate	O
MTL	O
activity	O
,	O
while	O
electrophysiological	B-P
studies	I-P
have	O
emphasized	O
the	O
important	O
role	O
of	O
theta	O
oscillations	O
(	O
3-8	O
Hz	O
)	O
in	O
the	O
MTL	O
.	O

However	O
,	O
it	O
is	O
still	O
unknown	O
whether	O
increases	O
or	O
decreases	O
in	O
theta	O
power	O
co-occur	O
with	O
increased	O
BOLD	B-P
signal	O
in	O
the	O
MTL	O
during	O
memory	O
encoding	O
.	O

To	O
investigate	O
this	O
question	O
,	O
we	O
recorded	O
EEG	B-P
and	O
fMRI	B-P
separately	O
,	O
while	O
human	O
participants	O
used	O
the	O
spatial	O
method	O
of	O
loci	O
or	O
the	O
pegword	O
method	O
,	O
a	O
similarly	O
associative	O
but	O
nonspatial	O
mnemonic	O
.	O

The	O
more	O
effective	O
spatial	O
mnemonic	O
induced	O
a	O
pronounced	O
theta	O
power	O
decrease	O
source	O
localized	O
to	O
the	O
left	O
MTL	O
compared	O
with	O
the	O
nonspatial	O
associative	O
mnemonic	O
strategy	O
.	O

This	O
effect	O
was	O
mirrored	O
by	O
BOLD	B-P
signal	O
increases	O
in	O
the	O
MTL	O
.	O

Successful	O
encoding	O
,	O
irrespective	O
of	O
the	O
strategy	O
used	O
,	O
elicited	O
decreases	O
in	O
left	O
temporal	O
theta	O
power	O
and	O
increases	O
in	O
MTL	O
BOLD	B-P
activity	O
.	O

This	O
pattern	O
of	O
results	O
suggests	O
a	O
negative	O
relationship	O
between	O
theta	O
power	O
and	O
BOLD	B-P
signal	O
changes	O
in	O
the	O
MTL	O
during	O
memory	O
encoding	O
and	O
spatial	O
processing	O
.	O

The	O
findings	O
extend	O
the	O
well	O
known	O
negative	O
relation	O
of	O
alpha	O
/	O
beta	O
oscillations	O
and	O
BOLD	B-P
signals	O
in	O
the	O
cortex	O
to	O
theta	O
oscillations	O
in	O
the	O
MTL	O
.	O

Differences	O
in	O
pain	O
experience	O
and	O
cooperation	O
between	O
consecutive	O
surgeries	O
in	O
patients	O
undergoing	O
phacoemulsification	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
pain	O
experience	O
and	O
cooperation	O
between	O
consecutive	O
surgeries	O
in	O
patients	O
undergoing	O
phacoemulsification	O
in	O
both	O
eyes	O
,	O
using	O
sub-Tenon	O
's	O
local	O
anesthesia	O
without	O
sedation	O
.	O

In	O
this	O
study	O
,	O
268	O
patients	O
with	O
bilateral	O
senile	O
cataracts	O
were	O
recruited	O
.	O

All	O
operations	O
were	O
performed	O
without	O
sedation	O
,	O
using	O
a	O
clear	O
corneal	O
phacoemulsification	O
technique	O
and	O
sub-Tenon	O
's	O
local	O
anesthesia	O
,	O
by	O
one	O
of	O
four	O
surgeons	O
.	O

The	O
first	O
surgery	O
was	O
performed	O
on	O
the	O
eye	O
with	O
the	O
higher	O
grade	O
cataract	O
.	O

The	O
other	O
eye	O
was	O
operated	O
on	O
within	O
3	O
months	O
by	O
the	O
same	O
surgeon	O
(	O
mean	O
interval	O
1.9	O
±	O
1.1	O
months	O
)	O
.	O

All	O
patients	O
were	O
asked	O
to	O
grade	O
their	O
pain	O
experience	O
during	O
induction	O
and	O
maintenance	O
of	O
anesthesia	O
and	O
also	O
during	O
the	O
phacoemulsification	O
surgery	O
,	O
using	O
a	O
visual	B-P
analogue	I-P
scale	I-P
(	O
VAS	B-P
)	O
from	O
0	O
(	O
no	O
pain	O
)	O
to	O
10	O
(	O
unbearable	O
pain	O
)	O
administered	O
after	O
the	O
surgery	O
.	O

The	O
cooperation	O
of	O
the	O
patient	O
was	O
graded	O
from	O
0	O
(	O
no	O
event	O
)	O
to	O
3	O
(	O
markedeye	O
and	O
head	O
movement	O
and	O
lid	O
squeezing	O
)	O
by	O
the	O
attending	O
surgeon	O
.	O

The	O
VAS	O
scores	O
and	O
cooperation	O
scores	O
of	O
the	O
patients	O
were	O
the	O
outcome	O
measurements	O
.	O

The	O
mean	O
pain	O
score	O
was	O
2.11	O
±	O
0.79	O
in	O
the	O
first	O
eye	O
and	O
3.33	O
±	O
0.80	O
in	O
the	O
second	O
eye	O
during	O
the	O
administration	O
of	O
sub-Tenon	O
's	O
anesthesia	O
,	O
and	O
1.50	O
±	O
0.60	O
in	O
the	O
first	O
eye	O
and	O
2.10	O
±	O
0.57	O
in	O
the	O
second	O
eye	O
during	O
the	O
phacoemulsification	O
surgery	O
.	O

The	O
patient	O
cooperation	O
score	O
was	O
1.60	O
±	O
0.75	O
in	O
the	O
first	O
surgery	O
and	O
2.08	O
±	O
0.72	O
in	O
the	O
second	O
surgery	O
.	O

The	O
differences	O
between	O
the	O
first	O
and	O
second	O
surgeries	O
were	O
statistically	O
significant	O
for	O
all	O
outcome	O
measures	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Patients	O
who	O
previously	O
underwent	O
phaco	O
surgery	O
in	O
one	O
eye	O
experienced	O
more	O
pain	O
and	O
showed	O
worse	O
cooperation	O
during	O
the	O
phaco	O
surgery	O
in	O
the	O
second	O
eye	O
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	O
,	O
viz.	O
,	O
less	O
than	O
3	O
months	O
.	O

Therefore	O
,	O
if	O
the	O
surgeon	O
has	O
difficulty	O
in	O
the	O
first	O
operation	O
gaining	O
the	O
patient	O
's	O
cooperation	O
,	O
the	O
surgeon	O
must	O
be	O
careful	O
:	O
if	O
contralateral	O
eye	O
surgery	O
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	O
/	O
analgesia	O
should	O
be	O
considered	O
or	O
the	O
surgery	O
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	O
of	O
recent	O
memory	O
on	O
the	O
patient	O
's	O
subsequent	O
pain	O
experience	O
.	O

T2-Imaging	B-P
Changes	O
in	O
the	O
Nigrosome-1	O
Relate	O
to	O
Clinical	O
Measures	O
of	O
Parkinson	O
's	O
Disease	O
.	O

The	O
nigrosome-1	O
region	O
of	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
undergoes	O
the	O
greatest	O
and	O
earliest	O
dopaminergic	O
neuron	O
loss	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

As	O
T2-weighted	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	I-P
MRI	I-P
)	I-P
scans	I-P
are	O
often	O
collected	O
with	O
routine	O
clinical	O
MRI	B-P
protocols	O
,	O
this	O
investigation	O
aims	O
to	O
determine	O
whether	O
T2-imaging	B-P
changes	O
in	O
the	O
nigrosome-1	O
are	O
related	O
to	O
clinical	O
measures	O
of	O
PD	O
and	O
to	O
assess	O
their	O
potential	O
as	O
a	O
more	O
clinically	O
accessible	O
biomarker	O
for	O
PD	O
.	O

Voxel	O
intensity	O
ratios	O
were	O
calculated	O
for	O
T2-weighted	B-P
MRI	I-P
scans	I-P
from	O
47	O
subjects	O
from	O
the	O
Parkinson	O
's	O
Progression	O
Markers	O
Initiative	O
database	O
.	O

Three	O
approaches	O
were	O
used	O
to	O
delineate	O
the	O
SN	O
and	O
nigrosome-1	O
:	O
(	O
1	O
)	O
manual	O
segmentation	O
,	O
(	O
2	O
)	O
automated	O
segmentation	O
,	O
and	O
(	O
3	O
)	O
area	O
voxel	O
-based	O
morphometry	O
.	O

Voxel	O
intensity	O
ratios	O
were	O
calculated	O
from	O
voxel	O
intensity	O
values	O
taken	O
from	O
the	O
nigrosome-1	O
and	O
two	O
areas	O
of	O
the	O
remaining	O
SN	O
.	O

Linear	O
regression	O
analyses	O
were	O
conducted	O
relating	O
voxel	O
intensity	O
ratios	O
with	O
the	O
Movement	O
Disorder	O
Society-Unified	O
Parkinson	O
's	O
Disease	O
Rating	O
Scale	O
(	O
MDS-UPDRS	O
)	O
sub-scores	O
for	O
each	O
subject	O
.	O

For	O
manual	O
segmentation	O
,	O
linear	O
regression	O
tests	O
consistently	O
identified	O
the	O
voxel	O
intensity	O
ratio	O
derived	O
from	O
the	O
dorsolateral	O
SN	O
and	O
nigrosome-1	O
(	O
IR2	O
)	O
as	O
predictive	O
of	O
nBehav	O
(	O
p	O
=	O
0.0377	O
)	O
and	O
nExp	O
(	O
p	O
=	O
0.03856	O
)	O
.	O

For	O
automated	O
segmentation	O
,	O
linear	O
regression	O
tests	O
identified	O
IR2	O
as	O
predictive	O
of	O
Subscore	O
IA	O
(	O
nBehav	O
)	O
(	O
p	O
=	O
0.01134	O
)	O
,	O
Subscore	O
IB	O
(	O
nExp	O
)	O
(	O
p	O
=	O
0.00336	O
)	O
,	O
Score	O
II	O
(	O
mExp	O
)	O
(	O
p	O
=	O
0.02125	O
)	O
,	O
and	O
Score	O
III	O
(	O
mSign	O
)	O
(	O
p	O
=	O
0.008139	O
)	O
.	O

For	O
the	O
voxel	O
-based	O
morphometric	O
approach	O
,	O
univariate	O
simple	O
linear	O
regression	O
analysis	O
identified	O
IR2	O
as	O
yielding	O
significant	O
results	O
for	O
nBehav	O
(	O
p	O
=	O
0.003102	O
)	O
,	O
mExp	O
(	O
p	O
=	O
0.0172	O
)	O
,	O
and	O
mSign	O
(	O
p	O
=	O
0.00393	O
)	O
.	O

Neuroimaging	B-P
biomarkers	O
may	O
be	O
used	O
as	O
a	O
proxy	O
of	O
changes	O
in	O
the	O
nigrosome-1	O
,	O
measured	O
by	O
MDS-UPDRS	O
scores	O
as	O
an	O
indicator	O
of	O
the	O
severity	O
of	O
PD	O
.	O

The	O
voxel	O
intensity	O
ratio	O
derived	O
from	O
the	O
dorsolateral	O
SN	O
and	O
nigrosome-1	O
was	O
consistently	O
predictive	O
of	O
non-motor	O
complex	O
behaviors	O
in	O
all	O
three	O
analyses	O
and	O
predictive	O
of	O
non-motor	O
experiences	O
of	O
daily	O
living	O
,	O
motor	O
experiences	O
of	O
daily	O
living	O
,	O
and	O
motor	O
signs	O
of	O
PD	O
in	O
two	O
of	O
the	O
three	O
analyses	O
.	O

These	O
results	O
suggest	O
that	O
T2	O
changes	O
in	O
the	O
nigrosome-1	O
may	O
relate	O
to	O
certain	O
clinical	O
measures	O
of	O
PD	O
.	O

T2	O
changes	O
in	O
the	O
nigrosome-1	O
may	O
be	O
considered	O
when	O
developing	O
a	O
more	O
accessible	O
clinical	O
diagnostic	B-P
tool	I-P
for	O
patients	O
with	O
suspected	O
PD	O
.	O

Aptamer	O
-based	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
sensor	O
for	O
thrombin	O
based	O
on	O
supramolecular	O
recognition	O
,	O
oriented	O
assembly	O
,	O
and	O
local	O
field	O
coupling	O
.	O

A	O
supramolecular	O
recognition	O
and	O
oriented	O
assembly	O
system	O
was	O
developed	O
on	O
chip	O
for	O
the	O
highly	O
selective	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
detection	O
of	O
thrombin	O
by	O
means	O
of	O
the	O
aptamer	O
-based	O
SERS	O
tag	O
method	O
.	O

A	O
15-base	O
thrombin-binding	O
aptamer	O
(	O
TBA15	O
)	O
with	O
a	O
thiol	O
end	O
was	O
first	O
immobilized	O
on	O
an	O
Ag	O
nanoprism	O
array	O
by	O
the	O
S-Ag	O
bond	O
.	O

This	O
aptamer	O
has	O
high	O
binding	O
affinity	O
with	O
thrombin	O
when	O
it	O
folds	O
into	O
a	O
G-quadruplex	O
structure	O
.	O

After	O
the	O
recognition	O
between	O
the	O
aptamer	O
and	O
thrombin	O
,	O
a	O
bridge	O
is	O
built	O
between	O
the	O
SERS	O
tag	O
(	O
4-mercaptobenzoic	O
acid	O
marked	O
Ag	O
nanoparticle	O
)	O
and	O
the	O
fixed	O
thrombin	O
based	O
on	O
the	O
activation	O
of	O
the	O
carboxylic	O
group	O
of	O
4-mercaptobenzoic	O
acid	O
.	O

Thus	O
,	O
the	O
quantitative	O
detection	O
of	O
thrombin	O
can	O
be	O
achieved	O
based	O
on	O
the	O
SERS	O
intensity	O
of	O
the	O
immobilized	O
SERS	O
tags	O
.	O

The	O
obvious	O
advantages	O
of	O
this	O
sensing	O
method	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
remarkable	O
SERS	O
enhancement	O
due	O
to	O
the	O
high	O
electric	O
field	O
coupling	O
effect	O
via	O
the	O
gap	O
structure	O
formation	O
,	O
which	O
improves	O
the	O
sensitivity	O
of	O
the	O
SERS	O
detection	O
and	O
the	O
limit	O
of	O
detection	O
of	O
this	O
method	O
arrives	O
in	O
1.6	O
×	O
10	O
(	O
-11	O
)	O
M	O
,	O
(	O
2	O
)	O
high	O
selectivity	O
based	O
on	O
the	O
specific	O
aptamer	O
recognition	O
toward	O
thrombin	O
,	O
which	O
can	O
be	O
extended	O
to	O
other	O
enzymes	O
easily	O
by	O
changing	O
a	O
proper	O
sequence	O
,	O
(	O
3	O
)	O
high	O
repeatability	O
of	O
SERS	O
signals	O
according	O
to	O
a	O
highly	O
ordered	O
structure	O
,	O
and	O
(	O
4	O
)	O
highly	O
efficient	O
oriented	O
assembly	O
of	O
a	O
sandwich	O
structure	O
over	O
an	O
Ag	O
nanoprism	O
array	O
.	O

The	O
proposed	O
method	O
is	O
expected	O
to	O
be	O
a	O
practical	O
implement	O
in	O
medical	B-P
diagnosis	I-P
.	O

Graphical	O
Abstract	O
Illustration	O
of	O
the	O
aptamer	O
-based	O
SERS	O
sensor	O
for	O
thrombin	O
detection	O
.	O

Clinical	O
application	O
of	O
a	O
gadolinium	O
-based	O
capsule	O
as	O
an	O
MRI	O
contrast	O
agent	O
in	O
slow	O
transit	O
constipation	O
diagnostics	O
.	O

As	O
a	O
traditional	O
method	O
for	O
the	O
assessment	O
of	O
colon	O
dynamics	O
,	O
radio-opaque	O
markers	O
(	O
ROMs	O
)	O
are	O
limited	O
in	O
clinical	O
use	O
because	O
of	O
their	O
ionizing	O
radiation	O
.	O

We	O
compared	O
the	O
accuracy	O
and	O
applicability	O
of	O
gadolinium	O
-based	O
capsules	O
with	O
ROMs	O
in	O
the	O
measurement	O
of	O
colon	O
dynamics	O
in	O
healthy	O
controls	O
and	O
slow	O
transit	O
constipation	O
(	O
STC	O
)	O
patients	O
.	O

Seven	O
patients	O
with	O
STC	O
and	O
nine	O
healthy	O
controls	O
under	O
a	O
normal	O
diet	O
orally	O
consumed	O
ROMs	O
and	O
gadolinium	O
-based	O
capsules	O
simultaneously	O
.	O

All	O
subjects	O
underwent	O
X-ray	B-P
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
.	O

Healthy	O
control	O
images	O
were	O
acquired	O
at	O
12	O
,	O
24	O
,	O
and	O
48	O
h	O
,	O
and	O
STC	O
patient	O
images	O
were	O
acquired	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h.	O
The	O
scores	O
based	O
on	O
the	O
position	O
of	O
the	O
labeling	O
capsules	O
and	O
ROMs	O
in	O
the	O
colon	O
and	O
the	O
colon	B-P
transit	I-P
times	I-P
(	O
CTTs	B-P
)	O
in	O
the	O
two	O
groups	O
were	O
compared	O
.	O

The	O
CTTs	B-P
obtained	O
via	O
the	O
ROMs	O
were	O
34.7±17.4	O
and	O
67.3±6.5	O
h	O
in	O
the	O
healthy	O
controls	O
and	O
STC	O
patients	O
,	O
respectively	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
CTTs	B-P
obtained	O
via	O
MRI	B-P
were	O
30.9±15.9	O
and	O
74.1±7.2	O
h	O
in	O
the	O
healthy	O
controls	O
and	O
STC	O
patients	O
,	O
respectively	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
CTTs	B-P
of	O
the	O
STC	O
patients	O
were	O
significantly	O
longer	O
than	O
the	O
healthy	O
controls	O
.	O

The	O
correlation	O
(	O
rs	O
)	O
between	O
the	O
scores	O
based	O
on	O
the	O
position	O
of	O
the	O
labeling	O
capsule	O
and	O
ROMs	O
in	O
the	O
healthy	O
group	O
and	O
the	O
STC	O
patients	O
was	O
.880	O
(	O
P	O
<	O
.05	O
)	O
and	O
.889	O
(	O
P	O
<	O
.05	O
)	O
,	O
respectively	O
.	O

As	O
a	O
MRI	O
contrast	O
label	O
,	O
gadolinium	O
-based	O
capsules	O
exhibit	O
results	O
comparable	O
to	O
ROMs	O
in	O
colon	O
motility	O
measurements	O
.	O

Assessment	O
of	O
the	O
Relationship	O
Between	O
Clinicophysiologic	O
and	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
Findings	O
of	O
the	O
Temporomandibular	O
Disorder	O
Patients	O
.	O

Temporomandibular	O
joint	O
disorders	O
(	O
TMJDs	O
)	O
are	O
a	O
complex	O
group	O
of	O
disorders	O
that	O
comprise	O
dysfunctions	O
of	O
the	O
temporomandibular	O
joint	O
(	O
TMJ	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
objective	O
and	O
subjective	O
findings	O
of	O
the	O
TMJD	O
patients	O
by	O
using	O
Helkimo	O
anamnesis	O
(	O
Ai	O
)	O
and	O
clinical	O
dysfunction	O
(	O
Di	O
)	O
indices	O
,	O
and	O
tried	O
to	O
document	O
a	O
relation	O
between	O
these	O
findings	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
results.Ninety-eight	O
patients	O
who	O
were	O
admitted	O
to	O
our	O
clinic	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
clinical	O
evaluation	O
was	O
performed	O
by	O
using	O
Ai	O
,	O
an	O
8-question-survey	O
based	O
on	O
the	O
objective	O
symptoms	O
of	O
patients	O
;	O
Di	O
,	O
concluded	O
as	O
the	O
score	O
of	O
5	O
objective	O
measurements	O
of	O
physical	O
examination	O
.	O

The	O
morphology	O
of	O
the	O
TMJ	O
was	O
evaluated	O
by	O
MRI	B-P
,	O
and	O
the	O
findings	O
were	O
analyzed	O
and	O
statistically	O
compared	O
with	O
respect	O
to	O
the	O
Di	O
.The	O
most	O
commonly	O
seen	O
symptoms	O
were	O
noise	O
during	O
mandibular	O
movement	O
(	O
58	O
%	O
)	O
,	O
pain	O
around	O
the	O
joint	O
(	O
42.5	O
%	O
)	O
,	O
and	O
pain	O
with	O
mandibular	O
movements	O
(	O
40	O
%	O
)	O
.	O

Seventeen	O
patients	O
(	O
17.3	O
%	O
)	O
were	O
Di0	O
,	O
47	O
(	O
48	O
%	O
)	O
were	O
DiI	O
,	O
24	O
(	O
24.5	O
%	O
)	O
were	O
DiII	O
,	O
and	O
10	O
(	O
10.2	O
%	O
)	O
were	O
DiIII	O
.	O

Thirty-seven	O
patients	O
(	O
37.8	O
%	O
)	O
had	O
abnormal	O
MRI	B-P
findings	O
,	O
whereas	O
61	O
patients	O
(	O
62.2	O
%	O
)	O
had	O
normal	O
MRI	B-P
.	O

The	O
most	O
commonly	O
encountered	O
pathology	O
was	O
anterior	O
disc	O
displacement	O
with	O
reduction	O
,	O
which	O
was	O
reported	O
in	O
15	O
patients	O
.	O

Increased	O
TMJ	O
Di	O
,	O
which	O
points	O
a	O
more	O
progressed	O
TMJD	O
,	O
was	O
found	O
to	O
be	O
significantly	O
related	O
with	O
the	O
pathological	O
MRI	B-P
findings	O
(	O
P	O
<	O
0.05	O
)	O
.	O

MRI	B-P
is	O
especially	O
effective	O
in	O
particularly	O
those	O
with	O
high	O
Di	O
;	O
therefore	O
,	O
the	O
results	O
of	O
the	O
study	O
may	O
give	O
a	O
prospect	O
in	O
which	O
types	O
of	O
patients	O
does	O
MRI	B-P
give	O
a	O
valuable	O
data	O
toward	O
diagnosis	O
,	O
in	O
which	O
stages	O
of	O
the	O
TMJD	O
should	O
we	O
expect	O
pathological	O
findings	O
,	O
and	O
thereby	O
preventing	O
unnecessary	O
use	O
of	O
MRI	B-P
in	O
patients	O
with	O
symptoms	O
of	O
TMJD	O
.	O

Dynamic	B-P
CT	I-P
myocardial	I-P
perfusion	I-P
imaging	I-P
identifies	O
early	O
perfusion	O
abnormalities	O
in	O
diabetes	O
and	O
hypertension	O
:	O
Insights	O
from	O
a	O
multicenter	O
registry	O
.	O

To	O
identify	O
patients	O
with	O
early	O
signs	O
of	O
myocardial	O
perfusion	O
reduction	O
,	O
a	O
reference	O
base	O
for	O
perfusion	O
measures	O
is	O
needed	O
.	O

To	O
analyze	O
perfusion	O
parameters	O
derived	O
from	O
dynamic	B-P
computed	I-P
tomography	I-P
perfusion	I-P
imaging	I-P
(	O
CTPI	B-P
)	O
in	O
patients	O
with	O
suspected	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
,	O
and	O
relationship	O
with	O
risk	O
factors	O
.	O

In	O
this	O
multicenter	O
study	O
,	O
coronary	B-P
CT	I-P
angiography	I-P
(	O
cCTA	B-P
)	O
and	O
dynamic	B-P
CTPI	I-P
were	O
performed	O
by	O
second-generation	B-P
dual-source	I-P
CT	I-P
in	O
patients	O
suspected	O
of	O
CAD	O
.	O

Risk	O
factors	O
were	O
collected	O
from	O
hospital	O
records	O
.	O

Patients	O
with	O
visual	O
perfusion	O
defects	O
on	O
CTPI	B-P
,	O
previous	O
coronary	O
intervention	O
,	O
or	O
missing	O
risk	O
factor	O
details	O
were	O
excluded	O
.	O

This	O
analysis	O
included	O
98	O
patients	O
(	O
mean	O
age	O
±	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
59.0	O
±	O
8.6yrs	O
;	O
73	O
male	O
)	O
.	O

Global	O
measures	O
of	O
left	O
ventricular	O
myocardial	O
blood	O
flow	O
(	O
MBF	O
)	O
,	O
myocardial	O
blood	O
volume	O
(	O
MBV	O
)	O
and	O
volume	O
transfer	O
constant	O
(	O
K	O
(	O
trans	O
)	O
)	O
were	O
calculated	O
.	O

Mean	O
MBF	O
was	O
139.3	O
±	O
31.4	O
mL/100	O
mL/min	O
,	O
MBV	O
19.1	O
±	O
2.7	O
mL/100	O
mL	O
,	O
and	O
Ktrans	O
85.0	O
±	O
17.5	O
mL/100	O
mL/min	O
.	O

No	O
significant	O
differences	O
in	O
perfusion	O
parameters	O
were	O
found	O
by	O
gender	O
or	O
age	O
category	O
.	O

Hypertension	O
and	O
diabetes	O
mellitus	O
resulted	O
in	O
lower	O
perfusion	O
parameters	O
(	O
hypertension	O
vs	O
normotension	O
:	O
MBV	O
18.5	O
±	O
3.0	O
vs	O
19.7	O
±	O
2.3	O
mL/100	O
mL	O
and	O
K	O
(	O
trans	O
)	O
82.0	O
±	O
18.0	O
vs	O
89.0	O
±	O
16.0	O
,	O
p	O
<	O
0.05	O
;	O
diabetes	O
vs	O
no	O
diabetes	O
:	O
MBF	O
128.5	O
±	O
31.5	O
vs	O
144.0	O
±	O
30.5	O
mL/100	O
mL/min	O
and	O
MBV	O
17.9	O
±	O
2.4	O
vs	O
19.4	O
±	O
2.8	O
mL/100	O
mL	O
,	O
p	O
<	O
0.05	O
)	O
.	O

In	O
patients	O
with	O
hyperlipidemia	O
,	O
MBF	O
was	O
higher	O
(	O
146.8	O
±	O
34.4	O
vs	O
130.7	O
±	O
24.3	O
mL/100	O
mL/min	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Smoking	O
and	O
family	O
history	O
did	O
not	O
show	O
perfusion	O
parameter	O
differences	O
.	O

Dynamic	B-P
CTPI	I-P
identifies	O
early	O
perfusion	O
disturbances	O
in	O
conditions	O
like	O
diabetes	O
and	O
hypertension	O
.	O

With	O
further	O
standardization	O
,	O
absolute	O
perfusion	O
measures	O
may	O
improve	O
CAD	O
risk	O
stratification	O
in	O
patients	O
without	O
visual	O
perfusion	O
defects	O
.	O

MRI	B-P
findings	O
of	O
isolated	O
tubal	O
torsions	O
:	O
case	O
series	O
of	O
12	O
patients	O
:	O
MRI	B-P
findings	O
suggesting	O
isolated	O
tubal	O
torsions	O
,	O
correlating	O
with	O
surgical	O
findings	O
.	O

To	O
investigate	O
specific	O
MRI	B-P
findings	O
for	O
the	O
prompt	O
diagnosis	O
of	O
tubal	O
torsion	O
by	O
reviewing	O
12	O
cases	O
.	O

The	O
MRI	B-P
findings	O
presenting	O
surgically	O
and	O
pathologically	O
proven	O
isolated	O
tubal	O
torsion	O
were	O
evaluated	O
.	O

Key	O
specific	O
findings	O
,	O
including	O
whirlpool	O
sign	O
and	O
plicae	O
tubaliae	O
,	O
were	O
frequently	O
associated	O
with	O
the	O
diseases	O
and	O
were	O
grouped	O
for	O
three	O
types	O
.	O

Knowledge	O
of	O
specific	O
MRI	B-P
findings	O
and	O
the	O
types	O
of	O
tubal	O
torsion	O
may	O
lead	O
to	O
a	O
correct	O
and	O
prompt	O
diagnosis	O
,	O
resulting	O
in	O
preservation	O
of	O
fertility	O
.	O

Helicobacter	O
pylori	O
prevalence	O
and	O
clinical	O
significance	O
in	O
patients	O
with	O
quiescent	O
Crohn	O
's	O
disease	O
.	O

Helicobacter	O
pylori	O
(	O
HP	O
)	O
infection	O
is	O
present	O
in	O
about	O
50	O
%	O
of	O
the	O
global	O
population	O
,	O
and	O
is	O
associated	O
with	O
chronic	O
gastritis	O
,	O
peptic	O
disease	O
and	O
gastric	O
malignancies	O
.	O

HP	O
prevalence	O
in	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
patients	O
was	O
shown	O
to	O
be	O
low	O
compared	O
to	O
the	O
general	O
population	O
,	O
and	O
its	O
influence	O
on	O
disease	B-P
activity	I-P
is	O
yet	O
to	O
be	O
determined	O
.	O

Our	O
aims	O
were	O
to	O
determine	O
the	O
prevalence	O
of	O
HP	O
in	O
a	O
selected	O
group	O
of	O
CD	O
patients	O
with	O
quiescent	O
disease	O
,	O
and	O
to	O
assess	O
the	O
influence	O
of	O
its	O
eradication	O
on	O
disease	B-P
activity	I-P
and	O
endoscopic	B-P
and	O
laboratory	O
activity	O
measures	O
.	O

Consecutive	O
CD	O
patients	O
with	O
quiescent	O
disease	O
underwent	O
meticulous	O
disease	O
evaluation	O
with	O
MR	B-P
enterography	I-P
(	O
MRE	B-P
)	O
,	O
video	B-P
capsule	I-P
endoscopy	I-P
(	O
VCE	B-P
)	O
,	O
CRP	O
,	O
fecal	O
calprotectin	O
and	O
CDAI	O
.	O

All	O
patients	O
were	O
tested	O
for	O
the	O
presence	O
of	O
HP	O
using	O
stool	O
antigen	O
detection	O
kit	O
.	O

Patients	O
infected	O
with	O
HP	O
were	O
offered	O
eradication	O
treatment	O
with	O
sequential	O
therapy	O
.	O

HP	O
eradication	O
was	O
confirmed	O
using	O
urease	O
breath	O
test	O
and	O
stool	O
antigen	O
test	O
.	O

The	O
influence	O
of	O
HP	O
eradication	O
on	O
disease	B-P
activity	I-P
was	O
assessed	O
.	O

Out	O
of	O
56	O
patients	O
enrolled	O
,	O
six	O
patients	O
(	O
10.7	O
%	O
)	O
had	O
HP	O
infection	O
.	O

Of	O
them	O
,	O
five	O
patients	O
had	O
gastro-	O
duodenitis	O
per	O
VCE	B-P
.	O

All	O
HP	O
positive	O
patients	O
were	O
offered	O
eradication	O
treatment	O
and	O
underwent	O
successful	O
eradication	O
.	O

Notably	O
,	O
23	O
(	O
50	O
%	O
)	O
of	O
patients	O
had	O
proximal	O
disease	O
per	O
VCE	B-P
,	O
most	O
of	O
them	O
(	O
78	O
%	O
)	O
were	O
HP	O
negative	O
.	O

CDAI	O
,	O
CRP	O
,	O
fecal	O
calprotectin	O
and	O
VCE	B-P
Lewis	O
inflammatory	O
score	O
did	O
not	O
change	O
significantly	O
following	O
HP	O
eradication	O
,	O
Gastric	O
findings	O
on	O
VCE	B-P
were	O
not	O
impacted	O
by	O
HP	O
eradication	O
.	O

The	O
prevalence	O
of	O
HP	O
infection	O
in	O
patients	O
with	O
quiescent	O
CD	O
is	O
relatively	O
low	O
.	O

Eradication	O
of	O
the	O
bacteria	O
did	O
not	O
significantly	O
change	O
neither	O
disease	B-P
activity	I-P
measures	I-P
nor	O
the	O
presence	O
of	O
gastro-	O
duodenitis	O
per	O
VCE	B-P
,	O
suggesting	O
it	O
might	O
be	O
part	O
of	O
proximal	O
CD	O
.	O

The	O
influence	O
of	O
HP	O
on	O
CD	O
activity	O
merits	O
further	O
investigation	O
.	O

Defining	O
the	O
sham	O
environment	O
for	O
post-myocardial	O
infarction	O
studies	O
in	O
mice	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
sham	O
surgery	O
in	O
a	O
minimally	O
invasive	O
surgical	O
model	O
of	O
permanent	O
coronary	O
artery	O
occlusion	O
used	O
to	O
generate	O
myocardial	O
infarction	O
(	O
MI	O
)	O
in	O
mice	O
.	O

Adult	O
male	O
C57BL/6J	O
mice	O
(	O
3-6	O
mo	O
old	O
)	O
were	O
divided	O
into	O
five	O
groups	O
:	O
day	O
(	O
D	O
)	O
0	O
(	O
no	O
surgical	O
operation	O
)	O
,	O
D1	O
Sham	O
,	O
D1	O
MI	O
,	O
D7	O
Sham	O
,	O
and	O
D7	O
MI	O
.	O

A	O
refined	O
MI	O
surgery	O
technique	O
was	O
used	O
to	O
approach	O
the	O
coronary	O
artery	O
without	O
the	O
ribs	O
being	O
cut	O
.	O

Both	O
sham	O
and	O
MI	O
mice	O
had	O
the	O
left	O
ventricle	O
(	O
LV	O
)	O
exposed	O
through	O
a	O
small	O
incision	O
.	O

To	O
test	O
the	O
effects	O
of	O
surgery	O
alone	O
,	O
the	O
suture	O
was	O
passed	O
around	O
the	O
coronary	O
artery	O
but	O
not	O
ligated	O
.	O

The	O
MI	O
mice	O
were	O
subjected	O
to	O
permanent	O
coronary	O
artery	O
ligation	O
.	O

The	O
mice	O
were	O
killed	O
at	O
D1	O
or	O
D7	O
postsurgical	O
procedure	O
.	O

Compared	O
with	O
D0	O
no	O
surgery	O
controls	O
,	O
the	O
D1	O
and	O
D7	O
sham	O
groups	O
exhibited	O
no	O
surgical	O
mortality	O
and	O
similar	O
necropsy	B-P
and	O
echocardiographic	B-P
variables	O
.	O

Surgery	O
alone	O
did	O
not	O
induce	O
an	O
inflammatory	O
cell	O
response	O
,	O
as	O
evidenced	O
by	O
the	O
lack	O
of	O
leukocyte	O
infiltration	O
in	O
the	O
sham	O
groups	O
.	O

Analysis	O
of	O
165	O
inflammatory	O
cytokines	O
and	O
extracellular	O
matrix	O
factors	O
in	O
sham	O
revealed	O
that	O
a	O
minor	O
gene	O
response	O
was	O
initiated	O
but	O
not	O
translated	O
to	O
protein	O
levels	O
.	O

Collagen	O
deposition	O
did	O
not	O
occur	O
in	O
the	O
absence	O
of	O
MI	O
.	O

In	O
contrast	O
,	O
the	O
D1	O
and	O
D7	O
MI	O
groups	O
showed	O
the	O
expected	O
robust	O
inflammatory	O
and	O
scar	O
formation	O
responses	O
.	O

When	O
a	O
minimally	O
invasive	O
procedure	O
to	O
generate	O
MI	O
in	O
mice	O
was	O
used	O
,	O
the	O
D0	O
(	O
no	O
surgical	O
operation	O
)	O
control	O
was	O
an	O
adequate	O
replacement	O
for	O
the	O
use	O
of	O
sham	O
surgery	O
groups	O
.	O

Tissue	O
factor	O
-	O
dependent	O
coagulation	O
activation	O
by	O
heme	O
:	O
A	O
thromboelastometry	B-P
study	I-P
.	O

Heme	O
has	O
been	O
characterized	O
as	O
potent	O
trigger	O
of	O
inflammation	O
.	O

In	O
hemostasis	O
,	O
although	O
heme	O
has	O
been	O
shown	O
to	O
both	O
induce	O
and	O
inhibit	O
different	O
compartments	O
of	O
hemostasis	O
,	O
its	O
net	O
effect	O
on	O
the	O
hemostatic	O
balance	O
,	O
and	O
the	O
biological	O
relevance	O
of	O
these	O
effects	O
remain	O
to	O
be	O
determined	O
.	O

Herein	O
we	O
evaluated	O
the	O
effect	O
of	O
heme	O
on	O
hemostasis	O
using	O
a	O
global	O
assay	O
able	O
to	O
generate	O
clinically	O
relevant	O
data	O
in	O
several	O
other	O
complex	O
hemostatic	O
diseases	O
.	O

Citrated	O
whole	O
blood	O
samples	O
from	O
healthy	O
participants	O
were	O
stimulated	O
by	O
heme	O
or	O
vehicle	O
and	O
incubated	O
for	O
4h	O
at	O
37°C	O
.	O

Rotational	B-P
thromboelastometry	I-P
was	O
immediately	O
performed	O
.	O

The	O
participation	O
of	O
tissue	O
factor	O
in	O
coagulation	O
activation	O
was	O
evaluated	O
using	O
inhibitory	O
antibody	O
.	O

Heme	O
was	O
able	O
of	O
inducing	O
ex	O
vivo	O
coagulation	O
activation	O
in	O
whole	O
blood	O
,	O
affecting	O
predominantly	O
parameters	O
associated	O
with	O
the	O
initial	O
phases	O
of	O
clot	O
formation	O
.	O

This	O
activation	O
effect	O
was	O
at	O
least	O
partially	O
dependent	O
on	O
hematopoietic	O
tissue	O
factor	O
,	O
since	O
the	O
effects	O
of	O
heme	O
were	O
partially	O
abrogated	O
by	O
the	O
inhibition	O
of	O
human	O
tissue	O
factor	O
.	O

In	O
conclusion	O
,	O
using	O
a	O
global	O
hemostasis	O
assay	O
,	O
our	O
study	O
confirmed	O
that	O
heme	O
is	O
able	O
to	O
activate	O
coagulation	O
in	O
whole	O
blood	O
,	O
in	O
a	O
tissue	O
factor	O
-	O
dependent	O
way	O
.	O

These	O
findings	O
could	O
explain	O
the	O
disturbance	O
in	O
hemostatic	O
balance	O
observed	O
in	O
conditions	O
associated	O
with	O
the	O
release	O
of	O
heme	O
such	O
as	O
sickle	O
cell	O
disease	O
.	O

MyHEART	O
:	O
A	O
Non	O
Randomized	O
Feasibility	O
Study	O
of	O
a	O
Young	O
Adult	O
Hypertension	O
Intervention	O
.	O

In	O
the	O
United	O
States	O
,	O
young	O
adults	O
(	O
18-39	O
year-olds	O
)	O
have	O
the	O
lowest	O
hypertension	O
control	O
rates	O
(	O
35	O
%	O
)	O
compared	O
to	O
middle-aged	O
(	O
58	O
%	O
)	O
and	O
older	O
(	O
54	O
%	O
)	O
adults	O
.	O

Ambulatory	O
care	O
for	O
hypertension	O
management	O
often	O
focuses	O
on	O
medication	O
with	O
little	O
time	O
for	O
self-management	O
and	O
behavioral	O
counseling	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
feasibility	O
of	O
MyHEART	O
,	O
a	O
telephone-based	O
health	O
coach	O
self-management	O
intervention	O
for	O
young	O
adults	O
.	O

The	O
goals	O
were	O
to	O
determine	O
the	O
intervention	O
's	O
ability	O
to	O
:	O
1	O
)	O
recruit	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
,	O
2	O
)	O
maintain	O
ongoing	O
communication	O
between	O
the	O
coach	O
and	O
participants	O
,	O
3	O
)	O
increase	O
participants	O
'	O
engagement	O
in	O
self-management	O
,	O
4	O
)	O
document	O
coach	O
-	O
patient	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
5	O
)	O
assess	O
patient	O
acceptability	O
.	O

Eligible	O
participants	O
were	O
identified	O
through	O
the	O
electronic	O
health	O
record	O
.	O

Inclusion	O
criteria	O
included	O
18-39	O
year-olds	O
,	O
with	O
ICD-9	O
hypertension	O
diagnoses	O
and	O
uncontrolled	O
hypertension	O
(	O
≥	O
140/90	O
mmHg	O
)	O
,	O
receiving	O
regular	O
primary	O
care	O
at	O
a	O
large	O
multispecialty	O
group	O
practice	O
.	O

The	O
intervention	O
consisted	O
of	O
6	O
telephone	O
self-management	O
sessions	O
by	O
a	O
health	O
coach	O
targeting	O
lifestyle	O
modifications	O
.	O

Patients	O
completed	O
an	O
open-ended	O
acceptability	O
survey	O
.	O

Study	O
uptake	O
was	O
47	O
%	O
(	O
9	O
enrolled/19	O
eligible	O
)	O
.	O

Mean	O
(	O
SD	O
)	O
age	O
was	O
35.8	O
(	O
2.6	O
)	O
years	O
,	O
78	O
%	O
male	O
,	O
and	O
33	O
%	O
Black	O
.	O

Over	O
85	O
%	O
of	O
enrolled	O
young	O
adults	O
maintained	O
communication	O
with	O
their	O
health	O
coach	O
.	O

At	O
baseline	O
,	O
11	O
%	O
reported	O
checking	O
their	O
blood	O
pressure	O
outside	O
of	O
clinic	O
;	O
44	O
%	O
reported	O
blood	O
pressure	O
monitoring	O
after	O
the	O
study	O
.	O

All	O
coach	O
-	O
patient	O
encounters	O
were	O
successfully	O
documented	O
in	O
the	O
electronic	O
health	O
record	O
for	O
primary	O
care	O
provider	O
review	O
.	O

Open-ended	O
responses	O
from	O
all	O
surveys	O
indicated	O
that	O
participants	O
had	O
a	O
positive	O
experience	O
with	O
the	O
MyHEART	O
intervention	O
.	O

This	O
study	O
demonstrated	O
that	O
MyHEART	O
was	O
feasible	O
and	O
acceptable	O
to	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
.	O

Health	O
coaches	O
can	O
effectively	O
maintain	O
ongoing	O
communication	O
with	O
young	O
adults	O
,	O
document	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
increase	O
engagement	O
with	O
home	B-P
blood	I-P
pressure	I-P
monitoring	I-P
.	O

The	O
results	O
of	O
this	O
study	O
will	O
inform	O
a	O
multi-center	O
young	O
adult	O
randomized	O
controlled	O
trial	O
of	O
MyHEART	O
.	O

Tailor-made	O
drug	O
carrier	O
:	O
Comparison	O
of	O
formation-dependent	O
physicochemical	O
properties	O
within	O
self-assembled	O
aggregates	O
for	O
an	O
optimal	O
drug	O
carrier	O
.	O

Self-assembled	O
surfactant	O
aggregates	O
,	O
such	O
as	O
micelles	O
and	O
vesicles	O
,	O
have	O
been	O
investigated	O
for	O
their	O
application	O
as	O
drug	O
carriers	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
.	O

However	O
,	O
the	O
characteristics	O
that	O
decide	O
which	O
aggregate	O
is	O
the	O
best	O
drug	O
carrier	O
for	O
each	O
disease	O
have	O
not	O
yet	O
been	O
clarified	O
.	O

In	O
order	O
to	O
design	O
an	O
optimal	O
drug	O
carrier	O
for	O
each	O
disease	O
,	O
various	O
kinds	O
of	O
self-assembled	O
aggregates	O
,	O
such	O
as	O
spherical	O
micelles	O
,	O
lens-like	O
vesicles	O
,	O
and	O
tube-like	O
vesicles	O
,	O
were	O
evaluated	O
by	O
``	O
multiple	O
techniques	O
``	O
including	O
dynamic	O
light	O
scattering	O
,	O
differential	O
scanning	O
calorimetry	O
,	O
nuclear	B-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
,	O
and	O
fluorescence	O
measurement	O
using	O
the	O
Laurdan	O
probe	O
.	O

These	O
studies	O
led	O
to	O
the	O
compilation	O
of	O
a	O
database	O
on	O
the	O
formation-dependent	O
properties	O
of	O
self-assembled	O
aggregates	O
.	O

As	O
the	O
relationship	O
between	O
physicochemical	O
properties	O
of	O
self-assembled	O
aggregates	O
and	O
their	O
functions	O
as	O
drug	O
carriers	O
have	O
been	O
extensively	O
reported	O
,	O
this	O
database	O
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	O
drug	O
carrier	O
,	O
i.e.	O
,	O
a	O
tailor-made	O
drug	O
carrier	O
.	O

Size	O
matters	O
to	O
function	O
:	O
Brain	O
volume	O
correlates	O
with	O
intrinsic	O
brain	O
activity	O
across	O
healthy	O
individuals	O
.	O

A	O
fundamental	O
issue	O
in	O
neuroscience	O
is	O
to	O
understand	O
the	O
structural	O
substrates	O
of	O
neural	O
activities	O
.	O

Intrinsic	O
brain	O
activity	O
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive	O
functions	O
.	O

Structurally	O
,	O
cognitive	O
functions	O
have	O
also	O
shown	O
a	O
relation	O
with	O
brain	O
volume	O
/	O
size	O
.	O

Therefore	O
,	O
an	O
association	O
between	O
intrinsic	O
brain	O
activities	O
and	O
brain	O
volume	O
/	O
size	O
can	O
be	O
hypothesized	O
,	O
and	O
brain	O
volume	O
/	O
size	O
may	O
impact	O
intrinsic	O
brain	O
activity	O
in	O
human	O
brains	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explicitly	O
investigate	O
this	O
brain	O
structure	O
-	O
function	O
relationship	O
using	O
two	O
large	O
independent	O
cohorts	O
of	O
176	O
and	O
236	O
young	O
adults	O
.	O

Structural	O
-	O
MRI	B-P
was	O
performed	O
to	O
estimate	O
the	O
brain	O
volume	O
,	O
and	O
resting-state	B-P
functional-MRI	I-P
was	O
applied	O
to	O
extract	O
the	O
amplitude	O
of	O
low-frequency	O
fluctuations	O
(	O
ALFF	O
)	O
,	O
an	O
imaging	O
measure	O
of	O
intrinsic	O
brain	O
activity	O
.	O

Intriguingly	O
,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	O
correlation	O
between	O
whole-brain	O
size	O
and	O
ALFF	O
.	O

Moreover	O
,	O
specific	O
brain	O
lobes	O
/	O
regions	O
,	O
including	O
the	O
frontal	O
lobe	O
,	O
the	O
left	O
middle	O
frontal	O
gyrus	O
,	O
anterior	O
cingulate	O
gyrus	O
,	O
Rolandic	O
operculum	O
,	O
and	O
insula	O
,	O
also	O
showed	O
a	O
reliable	O
,	O
positive	O
volume	O
-	O
ALFF	O
correlation	O
in	O
the	O
two	O
cohorts	O
.	O

These	O
findings	O
offer	O
direct	O
,	O
empirical	O
evidence	O
of	O
a	O
strong	O
association	O
between	O
brain	O
size	O
/	O
volume	O
and	O
intrinsic	O
brain	O
activity	O
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	O
substrates	O
of	O
the	O
intrinsic	O
brain	O
activity	O
of	O
the	O
human	O
brain	O
.	O

Fracture	O
of	O
the	O
os	O
trigonum	O
:	O
A	O
report	O
of	O
two	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

We	O
report	O
two	O
cases	O
of	O
acute	O
fractures	O
of	O
the	O
os	O
trigonum	O
.	O

The	O
os	O
trigonum	O
fracture	O
related	O
to	O
the	O
first	O
case	O
was	O
sustained	O
following	O
a	O
hyper-plantar	O
flexion	O
injury	O
during	O
a	O
game	O
of	O
soccer	O
.	O

The	O
second	O
case	O
involved	O
a	O
patient	O
who	O
fell	O
from	O
height	O
and	O
also	O
sustained	O
open	O
fractures	O
of	O
the	O
left	O
distal	O
tibia	O
and	O
lateral	O
malleolus	O
as	O
well	O
as	O
the	O
right	O
calcaneus	O
.	O

In	O
both	O
cases	O
,	O
a	O
preliminary	O
diagnosis	O
of	O
a	O
posterior	O
talar	O
process	O
fracture	O
was	O
made	O
from	O
the	O
initial	O
radiographs	B-P
of	O
the	O
ankle	O
.	O

The	O
correct	O
diagnosis	O
of	O
an	O
os	O
trigonum	O
fracture	O
rather	O
than	O
a	O
fracture	O
of	O
the	O
posterior	O
talar	O
process	O
was	O
only	O
made	O
following	O
further	O
assessment	O
with	O
CT	B-P
imaging	I-P
.	O

Given	O
that	O
the	O
course	O
of	O
treatment	O
is	O
largely	O
determined	O
by	O
imaging	B-P
findings	O
,	O
CT	B-P
for	O
further	O
imaging	B-P
evaluation	O
should	O
be	O
performed	O
in	O
cases	O
of	O
suspected	O
acute	O
bony	O
injuries	O
of	O
the	O
posterior	O
ankle	O
,	O
particularly	O
when	O
the	O
limitations	O
of	O
using	O
radiographs	B-P
for	O
the	O
assessment	O
of	O
such	O
injuries	O
are	O
expected	O
to	O
be	O
encountered	O
.	O

Limits	O
of	O
the	O
possible	O
:	O
diagnostic	O
image	O
quality	O
in	O
coronary	B-P
angiography	I-P
with	O
third-generation	B-P
dual-source	I-P
CT	I-P
.	O

The	O
usage	O
of	O
coronary	B-P
CT	I-P
angiography	I-P
(	O
CTA	B-P
)	O
is	O
appropriate	O
in	O
patients	O
with	O
acute	O
or	O
chronic	O
chest	O
pain	O
;	O
however	O
the	O
diagnostic	O
accuracy	O
may	O
be	O
challenged	O
with	O
increased	O
Agatston	O
score	O
(	O
AS	O
)	O
,	O
increased	O
heart	O
rate	O
,	O
arrhythmia	O
and	O
severe	O
obesity	O
.	O

Thus	O
,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third-generation	B-P
dual-source	I-P
CT	I-P
(	O
DSCT	B-P
)	O
for	O
CTA	B-P
in	O
a	O
'real-life	O
'	O
clinical	O
setting	O
.	O

Two	O
hundred	O
and	O
sixty-eight	O
consecutive	O
patients	O
(	O
age	O
:	O
67	O
±	O
10	O
years	O
;	O
BMI	O
:	O
27	O
±	O
5	O
kg/m²	O
;	O
61	O
%	O
male	O
)	O
undergoing	O
clinically	O
indicated	O
CTA	B-P
with	O
DSCT	B-P
were	O
included	O
in	O
the	O
retrospective	O
single-center	O
analysis	O
.	O

A	O
contrast-enhanced	O
volume	O
dataset	O
was	O
acquired	O
in	O
sequential	B-P
(	O
SSM	B-P
)	O
(	O
n	O
=	O
151	O
)	O
or	O
helical	B-P
scan	I-P
mode	I-P
(	O
HSM	B-P
)	O
(	O
n	O
=	O
117	O
)	O
.	O

Coronary	O
segments	O
were	O
classified	O
in	O
diagnostic	O
or	O
non-diagnostic	O
image	O
quality	O
.	O

A	O
subset	O
underwent	O
invasive	B-P
angiography	I-P
to	O
determine	O
the	O
diagnostic	O
accuracy	O
of	O
CTA	B-P
.	O

SSM	B-P
(	O
96.8	O
±	O
6	O
%	O
)	O
and	O
HSM	B-P
(	O
97.5	O
±	O
8	O
%	O
)	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic	O
image	O
quality	O
.	O

However	O
,	O
AS	O
had	O
significant	O
influence	O
on	O
diagnostic	O
image	O
quality	O
exclusively	O
in	O
SSM	B-P
(	O
B	O
=	O
0.003	O
;	O
p	O
=	O
0.0001	O
)	O
,	O
but	O
not	O
in	O
HSM	B-P
.	O

Diagnostic	O
image	O
quality	O
significantly	O
decreased	O
in	O
SSM	B-P
in	O
patients	O
with	O
AS	O
≥2,000	O
(	O
p	O
=	O
0.03	O
)	O
.	O

SSM	B-P
(	O
sensitivity	O
:	O
93.9	O
%	O
;	O
specificity	O
:	O
96.7	O
%	O
;	O
PPV	O
:	O
88.6	O
%	O
;	O
NPV	O
:	O
98.3	O
%	O
)	O
and	O
HSM	B-P
(	O
sensitivity	O
:	O
97.4	O
%	O
;	O
specificity	O
:	O
94.3	O
%	O
;	O
PPV	O
:	O
86.0	O
%	O
;	O
NPV	O
:	O
99.0	O
%	O
)	O
provided	O
comparable	O
diagnostic	O
accuracy	O
(	O
p	O
=	O
n.s.	O
)	O
.	O

SSM	B-P
yielded	O
significantly	O
lower	O
radiation	O
doses	O
as	O
compared	O
to	O
HSM	B-P
(	O
2.1	O
±	O
2.0	O
vs.	O
5.1	O
±	O
3.3	O
mSv	O
;	O
p	O
=	O
0.0001	O
)	O
in	O
age	O
and	O
BMI	O
-matched	O
cohorts	O
.	O

SSM	B-P
in	O
third-generation	B-P
DSCT	I-P
enables	O
significant	O
dose	O
savings	O
and	O
provides	O
robust	O
diagnostic	O
image	O
quality	O
in	O
patients	O
with	O
AS	O
≤2000	O
independent	O
of	O
heart	O
rate	O
,	O
heart	O
rhythm	O
or	O
obesity	O
.	O

Quadrilateral	O
Space	O
Syndrome	O
:	O
A	O
Case	O
Report	O
.	O

We	O
present	O
a	O
case	O
of	O
quadrilateral	O
space	O
syndrome	O
(	O
QSS	O
)	O
in	O
a	O
patient	O
with	O
left	O
arm	O
pain	O
.	O

The	O
patient	O
sustained	O
a	O
trauma	O
to	O
his	O
left	O
arm	O
,	O
and	O
QSS	O
was	O
successfully	O
diagnosed	O
by	O
physical	O
examination	O
,	O
magnetic	B-P
resonance	I-P
image	I-P
,	O
electromyographic	B-P
evaluation	I-P
,	O
and	O
nerve	B-P
conduction	I-P
studies	I-P
.	O

Surgery	O
was	O
performed	O
to	O
decompress	O
the	O
axillary	O
nerve	O
and	O
the	O
patient	O
recovered	O
fully	O
with	O
minimal	O
residual	O
symptoms	O
.	O

Blood	O
flow	O
in	O
the	O
cerebral	O
venous	O
system	O
:	O
modeling	O
and	O
simulation	O
.	O

The	O
development	O
of	O
a	O
software	O
platform	O
incorporating	O
all	O
aspects	O
,	O
from	O
medical	B-P
imaging	I-P
data	O
,	O
through	O
three-dimensional	O
reconstruction	O
and	O
suitable	O
meshing	O
,	O
up	O
to	O
simulation	O
of	O
blood	O
flow	O
in	O
patient	O
-	O
specific	O
geometries	O
,	O
is	O
a	O
crucial	O
challenge	O
in	O
biomedical	O
engineering	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
fully	O
three-dimensional	O
blood	O
flow	O
simulation	O
is	O
carried	O
out	O
through	O
a	O
complete	O
rigid	O
macrovascular	O
circuit	O
,	O
namely	O
the	O
intracranial	O
venous	O
network	O
,	O
instead	O
of	O
a	O
reduced	O
order	O
simulation	O
and	O
partial	O
vascular	O
network	O
.	O

The	O
biomechanical	O
modeling	O
step	O
is	O
carefully	O
analyzed	O
and	O
leads	O
to	O
the	O
description	O
of	O
the	O
flow	O
governed	O
by	O
the	O
dimensionless	O
Navier-Stokes	O
equations	O
for	O
an	O
incompressible	O
viscous	O
fluid	O
.	O

The	O
equations	O
are	O
then	O
numerically	O
solved	O
with	O
a	O
free	O
finite	O
element	O
software	O
using	O
five	O
meshes	O
of	O
a	O
realistic	O
geometry	O
obtained	O
from	O
medical	O
images	O
to	O
prove	O
the	O
feasibility	O
of	O
the	O
pipeline	O
.	O

Some	O
features	O
of	O
the	O
intracranial	O
venous	O
circuit	O
in	O
the	O
supine	O
position	O
such	O
as	O
asymmetric	O
behavior	O
in	O
merging	O
regions	O
are	O
discussed	O
.	O

Cardiovascular	O
Toxicity	O
of	O
Illicit	O
Anabolic-Androgenic	O
Steroid	O
Use	O
.	O

Millions	O
of	O
individuals	O
have	O
used	O
illicit	O
anabolic-androgenic	O
steroids	O
(	O
AAS	O
)	O
,	O
but	O
the	O
long-term	O
cardiovascular	O
associations	O
of	O
these	O
drugs	O
remain	O
incompletely	O
understood	O
.	O

Using	O
a	O
cross-sectional	O
cohort	O
design	O
,	O
we	O
recruited	O
140	O
experienced	O
male	O
weightlifters	O
34	O
to	O
54	O
years	O
of	O
age	O
,	O
comprising	O
86	O
men	O
reporting	O
≥2	O
years	O
of	O
cumulative	O
lifetime	O
AAS	O
use	O
and	O
54	O
nonusing	O
men	O
.	O

Using	O
transthoracic	B-P
echocardiography	I-P
and	O
coronary	B-P
computed	I-P
tomography	I-P
angiography	I-P
,	O
we	O
assessed	O
3	O
primary	O
outcome	O
measures	O
:	O
left	O
ventricular	O
(	O
LV	O
)	O
systolic	O
function	O
(	O
left	O
ventricular	O
ejection	O
fraction	O
)	O
,	O
LV	O
diastolic	O
function	O
(	O
early	O
relaxation	O
velocity	O
)	O
,	O
and	O
coronary	O
atherosclerosis	O
(	O
coronary	O
artery	O
plaque	O
volume	O
)	O
.	O

Compared	O
with	O
nonusers	O
,	O
AAS	O
users	O
demonstrated	O
relatively	O
reduced	O
LV	O
systolic	O
function	O
(	O
mean	O
±	O
SD	O
left	O
ventricular	O
ejection	O
fraction	O
=	O
52±11	O
%	O
versus	O
63±8	O
%	O
;	O
P	O
<	O
0.001	O
)	O
and	O
diastolic	O
function	O
(	O
early	O
relaxation	O
velocity	O
=	O
9.3±2.4	O
cm/second	O
versus	O
11.1±2.0	O
cm/second	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Users	O
currently	O
taking	O
AAS	O
at	O
the	O
time	O
of	O
evaluation	O
(	O
N=58	O
)	O
showed	O
significantly	O
reduced	O
LV	O
systolic	O
(	O
left	O
ventricular	O
ejection	O
fraction	O
=	O
49±10	O
%	O
versus	O
58±10	O
%	O
;	O
P	O
<	O
0.001	O
)	O
and	O
diastolic	O
function	O
(	O
early	O
relaxation	O
velocity	O
=	O
8.9±2.4	O
cm/second	O
versus	O
10.1±2.4	O
cm/second	O
;	O
P=0.035	O
)	O
compared	O
with	O
users	O
currently	O
off	O
-	O
drug	O
(	O
N=28	O
)	O
.	O

In	O
addition	O
,	O
AAS	O
users	O
demonstrated	O
higher	O
coronary	O
artery	O
plaque	O
volume	O
than	O
nonusers	O
(	O
median	O
[	O
interquartile	O
range	O
]	O
3	O
[	O
0	O
,	O
174	O
]	O
mL	O
(	O
3	O
)	O
versus	O
0	O
[	O
0	O
,	O
69	O
]	O
mL	O
(	O
3	O
)	O
;	O
P=0.012	O
)	O
.	O

Lifetime	O
AAS	O
dose	O
was	O
strongly	O
associated	O
with	O
coronary	O
atherosclerotic	O
burden	O
(	O
increase	O
[	O
95	O
%	O
confidence	O
interval	O
]	O
in	O
rank	O
of	O
plaque	O
volume	O
for	O
each	O
10-	O
year	O
increase	O
in	O
cumulative	O
duration	O
of	O
AAS	O
use	O
:	O
0.60	O
SD	O
units	O
[	O
0.16-1.03	O
SD	O
units	O
]	O
;	O
P=0.008	O
)	O
.	O

Long-term	O
AAS	O
use	O
appears	O
to	O
be	O
associated	O
with	O
myocardial	O
dysfunction	O
and	O
accelerated	O
coronary	O
atherosclerosis	O
.	O

These	O
forms	O
of	O
AAS	O
-	O
associated	O
adverse	O
cardiovascular	O
phenotypes	O
may	O
represent	O
a	O
previously	O
underrecognized	O
public-health	O
problem	O
.	O

The	O
impact	O
of	O
noninvasive	O
follicular	O
thyroid	O
neoplasm	O
with	O
papillary-like	O
nuclear	O
features	O
on	O
the	O
performance	O
of	O
the	O
Afirma	O
gene	O
expression	O
classifier	O
.	O

A	O
recent	O
revision	O
in	O
thyroid	O
tumor	O
nomenclature	O
has	O
resulted	O
in	O
a	O
change	O
from	O
a	O
malignant	O
diagnosis	O
(	O
noninvasive	O
follicular	O
variant	O
of	O
papillary	O
thyroid	O
carcinoma	O
)	O
to	O
one	O
that	O
is	O
nonmalignant	O
(	O
noninvasive	O
follicular	O
thyroid	O
neoplasm	O
with	O
papillary-like	O
nuclear	O
features	O
[	O
NIFTP	O
]	O
)	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
this	O
change	O
on	O
the	O
performance	O
of	O
the	O
Afirma	O
gene	O
expression	O
classifier	O
(	O
GEC	O
)	O
.	O

The	O
authors	O
retrospectively	O
analyzed	O
consecutive	O
thyroid	B-P
fine-needle	I-P
aspiration	I-P
specimens	O
with	O
indeterminate	O
diagnoses	B-P
on	O
which	O
GEC	O
was	O
performed	O
.	O

Surgical	O
pathology	O
material	O
was	O
reviewed	O
with	O
the	O
reclassification	O
of	O
nodules	O
into	O
NIFTP	O
.	O

GEC	O
testing	O
was	O
performed	O
on	O
384	O
fine-needle	B-P
aspiration	I-P
specimens	O
diagnosed	O
as	O
atypia	O
of	O
undetermined	O
significance	O
(	O
AUS	O
)	O
(	O
304	O
cases	O
)	O
and	O
suspicious	O
for	O
a	O
follicular	O
neoplasm	O
(	O
SFN	O
)	O
(	O
80	O
cases	O
)	O
and	O
yielded	O
a	O
suspicious	O
result	O
in	O
152	O
of	O
the	O
AUS	O
cases	O
(	O
50	O
%	O
)	O
and	O
50	O
of	O
the	O
SFN	O
cases	O
(	O
63	O
%	O
)	O
.	O

Thyroidectomy	O
was	O
performed	O
on	O
177	O
patients	O
.	O

After	O
reclassifying	O
NIFTP	O
,	O
the	O
positive	O
predictive	O
value	O
of	O
GEC	O
decreased	O
from	O
42	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
39	O
%	O
-45	O
%	O
)	O
to	O
24	O
%	O
(	O
95	O
%	O
CI	O
,	O
22	O
%	O
-26	O
%	O
)	O
in	O
the	O
AUS	O
group	O
and	O
from	O
23	O
%	O
(	O
95	O
%	O
CI	O
,	O
19	O
%	O
-27	O
%	O
)	O
to	O
13	O
%	O
(	O
95	O
%	O
CI	O
,	O
9	O
%	O
-18	O
%	O
)	O
in	O
the	O
SFN	O
group	O
.	O

Total	O
thyroidectomy	O
was	O
performed	O
more	O
frequently	O
than	O
a	O
partial	O
thyroidectomy	O
in	O
patients	O
with	O
AUS	O
with	O
a	O
suspicious	O
GEC	O
result	O
compared	O
with	O
pre-GEC	O
controls	O
(	O
68	O
%	O
vs	O
49	O
%	O
;	O
P	O
=	O
.037	O
)	O
.	O

Reclassification	O
of	O
NIFTP	O
significantly	O
decreases	O
the	O
positive	O
predictive	O
value	O
of	O
GEC	O
in	O
indeterminate	O
thyroid	O
nodules	O
.	O

Nevertheless	O
,	O
the	O
majority	O
of	O
patients	O
with	O
indeterminate	O
thyroid	O
nodules	O
with	O
a	O
suspicious	O
GEC	O
result	O
in	O
the	O
study	O
institution	O
have	O
undergone	O
total	O
thyroidectomy	O
.	O

This	O
finding	O
raises	O
concerns	O
over	O
reliance	O
on	O
a	O
suspicious	O
GEC	O
result	O
by	O
clinicians	O
to	O
justify	O
total	O
thyroidectomy	O
.	O

Cancer	O
Cytopathol	O
2017	O
.	O

©	O
2017	O
American	O
Cancer	O
Society	O
.	O

A	O
study	O
of	O
acute	O
muscle	O
dysfunction	O
with	O
particular	O
reference	O
to	O
dengue	O
myopathy	O
.	O

Acute	O
myopathy	O
is	O
a	O
common	O
cause	O
of	O
acute	O
motor	O
quadriparesis	O
which	O
has	O
various	O
etiologies	O
with	O
different	O
courses	O
of	O
illness	O
and	O
prognosis	O
depending	O
on	O
the	O
cause	O
.	O

Understanding	O
this	O
diversity	O
helps	O
us	O
in	O
proper	O
approach	O
toward	O
diagnosis	O
,	O
predicting	O
the	O
prognosis	O
,	O
and	O
possible	O
complications	O
and	O
in	O
improving	O
the	O
treatments	O
that	O
are	O
being	O
provided	O
.	O

This	O
study	O
was	O
planned	O
to	O
study	O
the	O
clinical	O
,	O
electrophysiological	B-P
,	O
and	O
etiological	O
profile	O
of	O
patients	O
presenting	O
with	O
acute	O
myopathy	O
.	O

We	O
also	O
studied	O
how	O
dengue	O
-related	O
acute	O
myopathy	O
differs	O
from	O
other	O
causes	O
and	O
also	O
difference	O
between	O
myopathy	O
due	O
to	O
myositis	O
and	O
hypokalemia	O
in	O
cases	O
of	O
dengue	O
.	O

This	O
was	O
a	O
prospective	O
,	O
observational	O
study	O
involving	O
all	O
clinically	O
suspected	O
cases	O
of	O
acute	O
myopathy	O
of	O
not	O
more	O
than	O
4	O
weeks	O
duration	O
with	O
raised	O
serum	O
creatine	O
kinase	O
(	O
CK	O
)	O
level	O
.	O

They	O
were	O
subjected	O
to	O
detailed	O
clinical	O
evaluation	O
along	O
with	O
hematological	O
,	O
biochemical	O
,	O
microbiological	O
,	O
and	O
electrophysiological	B-P
studies	I-P
and	O
followed-up	O
for	O
outcome	O
at	O
1	O
and	O
3	O
months	O
.	O

Muscle	B-P
biopsy	I-P
and	O
histopathological	O
examination	O
were	O
done	O
in	O
selected	O
patients	O
after	O
taking	O
informed	O
consent	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
appropriate	O
methods	O
using	O
SPSS	O
version	O
16.0	O
(	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

We	O
evaluated	O
thirty	O
patients	O
of	O
acute	O
myopathy	O
with	O
raised	O
CK	O
level	O
.	O

Seventeen	O
patients	O
had	O
fever	O
,	O
11	O
had	O
myalgia	O
,	O
and	O
5	O
had	O
skin	O
lesions	O
.	O

All	O
presented	O
with	O
symmetric	O
weakness	O
,	O
17	O
(	O
56.7	O
%	O
)	O
patients	O
having	O
predominantly	O
proximal	O
weakness	O
,	O
neck	O
or	O
truncal	O
weakness	O
in	O
6	O
(	O
20	O
%	O
)	O
,	O
hyporeflexia	O
in	O
12	O
(	O
40	O
%	O
)	O
,	O
with	O
mean	O
Medical	O
Research	O
Council	O
(	O
MRC	O
)	O
sum	O
score	O
of	O
46.67	O
±	O
6.0	O
.	O

Eight	O
(	O
mean	O
modified	O
Barthel	O
index	O
[	O
MBI	O
]	O
at	O
presentation	O
-	O
15	O
±	O
3.7	O
)	O
patients	O
had	O
poor	O
functional	O
status	O
according	O
to	O
MBI	O
and	O
15	O
according	O
to	O
modified	O
Rankin	O
scale	O
(	O
MRS	O
)	O
(	O
mean	O
MRS	O
score	O
-	O
2.5	O
±	O
1.2	O
)	O
.	O

Etiology	O
was	O
dengue	O
viral	O
infection	O
in	O
14	O
patients	O
;	O
hypokalemia	O
due	O
to	O
various	O
causes	O
other	O
than	O
dengue	O
in	O
8	O
;	O
pyomyositis	O
in	O
3	O
;	O
dermatomyositis	O
,	O
polymyositis	O
,	O
thyrotoxicosis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
and	O
unknown	O
etiology	O
in	O
one	O
each	O
.	O

Only	O
eight	O
patients	O
had	O
abnormal	O
electrophysiology	B-P
and	O
seven	O
among	O
nine	O
biopsies	B-P
done	O
were	O
abnormal	O
.	O

At	O
1	O
month	O
,	O
24	O
(	O
80.0	O
%	O
)	O
and	O
23	O
(	O
76.7	O
%	O
)	O
patients	O
had	O
achieved	O
normal	O
MBI	O
and	O
MRS	O
scores	O
with	O
28	O
(	O
93.3	O
)	O
and	O
27	O
(	O
90	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
at	O
3	O
months	O
.	O

Dengue	O
with	O
hypokalemia	O
had	O
less	O
myalgia	O
,	O
more	O
of	O
hyporeflexia	O
,	O
and	O
lower	O
serum	O
CK	O
compared	O
to	O
those	O
without	O
hypokalemia	O
.	O

Dengue	O
infection	O
and	O
hypokalemia	O
due	O
to	O
various	O
causes	O
are	O
the	O
most	O
common	O
causes	O
of	O
acute	O
myopathy	O
and	O
are	O
associated	O
with	O
rapid	O
and	O
complete	O
recovery	O
within	O
1	O
month	O
.	O

Shorter	O
duration	O
of	O
illness	O
,	O
higher	O
MRC	O
sum	O
score	O
,	O
better	O
disability	O
status	O
at	O
presentation	O
,	O
lower	O
serum	O
CK	O
correlate	O
with	O
better	O
outcome	O
.	O

Biopsy	B-P
was	O
decisive	O
in	O
<	O
20	O
%	O
cases	O
;	O
hence	O
,	O
it	O
is	O
not	O
primary	O
investigation	O
in	O
acute	O
myopathy	O
.	O

Long	O
Non-Coding	O
RNA	O
SNHG6	O
as	O
a	O
Potential	O
Biomarker	O
for	O
Hepatocellular	O
Carcinoma	O
.	O

Long	O
Non-coding	O
RNAs	O
(	O
lncRNAs	O
)	O
refer	O
to	O
all	O
non-protein	O
coding	O
transcripts	O
longer	O
than	O
200	O
nucleotides	O
.	O

Their	O
critical	O
roles	O
in	O
different	O
biological	O
pathways	O
have	O
been	O
already	O
well	O
established	O
.	O

Altered	O
expression	O
of	O
lncRNAs	O
can	O
be	O
involved	O
in	O
the	O
cancer	O
initiation	O
and/or	O
progression	O
.	O

Since	O
patients	O
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
are	O
usually	O
diagnosed	O
in	O
late	O
stages	O
,	O
developing	O
diagnostic	B-P
methods	I-P
seems	O
to	O
be	O
essential	O
.	O

In	O
this	O
study	O
,	O
the	O
expression	O
levels	O
of	O
different	O
lncRNAs	O
were	O
systematically	O
analysed	O
in	O
different	O
genomic	O
and	O
transcriptome	O
datasets	O
.	O

The	O
analyses	O
showed	O
that	O
SNHG6	O
is	O
among	O
the	O
lncRNAs	O
with	O
distinctive	O
dysregulation	O
of	O
expression	O
and	O
copy	O
number	O
variation	O
in	O
HCC	O
tumors	O
compared	O
with	O
normal	O
tissues	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	O
of	O
SNHG6	O
is	O
highly	O
cancer	O
type	O
specific	O
.	O

Through	O
co-occurrence	O
analyses	O
,	O
we	O
found	O
that	O
SNHG6	O
and	O
its	O
related	O
co-expressed	O
genes	O
on	O
8q	O
are	O
involved	O
in	O
the	O
structural	O
integrity	O
of	O
ribosome	O
and	O
translation	O
.	O

This	O
comprehensive	O
in	O
silico	O
analysis	O
,	O
provides	O
a	O
resource	O
for	O
investigating	O
SNHG6	O
in	O
hepatocellular	O
carcinoma	O
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
researches	O
.	O

Multimorbidity	O
in	O
Heart	O
Failure	O
:	O
Effect	O
on	O
Outcomes	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
the	O
number	O
and	O
type	O
of	O
comorbid	O
conditions	O
on	O
death	O
and	O
hospitalizations	O
in	O
individuals	O
with	O
incident	O
heart	O
failure	O
(	O
HF	O
)	O
.	O

Population-based	O
cohort	O
study	O
.	O

Olmsted	O
County	O
,	O
Minnesota	O
.	O

Olmsted	O
County	O
,	O
Minnesota	O
,	O
residents	O
with	O
incident	O
HF	O
from	O
2000	O
to	O
2010	O
(	O
mean	O
age	O
76	O
±	O
14	O
,	O
56	O
%	O
female	O
)	O
(	O
N	O
=	O
1,714	O
)	O
.	O

The	O
prevalence	O
of	O
16	O
chronic	O
conditions	O
obtained	O
at	O
HF	O
diagnosis	O
classified	O
into	O
three	O
groups	O
:	O
cardiovascular	O
(	O
CV	O
)	O
related	O
,	O
other	O
physical	O
,	O
and	O
mental	O
.	O

The	O
mean	O
number	O
of	O
conditions	O
per	O
participant	O
was	O
2.6	O
±	O
1.5	O
for	O
CV	O
-related	O
conditions	O
,	O
1.3	O
±	O
1.1	O
for	O
other	O
physical	O
conditions	O
,	O
and	O
0.30	O
±	O
0.61	O
for	O
mental	O
conditions	O
.	O

After	O
a	O
mean	O
follow-up	O
of	O
4.2	O
years	O
,	O
1,073	O
death	O
s	O
and	O
6,306	O
hospitalizations	O
had	O
occurred	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
ejection	B-P
fraction	I-P
,	O
in-	O
or	O
outpatient	O
status	O
,	O
and	O
number	O
of	O
other	O
conditions	O
,	O
an	O
increase	O
of	O
one	O
other	O
physical	O
condition	O
was	O
associated	O
with	O
a	O
14	O
%	O
(	O
HR	O
=	O
1.14	O
,	O
95	O
%	O
CI	O
=	O
1.08-1.20	O
)	O
greater	O
risk	O
of	O
death	O
and	O
a	O
26	O
%	O
(	O
HR	O
=	O
1.26	O
,	O
95	O
%	O
CI	O
=	O
1.20-1.32	O
)	O
greater	O
risk	O
of	O
hospitalization	O
,	O
and	O
an	O
increase	O
of	O
one	O
mental	O
condition	O
was	O
associated	O
with	O
a	O
31	O
%	O
(	O
HR	O
=	O
1.31	O
,	O
95	O
%	O
CI	O
=	O
1.19-1.44	O
)	O
greater	O
risk	O
of	O
death	O
and	O
an	O
18	O
%	O
(	O
HR	O
=	O
1.18	O
,	O
95	O
%	O
CI	O
=	O
1.07-1.29	O
)	O
greater	O
risk	O
of	O
hospitalization	O
.	O

In	O
contrast	O
,	O
an	O
increase	O
of	O
one	O
CV	O
-related	O
condition	O
was	O
not	O
associated	O
with	O
greater	O
risk	O
of	O
death	O
and	O
was	O
associated	O
with	O
a	O
10	O
%	O
(	O
HR	O
=	O
1.10	O
,	O
95	O
%	O
CI	O
=	O
1.06-1.15	O
)	O
greater	O
risk	O
of	O
hospitalization	O
.	O

CV	O
-related	O
conditions	O
are	O
the	O
most	O
common	O
type	O
of	O
comorbid	O
conditions	O
in	O
individuals	O
with	O
HF	O
,	O
but	O
other	O
physical	O
and	O
mental	O
conditions	O
are	O
more	O
strongly	O
associated	O
with	O
death	O
and	O
hospitalizations	O
.	O

This	O
underscores	O
the	O
effect	O
of	O
non-CV	O
conditions	O
on	O
outcomes	O
in	O
HF	O
.	O

Association	O
of	O
Albuminuria	O
With	O
Cardiac	O
Dysfunction	O
in	O
US	O
Hispanics	O
/	O
Latinos	O
.	O

Higher	O
urine	O
albumin-to-creatinine	O
ratio	O
(	O
UACR	O
)	O
has	O
been	O
associated	O
with	O
cardiac	O
dysfunction	O
in	O
the	O
general	O
population	O
.	O

We	O
assessed	O
the	O
association	O
of	O
UACR	O
with	O
cardiac	O
structure	O
and	O
function	O
in	O
the	O
Echocardiographic	O
Study	O
of	O
Latinos	O
(	O
Echo-SOL	O
)	O
,	O
an	O
ancillary	O
study	O
of	O
the	O
Hispanic	O
Community	O
Health	O
Study	O
/	O
Study	O
of	O
Latinos	O
across	O
4	O
US	O
sites	O
.	O

Echo-SOL	O
participants	O
underwent	O
standard	O
2-dimensional	B-P
echocardiography	I-P
,	O
including	O
speckle-tracking	B-P
strain	I-P
analysis	I-P
.	O

UACR	O
was	O
categorized	O
as	O
normal	O
and	O
high-normal	O
(	O
based	O
on	O
the	O
midpoint	O
of	O
values	O
below	O
microalbuminuria	O
)	O
,	O
microalbuminuria	O
(	O
≥17	O
mg/g	O
for	O
men	O
;	O
≥25	O
mg/g	O
for	O
women	O
)	O
,	O
and	O
macroalbuminuria	O
(	O
≥250	O
mg/g	O
;	O
≥355	O
mg/g	O
)	O
.	O

Simultaneous	O
assessments	O
were	O
made	O
of	O
left	O
ventricular	O
(	O
LV	O
)	O
mass	O
index	O
and	O
hypertrophy	O
and	O
measures	O
of	O
LV	O
systolic	O
and	O
diastolic	O
dysfunction	O
.	O

We	O
assessed	O
the	O
association	O
of	O
UACR	O
with	O
subclinical	B-P
cardiac	I-P
measures	I-P
,	O
adjusting	O
for	O
sociodemographic	O
and	O
cardiometabolic	O
factors	O
.	O

Among	O
1,815	O
participants	O
(	O
median	O
age	O
54	O
,	O
women	O
65	O
%	O
)	O
,	O
42	O
%	O
had	O
normal	O
UACR	O
,	O
43	O
%	O
high-normal	O
UACR	O
,	O
13	O
%	O
microalbuminuria	O
,	O
and	O
2	O
%	O
macroalbuminuria	O
.	O

Prevalence	O
of	O
LV	O
hypertrophy	O
was	O
13	O
%	O
,	O
LV	O
systolic	O
dysfunction	O
(	O
ejection	O
fraction	O
<	O
50	O
%	O
)	O
3	O
%	O
,	O
and	O
diastolic	O
dysfunction	O
53	O
%	O
.	O

After	O
covariate	O
adjustment	O
,	O
both	O
micro-	O
and	O
macroalbuminuria	O
were	O
significantly	O
associated	O
with	O
a	O
twofold	O
increase	O
in	O
LV	O
hypertrophy	O
.	O

Microalbuminuria	O
but	O
not	O
macroalbuminuria	O
was	O
associated	O
with	O
worse	O
global	O
longitudinal	O
strain	O
.	O

Elevated	O
UACR	O
,	O
even	O
at	O
high-normal	O
levels	O
,	O
was	O
significantly	O
associated	O
with	O
greater	O
diastolic	O
dysfunction	O
.	O

In	O
conclusion	O
,	O
elevated	O
UACR	O
was	O
associated	O
with	O
LV	O
hypertrophy	O
and	O
diastolic	O
dysfunction	O
in	O
the	O
largest	O
known	O
population	O
sample	O
of	O
US	O
Hispanic	O
/	O
Latinos	O
.	O

Screening	B-P
and	O
detection	O
of	O
even	O
high-normal	O
UACR	O
could	O
be	O
of	O
value	O
to	O
guide	O
cardiovascular	O
disease	O
prevention	O
efforts	O
among	O
Hispanic	O
/	O
Latino	O
Americans	O
.	O

Cerebral	O
toxoplasmosis	O
in	O
patients	O
with	O
acquired	O
immune	O
deficiency	O
syndrome	O
in	O
the	O
neurological	O
emergency	O
department	O
of	O
a	O
tertiary	O
hospital	O
.	O

Cerebral	O
toxoplasmosis	O
is	O
the	O
most	O
common	O
cause	O
of	O
space	O
occupying	O
brain	O
lesion	O
in	O
patients	O
with	O
HIV/AIDS	O
in	O
Brazil	O
.	O

In	O
the	O
post-HAART	O
era	O
,	O
it	O
is	O
responsible	O
for	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

This	O
study	O
consists	O
of	O
a	O
case	O
series	O
of	O
56	O
patients	O
diagnosed	O
with	O
cerebral	O
toxoplasmosis	O
whose	O
clinical	O
features	O
,	O
brain	B-P
imaging	I-P
and	O
cerebrospinal	O
fluid	O
aspects	O
were	O
analyzed	O
.	O

Cerebral	O
toxoplasmosis	O
led	O
to	O
the	O
diagnosis	O
of	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
in	O
27	O
(	O
48.2	O
%	O
)	O
of	O
the	O
patients	O
,	O
while	O
29	O
(	O
51.2	O
%	O
)	O
others	O
already	O
knew	O
to	O
be	O
HIV	O
seropositive	O
.	O

However	O
,	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
cerebral	O
toxoplasmosis	O
,	O
only	O
9	O
(	O
16.6	O
%	O
)	O
reported	O
being	O
under	O
antiretroviral	O
therapy	O
and	O
5	O
(	O
8.9	O
%	O
)	O
were	O
receiving	O
primary	O
prophylaxis	O
for	O
toxoplasmosis	O
.	O

Headache	O
,	O
strength	O
deficit	O
and	O
fever	O
were	O
the	O
most	O
frequent	O
signs	O
and	O
symptoms	O
throughout	O
the	O
study	O
.	O

Fifty-three	O
patients	O
showed	O
changes	O
consistent	O
with	O
toxoplasmosis	O
in	O
CT	B-P
or	O
MRI	B-P
.	O

Thirty-four	O
(	O
60.7	O
%	O
)	O
CSF	O
samples	O
were	O
positive	O
in	O
the	O
indirect	O
haemagglutination	O
test	O
and	O
for	O
the	O
reaction	O
of	O
Toxoplasma	O
gondii	O
IgG	O
ELISA	O
,	O
while	O
31	O
(	O
55.4	O
%	O
)	O
were	O
positive	O
in	O
the	O
direct	O
haemagglutination	O
test	O
.	O

Fifty	O
(	O
89.3	O
%	O
)	O
patients	O
underwent	O
first-line	O
treatment	O
for	O
toxoplasmosis	O
.	O

Cerebral	O
toxoplasmosis	O
is	O
still	O
a	O
very	O
relevant	O
neurological	O
disease	O
in	O
individuals	O
with	O
AIDS	O
admitted	O
to	O
neurology	O
emergency	O
departments	O
.	O

Early	B-P
diagnosis	I-P
and	O
initiation	O
of	O
empiric	O
treatment	O
and	O
antiretroviral	O
therapy	O
are	O
important	O
for	O
good	O
prognosis	O
.	O

Assessment	O
of	O
periodontal	O
bone	O
level	O
revisited	O
:	O
a	O
controlled	O
study	O
on	O
the	O
diagnostic	O
accuracy	O
of	O
clinical	O
evaluation	O
methods	O
and	O
intra-oral	B-P
radiography	I-P
.	O

The	O
accuracy	O
of	O
analogue	B-P
and	O
especially	O
digital	B-P
intra-oral	I-P
radiography	I-P
in	O
assessing	O
interdental	O
bone	O
level	O
needs	O
further	O
documentation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
clinical	O
and	O
radiographic	B-P
bone	O
level	O
assessment	O
to	O
intra-surgical	O
bone	O
level	O
registration	O
(	O
1	O
)	O
and	O
to	O
identify	O
the	O
clinical	O
variables	O
rendering	O
interdental	O
bone	O
level	O
assessment	O
inaccurate	O
(	O
2	O
)	O
.	O

The	O
study	O
sample	O
included	O
49	O
interdental	O
sites	O
in	O
17	O
periodontitis	O
patients	O
.	O

Evaluation	O
methods	O
included	O
vertical	O
relative	O
probing	O
attachment	O
level	O
(	O
RAL-V	O
)	O
,	O
analogue	B-P
and	O
digital	B-P
intra-oral	I-P
radiography	I-P
and	O
bone	B-P
sounding	I-P
without	O
and	O
with	O
flap	O
elevation	O
.	O

The	O
latter	O
was	O
considered	O
the	O
true	O
bone	O
level	O
.	O

Five	O
examiners	O
evaluated	O
all	O
radiographs	B-P
.	O

Significant	O
underestimation	O
of	O
the	O
true	O
bone	O
level	O
was	O
observed	O
for	O
all	O
evaluation	O
methods	O
pointing	O
to	O
2.7	O
mm	O
on	O
average	O
for	O
analogue	B-P
radiography	I-P
,	O
2.5	O
mm	O
for	O
digital	B-P
radiography	I-P
,	O
1.8	O
mm	O
for	O
RAL-V	O
and	O
0.6	O
mm	O
for	O
bone	B-P
sounding	I-P
without	O
flap	O
elevation	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Radiographic	B-P
underestimation	O
of	O
the	O
true	O
bone	O
level	O
was	O
higher	O
in	O
the	O
(	O
pre	O
)	O
molar	O
region	O
(	O
p	O
≤	O
0.047	O
)	O
and	O
increased	O
with	O
defect	O
depth	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Variation	O
between	O
clinicians	O
was	O
huge	O
(	O
range	O
analogue	B-P
radiography	I-P
2.2-3.2	O
mm	O
;	O
range	O
digital	B-P
radiography	I-P
2.1-3.0	O
mm	O
)	O
.	O

All	O
evaluation	O
methods	O
significantly	O
underestimated	O
the	O
true	O
bone	O
level	O
.	O

Bone	B-P
sounding	I-P
was	O
most	O
accurate	O
,	O
whereas	O
intra-oral	B-P
radiographs	I-P
were	O
least	O
accurate	O
.	O

Deep	O
periodontal	O
defects	O
in	O
the	O
(	O
pre	O
)	O
molar	O
region	O
were	O
most	O
underrated	O
by	O
intra-oral	B-P
radiography	I-P
.	O

Bone	B-P
sounding	I-P
had	O
the	O
highest	O
accuracy	O
in	O
assessing	O
interdental	O
bone	O
level	O
.	O

Energy	O
Expenditure	O
and	O
Intensity	O
of	O
Classroom	O
Physical	O
Activity	O
in	O
Elementary	O
School	O
Children	O
.	O

There	O
is	O
limited	O
data	O
regarding	O
objectively	O
measured	O
energy	O
cost	O
and	O
intensity	O
of	O
classroom	O
instruction	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
current	O
study	O
was	O
to	O
objectively	O
measure	O
energy	O
cost	O
and	O
subsequently	O
calculate	O
MET	B-P
values	I-P
using	O
a	O
portable	O
indirect	O
calorimeter	O
(	O
IC	O
)	O
for	O
both	O
normal	O
classroom	O
instruction	O
(	O
NCI	O
)	O
and	O
active	O
classroom	O
instruction	O
(	O
ACI	O
)	O
.	O

We	O
assessed	O
energy	O
expenditure	O
(	O
EE	O
)	O
and	O
intensity	O
levels	O
(	O
METs	B-P
)	O
in	O
elementary	O
school	O
children	O
(	O
17	O
boys	O
and	O
15	O
girls	O
)	O
using	O
an	O
IC	O
(	O
COSMED	O
K4b2	O
)	O
.	O

Independent	O
t-tests	O
were	O
used	O
to	O
evaluate	O
potential	O
sex	O
and	O
grade	O
level	O
differences	O
for	O
age	O
,	O
BMI	O
,	O
VO2	B-P
,	O
EE	O
,	O
and	O
METs	B-P
.	O

The	O
average	O
EE	O
for	O
NCI	O
and	O
ACI	O
were	O
1.8	O
±	O
0.4	O
and	O
3.9	O
±	O
1.0	O
,	O
respectively	O
.	O

The	O
average	O
intensity	O
level	O
for	O
NCI	O
and	O
ACI	O
were	O
1.9	O
±	O
0.4	O
and	O
4.2	O
±	O
0.9	O
METs	B-P
,	O
respectively	O
.	O

PA	O
delivered	O
through	O
ACI	O
can	O
elicit	O
EE	O
at	O
a	O
moderate	O
intensity	O
level	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
ACI	O
as	O
a	O
convenient/feasible	O
avenue	O
for	O
increasing	O
PA	O
in	O
youth	O
without	O
decreasing	O
instruction	O
time	O
.	O

Inhibition	O
of	O
Sebum	O
Production	O
with	O
the	O
Acetyl	O
Coenzyme	O
A	O
Carboxylase	O
Inhibitor	O
Olumacostat	O
Glasaretil	O
.	O

Olumacostat	O
glasaretil	O
(	O
OG	O
)	O
is	O
a	O
small	O
molecule	O
inhibitor	O
of	O
acetyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
carboxylase	O
(	O
ACC	O
)	O
,	O
the	O
enzyme	O
that	O
controls	O
the	O
first	O
rate-limiting	O
step	O
in	O
fatty	O
acid	O
biosynthesis	O
.	O

Inhibition	O
of	O
ACC	O
activity	O
in	O
the	O
sebaceous	O
glands	O
is	O
designed	O
to	O
substantially	O
affect	O
sebum	O
production	O
,	O
because	O
over	O
80	O
%	O
of	O
human	O
sebum	O
components	O
contain	O
fatty	O
acids	O
.	O

OG	O
inhibits	O
de	O
novo	O
lipid	O
synthesis	O
in	O
primary	O
and	O
transformed	O
human	O
sebocytes	O
.	O

TrueMass	O
Sebum	O
Panel	O
analyses	O
showed	O
a	O
reduction	O
in	O
saturated	O
and	O
monounsaturated	O
fatty	O
acyl	O
chains	O
across	O
lipid	O
species	O
,	O
including	O
di-	O
and	O
triacylglycerols	O
,	O
phospholipids	O
,	O
cholesteryl	O
esters	O
,	O
and	O
wax	O
esters	O
in	O
OG	O
-	O
treated	O
sebocytes	O
.	O

There	O
was	O
no	O
shift	O
to	O
shorter	O
acyl	O
chain	O
lengths	O
observed	O
,	O
suggesting	O
that	O
the	O
fatty	O
acid	O
chain	O
elongation	O
process	O
was	O
not	O
affected	O
.	O

OG	O
is	O
a	O
pro-drug	O
of	O
the	O
ACC	O
inhibitor	O
5-	O
(	O
tetradecyloxy	O
)	O
-2-furoic	O
acid	O
and	O
was	O
designed	O
to	O
enhance	O
delivery	O
in	O
vivo	O
.	O

Topical	O
application	O
of	O
OG	O
but	O
not	O
5-	O
(	O
tetradecyloxy	O
)	O
-2-furoic	O
acid	O
significantly	O
reduced	O
hamster	O
ear	O
sebaceous	O
gland	O
size	O
,	O
indicating	O
that	O
this	O
pro-drug	O
approach	O
was	O
critical	O
to	O
obtain	O
the	O
desired	O
activity	O
in	O
vivo	O
.	O

High-performance	O
liquid	O
chromatography	O
analyses	O
of	O
hamster	O
ear	O
extracts	O
showed	O
that	O
OG	O
treatment	O
increased	O
ACC	O
levels	O
and	O
the	O
ratio	O
of	O
acetyl-CoA	O
to	O
free	O
CoA	O
in	O
these	O
animals	O
,	O
indicating	O
increased	O
fatty	O
acid	O
oxidation	O
.	O

These	O
changes	O
are	O
consistent	O
with	O
ACC	O
inhibition	O
.	O

Matrix-assisted	O
laser	O
desorption/ionization	O
imaging	B-P
showed	O
that	O
OG	O
applied	O
onto	O
Yorkshire	O
pig	O
ears	O
accumulated	O
in	O
sebaceous	O
glands	O
relative	O
to	O
the	O
surrounding	O
dermis	O
.	O

Sebaceous	O
gland	O
ACC	O
represents	O
an	O
attractive	O
therapeutic	O
target	O
given	O
its	O
central	O
role	O
in	O
formation	O
of	O
sebum	O
,	O
a	O
key	O
factor	O
in	O
acne	O
pathogenesis	O
.	O

Prevalence	O
of	O
high	O
fractional	O
exhaled	O
nitric	O
oxide	O
among	O
US	O
youth	O
with	O
asthma	O
.	O

High	O
fractional	O
exhaled	O
nitric	O
oxide	O
(	O
FeNO	O
)	O
is	O
an	O
indicator	O
of	O
poor	O
asthma	O
control	O
and	O
has	O
been	O
proposed	O
as	O
a	O
non-invasive	O
assessment	O
tool	O
to	O
guide	O
asthma	O
management	O
.	O

We	O
aimed	O
to	O
describe	O
the	O
prevalence	O
of	O
and	O
factors	O
associated	O
with	O
high	O
FeNO	O
among	O
US	O
youth	O
with	O
asthma	O
.	O

Data	O
from	O
716	O
children	O
and	O
adolescents	O
with	O
asthma	O
ages	O
6-19	O
years	O
who	O
participated	O
in	O
the	O
2007-2012	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
were	O
analyzed	O
.	O

Using	O
American	O
Thoracic	O
Society	O
guidelines	O
,	O
high	O
FeNO	O
was	O
defined	O
as	O
>	O
50	O
ppb	O
for	O
ages	O
12-19	O
years	O
and	O
>	O
35	O
ppb	O
for	O
ages	O
6-11	O
years	O
.	O

Multivariate	O
logistic	O
regression	O
examined	O
associations	O
between	O
high	O
FeNO	O
and	O
age	O
,	O
sex	O
,	O
race	O
/	O
Hispanic	O
origin	O
,	O
income	O
status	O
,	O
weight	O
status	O
,	O
tobacco	O
smoke	O
exposure	O
,	O
and	O
other	O
factors	O
associated	O
with	O
asthma	O
control	O
(	O
recent	O
use	O
of	O
inhaled	O
corticosteroids	O
,	O
recent	O
respiratory	O
illness	O
,	O
asthma	O
-related	O
respiratory	O
signs/symptoms	O
,	O
and	O
spirometry	B-P
)	O
.	O

About	O
16.5	O
%	O
of	O
youth	O
with	O
asthma	O
had	O
high	O
FeNO	O
.	O

The	O
prevalence	O
of	O
high	O
FeNO	O
was	O
higher	O
among	O
non-Hispanic	O
black	O
(	O
27	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
Hispanic	O
(	O
20.2	O
%	O
,	O
P	O
=	O
0.002	O
)	O
youth	O
than	O
non-Hispanic	O
white	O
(	O
9.7	O
%	O
)	O
youth	O
.	O

Differences	O
in	O
high	O
FeNO	O
prevalence	O
by	O
sex	O
(	O
girls	O
<	O
boys	O
)	O
,	O
weight	O
status	O
(	O
obese	O
<	O
normal	O
weight	O
)	O
,	O
tobacco	O
smoke	O
exposure	O
(	O
smokers	O
<	O
home	O
exposure	O
<	O
no	O
exposure	O
)	O
,	O
and	O
FEV1/FVC	O
(	O
normal	O
<	O
abnormal	O
)	O
were	O
also	O
observed	O
.	O

No	O
differences	O
were	O
noted	O
between	O
categories	O
for	O
the	O
remaining	O
covariates	O
.	O

High	O
FeNO	O
was	O
observed	O
to	O
be	O
associated	O
with	O
sex	O
,	O
race	O
/	O
Hispanic	O
origin	O
,	O
weight	O
status	O
,	O
tobacco	O
smoke	O
exposure	O
,	O
and	O
abnormal	O
FEV1/FVC	O
,	O
but	O
was	O
not	O
associated	O
with	O
asthma	O
-related	O
respiratory	O
symptoms	O
.	O

These	O
findings	O
may	O
help	O
inform	O
future	O
research	O
and	O
clinical	O
practice	O
guidelines	O
on	O
the	O
use	O
of	O
high	O
FeNO	O
in	O
the	O
assessment	O
of	O
asthma	O
control	O
.	O

A	O
Patient	O
Registry	O
to	O
Improve	O
Patient	O
Safety	O
:	O
Recording	O
General	O
Neurosurgery	O
Complications	O
.	O

To	O
improve	O
the	O
transparency	O
of	O
the	O
local	O
health	O
care	O
system	O
,	O
treatment	O
cost	O
was	O
recently	O
referenced	O
to	O
disease	O
related	O
groups	O
.	O

Treatment	O
quality	O
must	O
be	O
legally	O
documented	O
in	O
a	O
patient	O
registry	O
,	O
in	O
particular	O
for	O
the	O
highly	O
specialized	O
treatments	O
provided	O
by	O
neurosurgery	O
departments	O
.	O

In	O
2013	O
we	O
have	O
installed	O
a	O
patient	O
registry	O
focused	O
on	O
cranial	O
neurosurgery	O
.	O

Surgeries	O
are	O
characterized	O
by	O
indication	O
,	O
treatment	O
,	O
location	O
and	O
other	O
specific	O
neurosurgical	O
parameters	O
.	O

Preoperative	O
state	O
and	O
postoperative	O
outcome	O
are	O
recorded	O
prospectively	O
using	O
neurological	O
and	O
sociological	O
scales	O
.	O

Complications	O
are	O
graded	O
by	O
their	O
severity	O
in	O
a	O
therapy-oriented	O
complication	O
score	O
system	O
(	O
Clavien-Dindo-Grading	O
system	O
,	O
CDG	O
)	O
.	O

Results	O
are	O
presented	O
at	O
the	O
monthly	O
clinical	O
staff	O
meeting	O
.	O

Data	O
acquisition	O
compatible	O
with	O
the	O
clinic	O
workflow	O
permitted	O
to	O
include	O
all	O
eligible	O
patients	O
into	O
the	O
registry	O
.	O

Until	O
December	O
2015	O
,	O
we	O
have	O
registered	O
2880	O
patients	O
that	O
were	O
treated	O
in	O
3959	O
surgeries	O
and	O
8528	O
consultations	O
.	O

Since	O
the	O
registry	O
is	O
fully	O
operational	O
(	O
August	O
2014	O
)	O
,	O
we	O
have	O
registered	O
325	O
complications	O
on	O
1341	O
patient	O
discharge	O
forms	O
(	O
24	O
%	O
)	O
.	O

In	O
64	O
%	O
of	O
these	O
complications	O
,	O
no	O
or	O
only	O
pharmacological	O
treatment	O
was	O
required	O
.	O

At	O
discharge	O
,	O
there	O
was	O
a	O
clear	O
correlation	O
of	O
the	O
severity	O
of	O
the	O
complication	O
and	O
the	O
Karnofsky	B-P
Performance	I-P
Status	I-P
(	O
KPS	B-P
,	O
ρ	O
=	O
-0.3	O
,	O
slope	O
-6	O
KPS	B-P
percentage	O
points	O
per	O
increment	O
of	O
CDG	O
)	O
and	O
the	O
length	O
of	O
stay	O
(	O
ρ	O
=	O
0.4	O
,	O
slope	O
1.5	O
days	O
per	O
increment	O
of	O
CDG	O
)	O
.	O

While	O
the	O
therapy-oriented	O
complication	O
scores	O
correlate	O
reasonably	O
well	O
with	O
outcome	O
and	O
length	O
of	O
stay	O
,	O
they	O
do	O
not	O
account	O
for	O
new	O
deficits	O
that	O
can	O
not	O
be	O
treated	O
.	O

Outcome	O
grading	O
and	O
complication	O
severity	O
grading	O
thus	O
serve	O
a	O
complimentary	O
purpose	O
.	O

Overall	O
,	O
the	O
registry	O
serves	O
to	O
streamline	O
and	O
to	O
complete	O
information	O
flow	O
in	O
the	O
clinic	O
,	O
to	O
identify	O
complication	O
rates	O
and	O
trends	O
early	O
for	O
the	O
internal	O
quality	O
monitoring	O
and	O
communication	O
with	O
patients	O
.	O

Conversely	O
,	O
the	O
registry	O
influences	O
clinical	O
practice	O
in	O
that	O
it	O
demands	O
rigorous	O
documentation	O
and	O
standard	O
operating	O
procedures	O
.	O

Role	O
of	O
vision	O
in	O
sighted	O
and	O
blind	O
soccer	O
players	O
in	O
adapting	O
to	O
an	O
unstable	O
balance	B-P
task	I-P
.	O

This	O
study	O
tested	O
whether	O
a	O
compensatory	O
hypothesis	O
exists	O
on	O
postural	O
control	O
during	O
standing	O
unstable	O
balance	B-P
tasks	I-P
comparing	O
blind	O
soccer	O
players	O
(	O
n	O
=	O
7	O
)	O
to	O
sighted	O
soccer	O
players	O
(	O
n	O
=	O
15	O
)	O
and	O
sighted	O
sedentary	O
individuals	O
(	O
n	O
=	O
6	O
)	O
.	O

All	O
subjects	O
performed	O
a	O
pre	O
-	O
test	B-P
,	O
a	O
training	O
of	O
ten	O
practice	O
trials	O
on	O
a	O
single	O
day	O
,	O
and	O
a	O
post	O
-	O
test	B-P
balance	B-P
test	I-P
.	O

All	O
tests	B-P
were	O
performed	O
on	O
an	O
unstable	O
surface	O
placed	O
on	O
a	O
force	O
platform	O
and	O
under	O
closed-eyes	O
conditions	O
,	O
and	O
a	O
final	O
test	B-P
was	O
performed	O
with	O
open	O
eyes	O
.	O

Balance	O
performance	O
was	O
assessed	O
by	O
resultant	O
distance	O
(	O
RD	O
)	O
and	O
the	O
magnitude	O
of	O
mean	O
velocity	O
(	O
MV	O
)	O
of	O
the	O
centre	O
of	O
pressure	O
(	O
CoP	O
)	O
displacement	O
,	O
and	O
EMG	B-P
signals	O
from	O
the	O
gastrocnemius	O
lateralis	O
,	O
tibialis	O
anterior	O
,	O
rectus	O
femoris	O
,	O
and	O
peroneus	O
longus	O
were	O
measured	O
with	O
surface	B-P
electromyography	I-P
.	O

Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
on	O
EMG	B-P
muscular	O
activation	O
was	O
used	O
to	O
assess	O
EMG	O
pattern	O
differences	O
during	O
the	O
balance	B-P
tasks	I-P
.	O

All	O
groups	O
improved	O
their	O
performance	O
,	O
obtaining	O
low	O
scores	O
for	O
the	O
closed-eyes	O
condition	O
balance	B-P
task	I-P
after	O
the	O
training	O
period	O
in	O
RD	O
,	O
VM	O
,	O
and	O
aids	O
received	O
to	O
keep	O
balance	O
in	O
the	O
novel	O
task	O
,	O
and	O
no	O
differences	O
were	O
found	O
between	O
groups	O
or	O
in	O
interaction	O
effects	O
.	O

Sighted	O
individuals	O
and	O
the	O
control	O
group	O
showed	O
significantly	O
lower	O
RD	O
and	O
VM	O
scores	O
under	O
open-eyes	O
conditions	O
than	O
blind	O
participants	O
.	O

As	O
regards	O
neuromuscular	O
behaviour	O
,	O
three	O
principal	O
patterns	O
explained	O
84.15	O
%	O
of	O
the	O
variability	O
in	O
the	O
measured	O
data	O
.	O

The	O
theoretical	O
improvement	O
of	O
the	O
other	O
senses	O
caused	O
by	O
visual	O
deprivation	O
does	O
not	O
allow	O
blind	O
individuals	O
to	O
obtain	O
better	O
balance	O
than	O
sighted	O
individuals	O
under	O
closed-eyes	O
conditions	O
,	O
thereby	O
reinforcing	O
the	O
prominent	O
role	O
of	O
vision	O
in	O
integrating	O
and	O
processing	O
the	O
other	O
sensory	O
inputs	O
.	O

In	O
addition	O
,	O
blind	O
individuals	O
seem	O
to	O
increase	O
their	O
muscular	O
co-activation	O
as	O
a	O
safety	O
strategy	O
,	O
but	O
this	O
behaviour	O
is	O
not	O
different	O
to	O
that	O
shown	O
by	O
sighted	O
people	O
under	O
closed-eyes	O
conditions	O
.	O

Fully	O
Automated	O
Lipid	O
Pool	O
Detection	O
Using	O
Near	O
Infrared	O
Spectroscopy	O
.	O

Background	O
.	O

Detecting	O
and	O
identifying	O
vulnerable	O
plaque	O
,	O
which	O
is	O
prone	O
to	O
rupture	O
,	O
is	O
still	O
a	O
challenge	O
for	O
cardiologist	O
.	O

Such	O
lipid	O
core	O
-containing	O
plaque	O
is	O
still	O
not	O
identifiable	O
by	O
everyday	O
angiography	B-P
,	O
thus	O
triggering	O
the	O
need	O
to	O
develop	O
a	O
new	O
tool	O
where	O
NIRS	O
-	O
IVUS	B-P
can	O
visualize	O
plaque	O
characterization	O
in	O
terms	O
of	O
its	O
chemical	O
and	O
morphologic	O
characteristic	O
.	O

The	O
new	O
tool	O
can	O
lead	O
to	O
the	O
development	O
of	O
new	O
methods	O
of	O
interpreting	O
the	O
newly	O
obtained	O
data	O
.	O

In	O
this	O
study	O
,	O
the	O
algorithm	O
to	O
fully	O
automated	O
lipid	O
pool	O
detection	O
on	O
NIRS	O
images	O
is	O
proposed	O
.	O

Method	O
.	O

Designed	O
algorithm	O
is	O
divided	O
into	O
four	O
stages	O
:	O
preprocessing	O
(	O
image	O
enhancement	O
)	O
,	O
segmentation	O
of	O
artifacts	O
,	O
detection	O
of	O
lipid	O
areas	O
,	O
and	O
calculation	O
of	O
Lipid	O
Core	O
Burden	O
Index	O
.	O

Results	O
.	O

A	O
total	O
of	O
31	O
NIRS	O
chemograms	O
were	O
analyzed	O
by	O
two	O
methods	O
.	O

The	O
metrics	O
,	O
total	O
LCBI	O
,	O
maximal	O
LCBI	O
in	O
4	O
mm	O
blocks	O
,	O
and	O
maximal	O
LCBI	O
in	O
2	O
mm	O
blocks	O
,	O
were	O
calculated	O
to	O
compare	O
presented	O
algorithm	O
with	O
commercial	O
available	O
system	O
.	O

Both	O
intraclass	O
correlation	O
(	O
ICC	O
)	O
and	O
Bland-Altman	O
plots	O
showed	O
good	O
agreement	O
and	O
correlation	O
between	O
used	O
methods	O
.	O

Conclusions	O
.	O

Proposed	O
algorithm	O
is	O
fully	O
automated	O
lipid	O
pool	O
detection	O
on	O
near	O
infrared	O
spectroscopy	O
images	O
.	O

It	O
is	O
a	O
tool	O
developed	O
for	O
offline	O
data	O
analysis	O
,	O
which	O
could	O
be	O
easily	O
augmented	O
for	O
newer	O
functions	O
and	O
projects	O
.	O

Establishing	O
a	O
reference	O
interval	O
for	O
serum	O
anti-dsDNA	O
antibody	O
:	O
A	O
large	O
Chinese	O
Han	O
population	O
-based	O
multi-center	O
study	O
.	O

A	O
reference	O
interval	O
(	O
RI	O
)	O
for	O
the	O
circulating	O
concentration	O
of	O
anti-dsDNA	O
antibody	O
is	O
essential	O
for	O
clinicians	O
to	O
interpret	O
laboratory	O
results	O
and	O
make	B-P
clinical	I-P
decisions	I-P
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
establish	O
the	O
RI	O
for	O
anti-dsDNA	O
antibody	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

This	O
study	O
was	O
designed	O
and	O
carried	O
out	O
in	O
accordance	O
with	O
guideline	O
C28-A3	O
,	O
which	O
is	O
proposed	O
by	O
the	O
International	O
Federation	O
of	O
Clinical	O
Chemistry	O
and	O
the	O
Clinical	O
and	O
Laboratory	O
Standards	O
Institute	O
.	O

A	O
total	O
of	O
2,880	O
apparently	O
healthy	O
individuals	O
were	O
enrolled	O
using	O
a	O
posteriori	O
sampling	O
.	O

These	O
individuals	O
were	O
recruited	O
from	O
four	O
hospitals	O
,	O
representing	O
the	O
Han	O
populations	O
of	O
north	O
,	O
south	O
,	O
east	O
,	O
and	O
west	O
China	O
.	O

Serum	O
anti-dsDNA	O
antibody	O
levels	O
were	O
measured	O
using	O
the	O
three	O
analytical	O
systems	O
AESKU	O
,	O
EUROIMMUNE	O
,	O
and	O
INOVA	O
,	O
which	O
are	O
the	O
most	O
commonly	O
used	O
systems	O
in	O
China	O
.	O

Individuals	O
were	O
stratified	O
by	O
gender	O
,	O
age	O
,	O
and	O
region	O
,	O
and	O
the	O
RIs	O
were	O
obtained	O
by	O
nonparametric	O
methods	O
.	O

Gender	O
-specific	O
RIs	O
for	O
serum	O
anti-dsDNA	O
antibody	O
in	O
the	O
Chinese	O
Han	O
population	O
were	O
established	O
.	O

This	O
is	O
the	O
first	O
exploration	O
of	O
the	O
RI	O
for	O
anti-dsDNA	O
antibody	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

We	O
have	O
established	O
gender	O
-specific	O
RIs	O
for	O
each	O
assay	O
method	O
commonly	O
used	O
in	O
China	O
.	O

Primary	O
pituitary	O
diffuse	O
large	O
B-cell	O
lymphoma	O
with	O
somatotroph	O
hyperplasia	O
and	O
acromegaly	O
:	O
case	O
report	O
.	O

Diffuse	O
large	O
B-cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
the	O
most	O
common	O
type	O
of	O
non-Hodgkin	O
lymphoma	O
and	O
comprises	O
approximately	O
30	O
%	O
of	O
all	O
lymphomas	O
.	O

Patients	O
typically	O
present	O
with	O
a	O
nonpainful	O
mass	O
in	O
the	O
neck	O
,	O
groin	O
,	O
or	O
abdomen	O
associated	O
with	O
constitutional	O
symptoms	O
.	O

In	O
this	O
report	O
,	O
however	O
,	O
the	O
authors	O
describe	O
a	O
rare	O
case	O
of	O
a	O
61-	O
year	O
-old	O
woman	O
with	O
hyperprolactinemia	O
,	O
hypothyroidism	O
,	O
and	O
acromegaly	O
(	O
elevation	O
of	O
insulin-like	O
growth	O
factor-1	O
[	O
IGF-1	O
]	O
)	O
with	O
elevated	O
growth	O
hormone-releasing	O
hormone	O
(	O
GHRH	O
)	O
in	O
whom	O
an	O
MRI	B-P
demonstrated	O
diffuse	O
enlargement	O
of	O
the	O
pituitary	O
gland	O
.	O

Despite	O
medical	O
treatment	O
,	O
the	O
patient	O
had	O
persistent	O
elevation	O
of	O
IGF-1	O
.	O

She	O
underwent	O
a	O
transsphenoidal	B-P
biopsy	I-P
,	O
which	O
yielded	O
a	O
diagnosis	O
of	O
DLBCL	O
with	O
an	O
activated	O
B-cell	O
immunophenotype	O
with	O
somatotroph	O
hyperplasia	O
.	O

After	O
stereo-tactic	O
radiation	O
therapy	O
in	O
combination	O
with	O
chemotherapy	O
,	O
she	O
is	O
currently	O
in	O
remission	O
from	O
her	O
lymphoma	O
and	O
has	O
normalized	O
IGF-1	O
levels	O
without	O
medical	O
therapy	O
,	O
8	O
months	O
after	O
her	O
histopathological	O
diagnosis	O
.	O

This	O
is	O
the	O
only	O
reported	O
case	O
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential	B-P
diagnosis	I-P
,	O
multidisciplinary	B-P
evaluation	I-P
,	O
and	O
critical	O
intraoperative	O
decision-making	O
when	O
treating	O
atypical	O
sellar	O
lesions	O
.	O

Comparison	O
of	O
270	O
Versus	O
320	O
mg	O
I/mL	O
of	O
Iodixanol	O
in	O
1	O
Image	O
Assessment	O
of	O
Both	O
Renal	O
Arteries	O
and	O
Veins	O
With	O
Dual-Energy	B-P
Spectral	I-P
CT	I-P
Imaging	I-P
in	O
Late	O
Arterial	O
Phase	O
and	O
Their	O
Influence	O
on	O
Renal	O
Function	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
image	O
quality	O
of	O
renal	O
arteries	O
and	O
veins	O
with	O
dual-energy	B-P
spectral	I-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
imaging	I-P
in	O
late	O
arterial	O
phase	O
using	O
270	O
and	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
and	O
their	O
influence	O
on	O
renal	O
function	O
.	O

A	O
total	O
of	O
1062	O
patients	O
underwent	O
renal	B-P
CT	I-P
angiography	I-P
with	O
270	O
or	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
with	O
dual-energy	B-P
spectral	I-P
CT	I-P
imaging	I-P
in	O
late	O
arterial	O
phase	O
.	O

Image	O
quality	O
and	O
their	O
influence	O
on	O
renal	O
function	O
were	O
compared	O
.	O

There	O
were	O
no	O
significant	O
differences	O
of	O
CT	O
value	O
,	O
signal-to-noise	O
ratio	O
,	O
contrast-to-noise	O
ratio	O
,	O
and	O
subjective	O
score	O
of	O
renal	O
vessels	O
between	O
2	O
groups	O
(	O
all	O
P	O
>	O
0.05	O
)	O
.	O

The	O
incidence	O
of	O
contrast-induced	O
nephropathy	O
in	O
patients	O
with	O
abnormal	O
renal	O
function	O
using	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
was	O
significantly	O
higher	O
than	O
using	O
270	O
mg	O
I/mL	O
of	O
iodixanol	O
(	O
P	O
=	O
0.043	O
)	O
.	O

The	O
renal	O
arteries	O
and	O
veins	O
can	O
be	O
fully	O
assessed	O
in	O
late	O
arterial	O
phase	O
with	O
270	O
mg	O
I/mL	O
of	O
iodixanol	O
using	O
dual-energy	B-P
spectral	I-P
CT	I-P
scan	I-P
with	O
better	O
preserved	O
renal	O
function	O
.	O

Dysplasia	O
discrimination	O
in	O
intestinal	O
-	O
type	O
neoplasia	O
of	O
the	O
esophagus	O
and	O
colon	O
via	O
digital	B-P
image	I-P
analysis	I-P
.	O

Determining	O
gastrointestinal	O
tract	O
dysplasia	O
level	O
is	O
clinically	O
important	O
but	O
can	O
be	O
difficult	O
,	O
and	O
given	O
this	O
challenge	O
,	O
we	O
investigated	O
colonic	O
and	O
esophageal	O
dysplastic	O
progression	O
using	O
digital	B-P
image	I-P
analysis	I-P
(	O
IA	B-P
)	O
.	O

Whole	O
slide	O
images	O
were	O
obtained	O
for	O
colonic	O
normal	O
mucosa	O
(	O
NCM	O
)	O
,	O
hyperplastic	O
polyps	O
(	O
HP	O
)	O
,	O
conventional	O
tubular	O
adenomas	O
(	O
TA	O
)	O
,	O
and	O
adenomas	O
with	O
high-grade	O
dysplasia	O
(	O
HGD	O
)	O
,	O
and	O
esophageal	O
intestinal	O
metaplasia	O
negative	O
for	O
dysplasia	O
(	O
IM	O
)	O
,	O
indefinite	O
for	O
dysplasia	O
(	O
IFD	O
)	O
,	O
low-grade	O
dysplasia	O
(	O
LGD	O
)	O
,	O
and	O
HGD	O
.	O

Characteristic	O
nuclei	O
were	O
circumscribed	O
,	O
and	O
parameters	O
discriminating	O
groups	O
included	O
nuclear	O
circumference	O
(	O
μm	O
)	O
,	O
area	O
(	O
μm	O
(	O
2	O
)	O
)	O
,	O
and	O
15	O
positive	O
pixel	O
count	O
(	O
PPC	O
)	O
algorithm	O
IA	O
measurements	O
.	O

In	O
colon	O
polyps	O
and	O
esophageal	O
lesions	O
,	O
average	O
nuclear	O
area	O
and	O
circumference	O
ranged	O
30-108.6	O
μm	O
(	O
2	O
)	O
and	O
27.5-48.9	O
μm	O
,	O
respectively	O
.	O

Differences	O
for	O
average	O
nuclear	O
area	O
and	O
circumference	O
met	O
statistical	O
significance	O
(	O
p	O
<	O
0.05	O
)	O
between	O
diagnostic	O
groups	O
in	O
the	O
esophagus	O
and	O
colon	O
,	O
except	O
for	O
IM	O
versus	O
IFD	O
nuclear	O
area	O
.	O

Pixel	O
intensity	O
(	O
brightness	O
)	O
separated	O
lesions	O
within	O
both	O
groups	O
with	O
statistical	O
significance	O
except	O
for	O
colonic	O
TAs	O
versus	O
HPs	O
and	O
esophageal	O
LGD	O
versus	O
IM	O
.	O

HGD	O
nuclei	O
in	O
both	O
groups	O
demonstrated	O
more	O
pixel	O
staining	O
heterogeneity	O
than	O
other	O
lesions	O
.	O

Hierarchical	O
clustering	O
and	O
principal	O
component	O
analysis	O
demonstrated	O
that	O
lesions	O
with	O
similar	O
diagnoses	O
tended	O
to	O
cluster	O
together	O
on	O
a	O
low-	O
to	O
high-grade	O
spectrum	O
.	O

Our	O
results	O
confirm	O
that	O
quantitative	O
IA	O
is	O
an	O
effective	O
adjunct	O
reflecting	O
dysplasia	O
in	O
colon	O
polyps	O
and	O
Barrett	O
esophagus	O
lesions	O
.	O

Nuclear	O
area	O
,	O
circumference	O
,	O
and	O
PPC	O
algorithm	O
findings	O
distinguished	O
lesions	O
in	O
a	O
statistically	O
significant	O
manner	O
.	O

This	O
suggests	O
utility	O
for	O
future	O
studies	O
on	O
similar	O
methods	O
,	O
which	O
may	O
provide	O
an	O
adjunctive	O
ancillary	O
technique	O
for	O
pathologists	O
and	O
enhance	O
patient	O
care	O
.	O

Prognostic	O
implications	O
of	O
the	O
intrinsic	O
molecular	O
subtypes	O
in	O
male	O
breast	O
cancer	O
.	O

Intrinsic	O
molecular	O
subtyping	O
has	O
been	O
widely	O
used	O
in	O
female	O
breast	O
cancer	O
,	O
and	O
it	O
has	O
proven	O
its	O
significance	O
.	O

In	O
this	O
article	O
,	O
we	O
aimed	O
to	O
study	O
the	O
intrinsic	O
subtypes	O
of	O
male	O
breast	O
cancer	O
(	O
MBC	O
)	O
in	O
correlation	O
with	O
clinicopathological	O
features	O
.	O

We	O
retrospectively	O
identified	O
130	O
MBC	O
cases	O
from	O
2004	O
to	O
2013	O
.	O

Intrinsic	O
molecular	O
subtypes	O
were	O
determined	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
.	O

From	O
a	O
total	O
of	O
130	O
MBC	O
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	O
subtype	O
,	O
44.6	O
%	O
were	O
luminal	O
B	O
,	O
5	O
%	O
were	O
HER2	O
positive	O
and	O
5	O
%	O
were	O
triple	O
negative	O
tumors	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
IHC	B-P
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	O
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	O
(	O
PR	O
)	O
status	O
(	O
p=0.001	O
)	O
,	O
HER2	O
status	O
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

The	O
distribution	O
of	O
breast	O
cancer	O
intrinsic	O
subtypes	O
in	O
males	O
is	O
different	O
compared	O
to	O
its	O
female	O
counterpart	O
;	O
however	O
,	O
they	O
do	O
n't	O
seem	O
to	O
give	O
the	O
same	O
prognostic	O
value	O
.	O

Cardiovascular	O
comorbidity	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
in	O
the	O
Canary	O
Islands	O
(	O
CCECAN	O
study	O
)	O
.	O

Numerous	O
studies	O
have	O
shown	O
a	O
high	O
prevalence	O
of	O
cardiovascular	O
disease	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
prevalence	O
of	O
cardiovascular	O
risk	O
factors	O
and	O
comorbidity	O
in	O
a	O
Canary	O
Islands	O
population	O
diagnosed	O
with	O
COPD	O
,	O
and	O
compared	O
it	O
with	O
data	O
from	O
the	O
general	O
population	O
.	O

A	O
cross-sectional	O
study	O
was	O
carried	O
out	O
in	O
300	O
patients	O
with	O
COPD	O
and	O
524	O
subjects	O
without	O
respiratory	O
disease	O
(	O
control	O
group	O
)	O
.	O

The	O
two	O
groups	O
were	O
compared	O
using	O
standard	O
bivariate	O
methods	O
.	O

Logistic	O
regression	O
models	O
were	O
used	O
to	O
estimate	O
the	O
cardiovascular	O
risks	O
in	O
COPD	O
patients	O
compared	O
to	O
control	O
group	O
.	O

Patients	O
with	O
COPD	O
showed	O
a	O
high	O
prevalence	O
of	O
hypertension	O
(	O
72	O
%	O
)	O
,	O
dyslipidaemia	O
(	O
73	O
%	O
)	O
,	O
obesity	O
(	O
41	O
%	O
)	O
,	O
diabetes	O
type	O
2	O
(	O
39	O
%	O
)	O
,	O
and	O
sleep	O
apnoea	O
syndrome	O
(	O
30	O
%	O
)	O
from	O
mild	O
stages	B-P
of	I-P
the	I-P
disease	I-P
(	O
GOLD	O
2009	O
)	O
.	O

There	O
was	O
a	O
22	O
%	O
prevalence	O
of	O
cardiac	O
arrhythmia	O
,	O
16	O
%	O
of	O
ischaemic	O
heart	O
disease	O
,	O
16	O
%	O
heart	O
failure	O
,	O
12	O
%	O
peripheral	O
vascular	O
disease	O
,	O
and	O
8	O
%	O
cerebrovascular	O
disease	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
patients	O
with	O
COPD	O
had	O
a	O
higher	O
risk	O
of	O
dyslipidaemia	O
(	O
OR	O
3.24	O
,	O
95	O
%	O
CI	O
;	O
2.21-4.75	O
)	O
,	O
diabetes	O
type	O
2	O
(	O
OR	O
1.52	O
,	O
95	O
%	O
CI	O
;	O
1.01-2,28	O
)	O
,	O
and	O
ischaemic	O
heart	O
disease	O
(	O
OR	O
2.34	O
,	O
95	O
%	O
CI	O
;	O
1.22-4.49	O
)	O
.	O

In	O
the	O
case	O
of	O
dyslipidaemia	O
,	O
an	O
increased	O
risk	O
was	O
obtained	O
when	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
and	O
consumption	O
of	O
tobacco	O
(	O
OR	O
5.04	O
,	O
95	O
%	O
CI	O
;	O
2.36-10.74	O
)	O
.	O

Patients	O
with	O
COPD	O
resident	O
in	O
the	O
Canary	O
Islands	O
have	O
a	O
high	O
prevalence	O
of	O
hypertension	O
,	O
dyslipidaemia	O
,	O
ischaemic	O
heart	O
disease	O
,	O
and	O
cardiac	O
arrhythmia	O
.	O

Compared	O
to	O
general	O
population	O
,	O
patients	O
with	O
COPD	O
have	O
a	O
significant	O
increase	O
in	O
the	O
risk	O
of	O
dyslipidaemia	O
.	O

Safety	O
and	O
Efficacy	O
of	O
Flexible	O
Ureteroscopy	O
in	O
Combination	O
with	O
Holmium	O
Laser	O
Lithotripsy	O
for	O
the	O
Treatment	O
of	O
Bilateral	O
Upper	O
Urinary	O
Tract	O
Calculi	O
.	O

To	O
retrospectively	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
flexible	O
ureteroscopy	O
(	O
FURS	O
)	O
in	O
combination	O
with	O
holmium	O
laser	O
lithotripsy	O
for	O
the	O
treatment	O
of	O
bilateral	O
upper	O
urinary	O
calculi	O
.	O

The	O
stone-free	O
status	O
was	O
defined	O
as	O
the	O
absence	O
of	O
any	O
stones	O
or	O
asymptomatic	O
status	O
,	O
or	O
the	O
presence	O
of	O
clinically	O
insignificant	O
residual	O
fragments	O
<	O
4	O
mm	O
,	O
and	O
was	O
assessed	O
by	O
plain	O
kidney	O
,	O
ureter	O
,	O
and	O
bladder	B-P
X-ray	I-P
.	O

The	O
operative	O
time	O
,	O
stone-free	O
rates	O
(	O
SFRs	O
)	O
,	O
serum	O
creatinine	O
(	O
SCr	O
)	O
,	O
and	O
complications	O
were	O
recorded	O
.	O

During	O
the	O
operation	O
,	O
there	O
was	O
no	O
bleeding	O
,	O
ureteral	O
perforation	O
,	O
avulsion	O
,	O
and	O
rupture	O
.	O

Postoperative	O
hematuria	O
was	O
observed	O
in	O
2	O
patients	O
.	O

SCr	O
increased	O
significantly	O
on	O
the	O
first	O
day	O
after	O
the	O
procedure	O
compared	O
with	O
the	O
preoperative	O
SCr	O
,	O
but	O
after	O
4	O
weeks	O
,	O
the	O
renal	O
function	O
significantly	O
improved	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
SFR	O
was	O
71.6	O
%	O
(	O
63/88	O
)	O
on	O
the	O
first	O
day	O
after	O
the	O
first	O
surgical	O
procedure	O
;	O
it	O
then	O
increased	O
to	O
86.4	O
%	O
(	O
76/88	O
)	O
in	O
the	O
fourth	O
week	O
,	O
and	O
rose	O
to	O
97.4	O
%	O
(	O
76/78	O
)	O
after	O
the	O
second	O
operation	O
.	O

The	O
results	O
demonstrated	O
that	O
FURS	O
in	O
combination	O
with	O
holmium	O
laser	O
lithotripsy	O
represented	O
a	O
favorable	O
less-invasive	O
alternative	O
with	O
high	O
SFR	O
and	O
acceptable	O
complication	O
rates	O
in	O
the	O
treatment	O
of	O
bilateral	O
upper	O
urinary	O
tract	O
calculi	O
.	O

HIV-1	O
integrase	O
inhibitor	O
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
.	O

Transmitted	O
integrase	O
inhibitor	O
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world-wide	O
to	O
date	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
whether	O
transmitted	O
integrase	O
inhibitor	O
resistance	O
has	O
occurred	O
in	O
Scotland	O
and	O
if	O
so	O
,	O
could	O
there	O
be	O
a	O
case	O
for	O
performing	O
genotypic	O
integrase	O
resistance	O
testing	O
at	O
baseline	O
.	O

The	O
study	O
population	O
consisted	O
of	O
106	O
treatment	O
naïve	O
,	O
newly	O
diagnosed	O
,	O
HIV	O
positive	O
patients	O
.	O

The	O
patient	O
samples	O
were	O
collected	O
between	O
October	O
2015	O
and	O
March	O
2016	O
at	O
the	O
time	O
of	O
HIV	B-P
diagnosis	I-P
and	O
prior	O
to	O
initiation	O
of	O
anti-retroviral	O
therapy	O
.	O

The	O
integrase	O
region	O
was	O
amplified	O
and	O
sequenced	O
.	O

We	O
detected	O
integrase	O
inhibitor	O
resistance	O
(	O
T66I/T	O
)	O
at	O
baseline	O
in	O
one	O
patient	O
sample	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	O
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high-level	O
resistance	O
to	O
elvitegravir	O
and	O
intermediate	O
resistance	O
to	O
raltegravir	O
.	O

A	O
further	O
10	O
patients	O
had	O
accessory	O
mutations	O
which	O
have	O
minimal	O
or	O
no	O
effect	O
on	O
susceptibility	O
to	O
integrase	O
inhibitors	O
.	O

Transmitted	O
integrase	O
inhibitor	O
resistance	O
remains	O
rare	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
do	O
not	O
support	O
performing	O
integrase	O
resistance	O
testing	O
at	O
baseline	O
.	O

The	O
N-Methyl	O
d-Aspartate	O
Glutamate	O
Receptor	O
Antagonist	O
Ketamine	O
Disrupts	O
the	O
Functional	O
State	O
of	O
the	O
Corticothalamic	O
Pathway	O
.	O

The	O
non-competitive	O
N-methyl	O
d-aspartate	O
glutamate	O
receptor	O
(	O
NMDAR	O
)	O
antagonist	O
ketamine	O
elicits	O
a	O
brain	O
state	O
resembling	O
high-risk	O
states	O
for	O
developing	O
psychosis	O
and	O
early	O
stages	O
of	O
schizophrenia	O
characterized	O
by	O
sensory	O
and	O
cognitive	O
deficits	O
and	O
aberrant	O
ongoing	O
gamma	O
oscillations	O
(	O
30-80	O
Hz	O
)	O
in	O
cortical	O
and	O
subcortical	O
structures	O
,	O
including	O
the	O
thalamus	O
.	O

The	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
a	O
ketamine	O
-	O
induced	O
psychotic	O
-	O
relevant	O
state	O
disturbs	O
the	O
functional	O
state	O
of	O
the	O
corticothalamic	O
(	O
CT	O
)	O
pathway	O
.	O

Multisite	B-P
field	I-P
recordings	I-P
were	O
performed	O
in	O
the	O
somatosensory	O
CT	O
system	O
of	O
the	O
sedated	O
rat	O
.	O

Baseline	O
activity	O
was	O
challenged	O
by	O
activation	O
of	O
vibrissa	O
-	O
related	O
prethalamic	O
inputs	O
.	O

The	O
sensory	O
-	O
evoked	O
thalamic	O
response	O
was	O
characterized	O
by	O
a	O
short	O
-	O
latency	O
(	O
∼4	O
ms	O
)	O
prethalamic	O
-mediated	O
negative	O
sharp	O
potential	O
and	O
a	O
longer	O
latency	O
(	O
∼10	O
ms	O
)	O
CT	O
-mediated	O
negative	O
potential	O
.	O

Following	O
a	O
single	O
subcutaneous	O
injection	O
of	O
ketamine	O
(	O
2.5	O
mg/kg	O
)	O
,	O
spontaneously	O
occurring	O
and	O
sensory	O
-	O
evoked	O
thalamic	O
gamma	O
oscillations	O
increased	O
and	O
decreased	O
in	O
power	O
,	O
respectively	O
.	O

The	O
power	O
of	O
the	O
sensory	O
-related	O
gamma	O
oscillations	O
was	O
positively	O
correlated	O
with	O
both	O
the	O
amplitude	O
and	O
the	O
area	O
under	O
the	O
curve	O
of	O
the	O
corresponding	O
CT	O
potential	O
but	O
not	O
with	O
the	O
prethalamic	O
potential	O
.	O

The	O
present	O
results	O
show	O
that	O
the	O
layer	O
VI	O
CT	O
pathway	O
significantly	O
contributes	O
in	O
thalamic	O
gamma	O
oscillations	O
,	O
and	O
they	O
support	O
the	O
hypothesis	O
that	O
reduced	O
NMDAR	O
activation	O
disturbs	O
the	O
functional	O
state	O
of	O
CT	O
and	O
corticocortical	O
networks	O
.	O

The	O
Association	O
between	O
Sexually	O
Transmitted	O
Infections	O
,	O
Length	O
of	O
Service	O
and	O
Other	O
Demographic	O
Factors	O
in	O
the	O
U.S.	O
Military	O
.	O

Numerous	O
studies	O
have	O
found	O
higher	O
rates	O
of	O
sexually	O
transmitted	O
infections	O
(	O
STIs	O
)	O
among	O
military	O
personnel	O
than	O
the	O
general	O
population	O
,	O
but	O
the	O
cumulative	O
risk	O
of	O
acquiring	O
STIs	O
throughout	O
an	O
individual	O
's	O
military	O
career	O
has	O
not	O
been	O
described	O
.	O

Using	O
ICD-9	O
diagnosis	O
codes	O
,	O
we	O
analyzed	O
the	O
medical	O
records	O
of	O
100,005	O
individuals	O
from	O
all	O
service	O
branches	O
,	O
divided	O
in	O
equal	O
cohorts	O
(	O
n	O
=	O
6,667	O
)	O
between	O
1997	O
and	O
2011	O
.	O

As	O
women	O
receive	O
frequent	O
STI	O
screening	B-P
compared	O
to	O
men	O
,	O
these	O
groups	O
were	O
analyzed	O
separately	O
.	O

Incidence	O
rates	O
were	O
calculated	O
for	O
pathogen	O
-specific	O
STIs	O
along	O
with	O
syndromic	O
diagnoses	O
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
characterize	O
the	O
individuals	O
within	O
each	O
accession	O
year	O
cohort	O
;	O
repeat	O
infections	O
were	O
censored	O
.	O

The	O
total	O
sample	O
included	O
29,010	O
females	O
and	O
70,995	O
males	O
.	O

The	O
STI	O
incidence	O
rates	O
(	O
per	O
100	O
person-years	O
)	O
for	O
women	O
and	O
men	O
,	O
respectively	O
,	O
were	O
as	O
follows	O
:	O
chlamydia	O
(	O
3.5	O
and	O
0.7	O
)	O
,	O
gonorrhea	O
(	O
1.1	O
and	O
0.4	O
)	O
,	O
HIV	O
(	O
0.04	O
and	O
0.07	O
)	O
and	O
syphilis	O
(	O
0.14	O
and	O
0.15	O
)	O
.	O

During	O
the	O
study	O
period	O
,	O
22	O
%	O
of	O
women	O
and	O
3.3	O
%	O
of	O
men	O
received	O
a	O
pathogen-specific	O
STI	O
diagnosis	O
;	O
inclusion	O
of	O
syndromic	O
diagnoses	O
increased	O
STI	O
prevalence	O
to	O
41	O
%	O
and	O
5.5	O
%	O
,	O
respectively	O
.	O

In	O
multivariate	O
analyses	O
,	O
factors	O
associated	O
with	O
etiologic	O
and	O
syndromic	O
STIs	O
among	O
women	O
included	O
African	O
American	O
race	O
,	O
younger	O
age	O
and	O
fewer	O
years	O
of	O
education	O
.	O

In	O
the	O
overall	O
sample	O
,	O
increasing	O
number	O
of	O
years	O
of	O
service	O
was	O
associated	O
with	O
an	O
increased	O
likelihood	O
of	O
an	O
STI	O
diagnosis	O
(	O
p	O
<	O
0.001	O
for	O
trend	O
)	O
.	O

In	O
this	O
survey	O
of	O
military	O
personnel	O
,	O
we	O
found	O
very	O
high	O
rates	O
of	O
STI	O
acquisition	O
throughout	O
military	O
service	O
,	O
especially	O
among	O
women	O
,	O
demonstrating	O
that	O
STI-related	O
risk	O
is	O
significant	O
and	O
ongoing	O
throughout	O
military	O
service	O
.	O

Lower	O
STI	O
incidence	O
rates	O
among	O
men	O
may	O
represent	O
under-	O
diagnosis	O
and	O
demonstrate	O
a	O
need	O
for	O
enhancing	O
Male-Direct	O
sreening	O
and	O
diagnostic	B-P
interventions	I-P
.	I-P

Measuring	O
nonlinear	O
signal	O
combination	O
using	O
EEG	B-P
.	O

Relatively	O
little	O
is	O
known	O
about	O
the	O
processes	O
,	O
both	O
linear	O
and	O
nonlinear	O
,	O
by	O
which	O
signals	O
are	O
combined	O
beyond	O
V1	O
.	O

By	O
presenting	O
two	O
stimulus	O
components	O
simultaneously	O
,	O
flickering	O
at	O
different	O
temporal	O
frequencies	O
(	O
frequency	O
tagging	O
)	O
while	O
measuring	O
steady-state	O
visual	O
evoked	O
potentials	O
,	O
we	O
can	O
assess	O
responses	O
to	O
the	O
individual	O
components	O
,	O
including	O
direct	O
measurements	O
of	O
suppression	O
on	O
each	O
other	O
,	O
and	O
various	O
nonlinear	O
responses	O
to	O
their	O
combination	O
found	O
at	O
intermodulation	O
frequencies	O
.	O

The	O
result	O
is	O
a	O
rather	O
rich	O
dataset	O
of	O
frequencies	O
at	O
which	O
responses	O
can	O
be	O
found	O
.	O

We	O
presented	O
pairs	O
of	O
sinusoidal	O
gratings	O
at	O
different	O
temporal	O
frequencies	O
,	O
forming	O
plaid	O
patterns	O
that	O
were	O
``	O
coherent	O
``	O
(	O
looking	O
like	O
a	O
checkerboar	O
d	O
)	O
and	O
``	O
noncoherent	O
``	O
(	O
looking	O
like	O
a	O
pair	O
of	O
transparently	O
overlaid	O
gratings	O
)	O
,	O
and	O
found	O
clear	O
intermodulation	O
responses	O
to	O
compound	O
stimuli	O
,	O
indicating	O
nonlinear	O
summation	O
.	O

This	O
might	O
have	O
been	O
attributed	O
to	O
cross-orientation	O
suppression	O
except	O
that	O
the	O
pattern	O
of	O
intermodulation	O
responses	O
differed	O
for	O
coherent	O
and	O
noncoherent	O
patterns	O
,	O
whereas	O
the	O
effects	O
of	O
suppression	O
(	O
measured	O
at	O
the	O
component	O
frequencies	O
)	O
did	O
not	O
.	O

A	O
two-stage	O
model	O
of	O
nonlinear	O
summation	O
involving	O
conjunction	O
detection	O
with	O
a	O
logical	O
AND	O
gate	O
described	O
the	O
data	O
well	O
,	O
capturing	O
the	O
difference	O
between	O
coherent	O
and	O
noncoherent	O
plaids	O
over	O
a	O
wide	O
array	O
of	O
possible	O
response	O
frequencies	O
.	O

Multistimulus	O
frequency	O
-tagged	O
EEG	B-P
in	O
combination	O
with	O
computational	O
modeling	O
may	O
be	O
a	O
very	O
valuable	O
tool	O
in	O
studying	O
the	O
conjunction	O
of	O
these	O
signals	O
.	O

In	O
the	O
current	O
study	O
the	O
results	O
suggest	O
a	O
second-order	O
mechanism	O
responding	O
selectively	O
to	O
coherent	O
plaid	O
patterns	O
.	O

Histomorphometric	O
and	O
transcriptome	O
evaluation	O
of	O
early	O
healing	O
bone	O
treated	O
with	O
a	O
novel	O
human	O
particulate	O
dentin	O
powder	O
.	O

Human	O
particulate	O
dentin	O
(	O
HPD	O
)	O
shows	O
potential	O
as	O
an	O
alternative	O
bone	O
grafting	O
material	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
bone	O
healing	O
at	O
the	O
molecular	O
level	O
after	O
grafting	O
with	O
HPD	O
is	O
unclear	O
.	O

This	O
study	O
assessed	O
the	O
histological	O
and	O
global	O
gene	O
expression	O
of	O
bone	O
tissues	O
grafted	O
with	O
HPD	O
.	O

The	O
HPD	O
was	O
prepared	O
to	O
250-500	O
µm	O
in	O
size	O
.	O

X-ray	O
diffraction	O
(	O
XRD	O
)	O
and	O
energy	O
dispersive	O
x-ray	O
spectroscopy	O
(	O
EDX	O
)	O
were	O
performed	O
to	O
confirm	O
the	O
crystal	O
structure	O
,	O
organic	O
compound	O
residues	O
,	O
and	O
surface	O
morphology	O
,	O
respectively	O
.	O

Bony	O
defects	O
were	O
created	O
on	O
the	O
heads	O
of	O
24	O
New	O
Zealand	O
White	O
rabbits	O
.	O

Sterilized	O
HPD	O
was	O
used	O
as	O
the	O
grafting	O
material	O
.	O

The	O
quality	O
and	O
quantity	O
of	O
new	O
bone	O
formation	O
was	O
evaluated	O
using	O
micro-CT	B-P
and	O
histologic	O
analyses	O
during	O
the	O
8	O
week	O
experimental	O
periods	O
.	O

For	O
microarray	O
assay	O
,	O
bone	O
tissue	O
and	O
blood	O
samples	O
were	O
taken	O
at	O
3	O
,	O
5	O
and	O
7	O
d	O
post-implantation	O
.	O

The	O
results	O
of	O
XRD	O
and	O
EDX	O
showed	O
that	O
HPD	O
exhibited	O
physical	O
and	O
chemical	O
properties	O
similar	O
to	O
natural	O
hydroxyapatite	O
.	O

New	O
bone	O
formation	O
was	O
observed	O
after	O
HPD	O
implantation	O
compared	O
to	O
the	O
controls	O
,	O
as	O
shown	O
on	O
hematoxylin	O
and	O
eosin	O
staining	O
and	O
micro-CT	B-P
.	O

The	O
bone	O
volume	O
of	O
HPD	O
treated	O
animals	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
at	O
all	O
observation	O
times	O
.	O

Microarray	O
analysis	O
showed	O
that	O
vascular	O
development	O
coupled	O
with	O
immune	O
and	O
inflammatory	O
related	O
genes	O
were	O
expressed	O
in	O
the	O
early	O
healing	O
stage	O
.	O

The	O
gene	O
coding	O
for	O
the	O
IL-1	O
antagonist	O
,	O
IL1RN	O
,	O
was	O
expressed	O
to	O
inhibit	O
the	O
inflammatory	O
response	O
,	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
CCL2	O
gene	O
was	O
activated	O
to	O
2.3	O
times	O
the	O
normal	O
level	O
.	O

BMP2	O
,	O
RUNX2	O
,	O
COL1A	O
,	O
and	O
OPN	O
expression	O
were	O
also	O
up-regulated	O
.	O

CCL2	O
predominated	O
in	O
osteoblastogenesis	O
of	O
the	O
HPD	O
-	O
treated	O
bony	O
defect	O
in	O
the	O
early	O
stage	O
of	O
healing	O
.	O

HPD	O
accelerated	O
bone	O
regeneration	O
and	O
augmentation	O
.	O

These	O
results	O
suggested	O
that	O
HPD	O
provided	O
potential	O
as	O
a	O
bone	O
graft	O
resource	O
during	O
the	O
bone	O
healing	O
process	O
.	O

Co-infection	O
of	O
Acipenserid	O
herpesvirus	O
2	O
(	O
AciHV-2	O
)	O
and	O
Streptococcus	O
iniae	O
in	O
cultured	O
white	O
sturgeon	O
Acipenser	O
transmontanus	O
.	O

A	O
mortality	O
event	O
in	O
cultured	O
white	O
sturgeon	O
Acipenser	O
transmontanus	O
(	O
Richardson	O
,	O
1836	O
)	O
sub-adults	O
was	O
investigated	O
.	O

After	O
transfer	O
between	O
farms	O
,	O
high	O
mortality	O
was	O
observed	O
in	O
fish	O
,	O
associated	O
with	O
back	O
arching	O
,	O
abnormal	O
swimming	O
,	O
and	O
ulcerative	O
skin	O
lesions	O
.	O

Necropsy	B-P
of	O
moribund	O
individuals	O
revealed	O
hemorrhagic	O
ascites	O
and	O
petechial	O
hemorrhages	O
in	O
the	O
coelomic	O
peritoneum	O
and	O
serosa	O
of	O
internal	O
organs	O
.	O

Acipenserid	O
herpesvirus	O
2	O
(	O
AciHV-2	O
)	O
was	O
isolated	O
from	O
external	O
tissue	O
samples	O
,	O
then	O
identified	O
and	O
genotyped	O
by	O
sequencing	O
of	O
the	O
terminase	O
and	O
polymerase	O
genes	O
.	O

In	O
addition	O
,	O
Streptococcus	O
iniae	O
was	O
recovered	O
from	O
internal	O
organs	O
of	O
affected	O
fish	O
.	O

Histologic	O
changes	O
were	O
limited	O
to	O
interstitial	O
hematopoietic	O
areas	O
of	O
the	O
kidney	O
and	O
consisted	O
of	O
small	O
foci	O
of	O
necrosis	O
accompanied	O
by	O
fibrin	O
deposition	O
,	O
minimal	O
inflammatory	O
response	O
,	O
and	O
small	O
numbers	O
of	O
bacterial	O
cocci	O
compatible	O
with	O
streptococci	O
.	O

Identity	O
was	O
confirmed	O
by	O
partial	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
,	O
rpoB	O
,	O
and	O
gyrB	O
genes	O
.	O

Genetic	O
fingerprinting	O
demonstrated	O
a	O
genetic	O
profile	O
distinct	O
from	O
S.	O
iniae	O
isolates	O
recovered	O
from	O
previous	O
outbreaks	O
in	O
wild	O
and	O
cultured	O
fish	O
in	O
North	O
America	O
,	O
South	O
America	O
,	O
and	O
the	O
Caribbean	O
.	O

Although	O
the	O
isolates	O
were	O
resistant	O
to	O
white	O
sturgeon	O
complement	O
in	O
serum	O
killing	O
assays	O
,	O
in	O
vivo	O
challenges	O
failed	O
to	O
fulfill	O
Koch	O
's	O
postulates	O
.	O

However	O
,	O
the	O
clinical	O
presentation	O
,	O
coupled	O
with	O
consistent	O
recovery	O
of	O
S.	O
iniae	O
and	O
AciHV-2	O
from	O
moribund	O
fish	O
,	O
suggests	O
viral	O
and	O
bacterial	O
co-infection	O
were	O
the	O
proximate	O
cause	O
of	O
death	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
report	O
of	O
AciHV-2	O
and	O
S.	O
iniae	O
co-infection	O
in	O
cultured	O
white	O
sturgeon	O
.	O

Application	O
of	O
single	B-P
-	O
and	O
dual-energy	B-P
CT	I-P
brain	O
tissue	O
segmentation	O
to	O
PET	B-P
monitoring	O
of	O
proton	O
therapy	O
.	O

The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
ability	O
of	O
single	B-P
and	O
dual	B-P
energy	I-P
computed	I-P
tomography	I-P
(	O
SECT	B-P
,	O
DECT	B-P
)	O
to	O
estimate	O
tissue	O
composition	O
and	O
density	O
for	O
usage	O
in	O
Monte	O
Carlo	O
(	O
MC	O
)	O
simulations	O
of	O
irradiation	O
induced	O
β	O
(	O
+	O
)	O
activity	O
distributions	O
.	O

This	O
was	O
done	O
to	O
assess	O
the	O
impact	O
on	O
positron	B-P
emission	I-P
tomography	I-P
(	O
PET	B-P
)	O
range	O
verification	O
in	O
proton	O
therapy	O
.	O

A	O
DECT-based	B-P
brain	O
tissue	O
segmentation	O
method	O
was	O
developed	O
for	O
white	O
matter	O
(	O
WM	O
)	O
,	O
grey	O
matter	O
(	O
GM	O
)	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

The	O
elemental	O
composition	O
of	O
reference	O
tissues	O
was	O
assigned	O
to	O
closest	O
CT	O
numbers	O
in	O
DECT	B-P
space	O
(	O
DECTdist	O
)	O
.	O

The	O
method	O
was	O
also	O
applied	O
to	O
SECT	B-P
data	O
(	O
SECTdist	O
)	O
.	O

In	O
a	O
validation	O
experiment	O
,	O
the	O
proton	O
irradiation	O
induced	O
PET	B-P
activity	O
of	O
three	O
brain	O
equivalent	O
solutions	O
(	O
BES	O
)	O
was	O
compared	O
to	O
simulations	O
based	O
on	O
different	O
tissue	O
segmentations	O
.	O

Five	O
patients	O
scanned	B-P
with	O
a	O
dual	O
source	O
DECT	B-P
scanner	O
were	O
analyzed	O
to	O
compare	O
the	O
different	O
segmentation	O
methods	O
.	O

A	O
single	O
magnetic	O
resonance	O
(	O
MR	O
)	O
scan	O
was	O
used	O
for	O
comparison	O
with	O
an	O
established	O
segmentation	O
toolkit	O
.	O

Additionally	O
,	O
one	O
patient	O
with	O
SECT	B-P
and	O
post-treatment	O
PET	B-P
scans	I-P
was	O
investigated	O
.	O

For	O
BES	O
,	O
DECTdist	O
and	O
SECTdist	O
reduced	O
differences	O
to	O
the	O
reference	O
simulation	O
by	O
up	O
to	O
62	O
%	O
when	O
compared	O
to	O
the	O
conventional	O
stoichiometric	O
segmentation	O
(	O
SECTSchneider	O
)	O
.	O

In	O
comparison	O
to	O
MR	O
brain	O
segmentation	O
,	O
Dice	O
similarity	O
coefficients	O
for	O
WM	O
,	O
GM	O
and	O
CSF	O
were	O
0.61	O
,	O
0.67	O
and	O
0.66	O
for	O
DECTdist	O
and	O
0.54	O
,	O
0.41	O
and	O
0.66	O
for	O
SECTdist	O
.	O

MC	O
simulations	O
of	O
PET	B-P
treatment	O
verification	O
in	O
patients	O
showed	O
important	O
differences	O
between	O
DECTdist	O
/	O
SECTdist	O
and	O
SECTSchneider	O
for	O
patients	O
with	O
large	O
CSF	O
areas	O
within	O
the	O
treatment	O
field	O
but	O
not	O
in	O
WM	O
and	O
GM	O
.	O

Differences	O
could	O
be	O
misinterpreted	O
as	O
PET	B-P
derived	O
range	O
shifts	O
of	O
up	O
to	O
4	O
mm	O
.	O

DECTdist	O
and	O
SECTdist	O
yielded	O
comparable	O
activity	O
distributions	O
,	O
and	O
comparison	O
of	O
SECTdist	O
to	O
a	O
measured	O
patient	O
PET	B-P
scan	I-P
showed	O
improved	O
agreement	O
when	O
compared	O
to	O
SECTSchneider	O
.	O

The	O
agreement	O
between	O
predicted	O
and	O
measured	O
PET	B-P
activity	O
distributions	O
was	O
improved	O
by	O
employing	O
a	O
brain	O
specific	O
segmentation	O
applicable	O
to	O
both	O
DECT	B-P
and	O
SECT	B-P
data	O
.	O

Identification	O
of	O
a	O
novel	O
PSEN1	O
mutation	O
(	O
Leu232Pro	O
)	O
in	O
a	O
Korean	O
patient	O
with	O
early-onset	O
Alzheimer	O
's	O
disease	O
and	O
a	O
family	O
history	O
of	O
dementia	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
mutation	O
in	O
exon	O
7	O
of	O
presenilin	O
1	O
(	O
Leu232Pro	O
)	O
was	O
discovered	O
in	O
a	O
Korean	O
patient	O
with	O
early-onset	O
Alzheimer	O
's	O
disease	O
,	O
who	O
represented	O
memory	O
decline	O
at	O
37	O
years	O
of	O
age	O
,	O
followed	O
by	O
impairment	O
in	O
spatial	O
activity	O
and	O
concentrations	O
and	O
personality	O
changes	O
.	O

Imaging	B-P
analyses	I-P
with	O
magnetic	B-P
resonance	I-P
scan	I-P
showed	O
diffuse	O
atrophy	O
in	O
the	O
frontoparietal	O
regions	O
.	O

Targeted	O
next	O
generation	O
sequencing	O
and	O
Sanger	O
sequencing	O
identified	O
a	O
heterozygous	O
T	O
to	O
C	O
transition	O
at	O
position	O
695	O
(	O
c.695T	O
>	O
C	O
)	O
of	O
in	O
presenilin	O
1	O
gene	O
(	O
PSEN1	O
)	O
,	O
resulting	O
in	O
a	O
novel	O
missense	O
mutation	O
at	O
codon	O
232	O
from	O
leucine	O
to	O
proline	O
(	O
L232P	O
)	O
.	O

Several	O
family	O
members	O
of	O
the	O
patient	O
developed	O
dementia	O
,	O
suggesting	O
an	O
autosomal	O
dominant	O
inheritance	O
;	O
however	O
,	O
we	O
were	O
unable	O
to	O
perform	O
a	O
segregation	O
analysis	O
to	O
confirm	O
this	O
.	O

Since	O
the	O
proline	O
may	O
play	O
a	O
role	O
as	O
a	O
helix	O
breaker	O
,	O
this	O
mutation	O
could	O
significantly	O
disturb	O
the	O
transmembrane	O
helix	O
domain-V	O
of	O
PSEN1	O
and	O
perturb	O
its	O
protein	O
functions	O
.	O

This	O
hypothesis	O
was	O
supported	O
by	O
the	O
results	O
from	O
the	O
in	O
silico	O
analyses	O
,	O
predicted	O
a	O
major	O
kink	O
on	O
this	O
helix	O
.	O

Several	O
leucine	O
>	O
proline	O
substitutions	O
in	O
other	O
PSEN1	O
transmembrane	O
helices	O
revealed	O
aggressive	O
AD	O
phenotypes	O
.	O

Future	O
functional	O
studies	O
would	O
be	O
needed	O
to	O
evaluate	O
the	O
pathogenicity	O
of	O
this	O
mutation	O
in	O
AD	O
.	O

Analysis	O
of	O
soft-tissue	O
complications	O
of	O
volar	O
plate	O
fixation	O
for	O
managing	O
distal	O
radius	O
fractures	O
and	O
clinical	O
effect	O
while	O
preserving	O
pronator	O
quadratus	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analysis	O
soft-tissue	O
complications	O
of	O
volar	O
plate	O
fixation	O
and	O
it	O
's	O
prevention	O
strategies	O
along	O
with	O
exploring	O
clinical	O
effects	O
of	O
preserving	O
pronator	O
quadratus	O
(	O
PQ	O
)	O
muscle	O
.	O

From	O
February	O
2011	O
to	O
February	O
2013	O
,	O
sixty-five	O
patients	O
with	O
distal	O
radius	O
fracture	O
underwent	O
open	O
reduction	O
and	O
internal	O
fixation	O
with	O
the	O
volar	O
locking	O
palmar	O
plates	O
.	O

The	O
group	O
with	O
preserving	O
PQ	O
involved	O
30	O
patients	O
and	O
group	O
with	O
PQ	O
repair	O
involved	O
35	O
patients	O
.	O

Surgeons	O
must	O
took	O
great	O
care	O
of	O
not	O
-letting	O
drill	O
pierce	O
dorsal	O
cortical	O
bone	O
rapidly	O
and	O
dorsal	O
carpal	O
tangential	B-P
fluoroscopy	I-P
was	O
also	O
taken	O
in	O
addition	O
to	O
lateral	B-P
fluoroscopy	I-P
to	O
get	O
accurate	O
screw	O
length	O
.	O

Volar	O
plate	O
must	O
be	O
placed	O
not	O
go	O
beyond	O
the	O
watershed	O
region	O
of	O
distal	O
radius	O
.	O

The	O
wrist	O
pain	O
,	O
forearm	O
range	O
of	O
motion	O
,	O
grip	O
strength	O
,	O
wrist	O
functional	O
recovery	O
score	O
,	O
X-ray	B-P
and	I-P
CT	I-P
imaging	I-P
were	O
followed-up	O
after	O
surgery	O
.	O

Two	O
groups	O
were	O
compared	O
for	O
Clinical	O
efficacy	O
.	O

The	O
minimum	O
follow-up	O
for	O
the	O
whole	O
cohort	O
was	O
one	O
year	O
.	O

The	O
relevant	O
post	O
operative	O
data	O
were	O
collected	O
after	O
2	O
weeks	O
,	O
6	O
weeks	O
,	O
3	O
and	O
12	O
month	O
respectively	O
.	O

Fractures	O
healing	O
after	O
postoperative	O
3	O
months	O
are	O
significant	O
in	O
X	B-P
-ray	I-P
and	I-P
CT	I-P
imaging	I-P
.	O

Fixation	O
position	O
and	O
stability	O
were	O
good	O
,	O
but	O
each	O
group	O
had	O
one	O
case	O
with	O
a	O
screw	O
piercing	O
the	O
dorsal	O
cortical	O
.	O

The	O
-	O
differences	O
between	O
the	O
two	O
groups	O
were	O
significant	O
regarding	O
the	O
wrist	O
pain	O
,	O
forearm	O
range	O
of	O
motion	O
,	O
grip	B-P
and	O
strength	O
at	O
2	O
and	O
6	O
weeks	O
after	O
operation	O
,	O
but	O
not	O
significant	O
at	O
3	O
and	O
12	O
month	O
after	O
operation	O
.	O

The	O
differences	O
between	O
the	O
two	O
groups	O
were	O
also	O
significant	O
regarding	O
wrist	O
functional	O
scores	O
at	O
6	O
weeks	O
,	O
but	O
not	O
significant	O
at	O
3	O
and	O
12	O
month	O
after	O
operation	O
.	O

Drilling	O
the	O
dorsal	O
cortical	O
bone	O
gently	O
and	O
accurate	O
screws	O
length	O
can	O
avoid	O
extensor	O
tendon	O
injury	O
.	O

-	O
Dorsal	O
carpal	O
tangential	B-P
fluoroscopy	I-P
is	O
a	O
useful	O
supplement	O
for	O
accurate	O
screws	O
length	O
besides	O
lateral	B-P
fluoroscopy	I-P
.	O

Volar	O
plate	O
's	O
position	O
not	O
go	O
beyond	O
the	O
watershed	O
region	O
of	O
distal	O
radius	O
is	O
the	O
key	O
factor	O
in	O
reducing	O
the	O
flexor	O
tendon	O
injury	O
and	O
preservation	O
of	O
the	O
PQ	O
muscle	O
can	O
also	O
prevent	O
the	O
flexor	O
tendon	O
-injury	O
,	O
yield	O
better	O
early	O
wrist	O
function	O
and	O
shorten	O
rehabilitation	O
time	O
.	O

Blood	O
Pressure	O
and	O
All-Cause	O
Mortality	O
by	O
Level	O
of	O
Cognitive	O
Function	O
in	O
the	O
Elderly	O
:	O
Results	O
From	O
a	O
Population-Based	O
Study	O
in	O
Rural	O
Greece	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
whether	O
the	O
effect	O
of	O
blood	O
pressure	O
(	O
BP	O
)	O
on	O
mortality	O
differs	O
by	O
levels	O
of	O
cognitive	O
function	O
.	O

The	O
associations	O
of	O
brachial	O
systolic	O
BP	O
,	O
diastolic	O
BP	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
,	O
and	O
pulse	O
pressure	O
with	O
all-cause	O
mortality	O
were	O
prospectively	O
explored	O
(	O
follow-up	O
7.0±2.2	O
years	O
)	O
in	O
660	O
community-dwelling	O
individuals	O
(	O
≥60	O
years	O
)	O
using	O
adjusted	O
Cox	O
models	O
,	O
stratified	O
by	O
cognitive	O
impairment	O
(	O
Mini-Mental	B-P
State	I-P
Examination	I-P
[	O
MMSE	B-P
]	O
<	O
24	O
)	O
.	O

No	O
association	O
between	O
brachial	O
BP	O
variables	O
and	O
mortality	O
was	O
shown	O
for	O
the	O
total	O
sample	O
in	O
quartiles	O
analysis	O
;	O
however	O
,	O
MAP	O
in	O
the	O
highest	O
quartile	O
,	O
compared	O
with	O
the	O
second	O
,	O
was	O
associated	O
with	O
mortality	O
(	O
hazard	O
ratio	O
,	O
1.85	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
1.09-3.12	O
)	O
among	O
cognitively	O
impaired	O
individuals	O
.	O

The	O
fractional-polynomials	O
approach	O
for	O
BP	O
confirmed	O
this	O
finding	O
and	O
further	O
showed	O
,	O
solely	O
in	O
the	O
MMSE	B-P
<	O
24	O
subcohort	O
,	O
U-shaped	O
trends	O
of	O
MAP	O
and	O
systolic	O
BP	O
,	O
with	O
increased	O
mortality	O
risk	O
in	O
extremely	O
low	O
or	O
high	O
values	O
;	O
no	O
such	O
pattern	O
was	O
evident	O
for	O
patients	O
with	O
MMSE	B-P
≥24	O
.	O

Elderly	O
individuals	O
with	O
cognitive	O
impairment	O
might	O
be	O
more	O
susceptible	O
to	O
the	O
detrimental	O
effects	O
of	O
low	O
and	O
elevated	O
MAP	O
and	O
systolic	O
BP	O
.	O

Rifampicin	O
-	O
induced	O
adrenal	O
crisis	O
in	O
a	O
patient	O
with	O
tuberculosis	O
:	O
a	O
therapeutic	O
challenge	O
.	O

A	O
55-year-old	O
Indian	O
man	O
presented	O
with	O
productive	O
cough	O
and	O
a	O
large	O
left	O
pleural	O
effusion	O
.	O

Pleural	O
fluid	O
culture	O
grew	O
Mycobacterium	O
tuberculosis	O
,	O
and	O
he	O
was	O
started	O
on	O
antituberculosis	O
therapy	O
.	O

One	O
week	O
later	O
,	O
the	O
patient	O
presented	O
to	O
hospital	O
with	O
drowsiness	O
,	O
dehydration	O
and	O
hypotension	O
.	O

He	O
was	O
transferred	O
to	O
critical	O
care	O
and	O
only	O
improved	O
after	O
starting	O
hydrocortisone	O
and	O
stopping	O
rifampicin	O
.	O

His	O
short	O
synACTHen	O
test	O
subsequently	O
confirmed	O
primary	O
adrenal	O
insufficiency	O
,	O
and	O
a	O
CT	B-P
of	O
the	O
abdomen	O
showed	O
bilateral	O
adrenal	O
enlargement	O
.	O

Rifampicin	O
is	O
known	O
to	O
accelerate	O
cortisol	O
metabolism	O
.	O

We	O
report	O
the	O
rare	O
case	O
of	O
a	O
rifampicin	O
-	O
induced	O
adrenal	O
crisis	O
as	O
a	O
first	O
presentation	O
of	O
Addison	O
's	O
disease	O
in	O
a	O
patient	O
with	O
tuberculous	O
infiltration	O
of	O
the	O
adrenal	O
glands	O
.	O

Towards	O
next-generation	O
sequencing	O
analytics	O
for	O
foodborne	O
RNA	O
viruses	O
:	O
Examining	O
the	O
effect	O
of	O
RNA	O
input	O
quantity	O
and	O
viral	O
RNA	O
purity	O
.	O

Detection	O
and	O
identification	O
of	O
viruses	O
in	O
food	O
samples	O
are	O
technically	O
challenging	O
due	O
largely	O
to	O
the	O
low	O
viral	O
copy	O
number	O
in	O
contaminated	O
food	O
items	O
,	O
and	O
the	O
lack	O
of	O
effective	O
culture	O
enrichment	O
methods	O
that	O
are	O
amenable	O
to	O
regulatory	O
applications	O
for	O
many	O
of	O
the	O
common	O
foodborne	O
viruses	O
.	O

Using	O
an	O
Illumina	O
MiSeq	O
platform	O
and	O
two	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
cell-culture	O
adapted	O
strains	O
as	O
a	O
representative	O
enteric	O
virus	O
species	O
,	O
this	O
study	O
examined	O
the	O
limits	O
of	O
single-stranded	O
RNA	O
(	O
ssRNA	O
)	O
viral	O
detection	O
following	O
next-generation	O
sequencing	O
without	O
pre-amplification	O
of	O
the	O
viral	O
genome	O
.	O

Complete	O
viral	O
genome	O
sequences	O
were	O
obtained	O
from	O
HAV	O
samples	O
of	O
varying	O
purities	O
and	O
with	O
an	O
input	O
as	O
low	O
as	O
2ng	O
total	O
RNA	O
containing	O
1.4×10	O
(	O
5	O
)	O
copies	O
of	O
viral	O
RNA	O
.	O

In	O
addition	O
,	O
single	O
nucleotide	O
variations	O
were	O
reproducibly	O
detected	O
over	O
the	O
range	O
of	O
concentrations	O
examined	O
,	O
and	O
their	O
identity	O
confirmed	O
by	O
alternate	O
sequencing	O
technology	O
.	O

In	O
summary	O
,	O
next-generation	O
sequencing	O
technology	O
has	O
the	O
potential	O
for	O
sensitive	O
detection	O
/	O
identification	O
of	O
a	O
viral	O
genome	O
at	O
a	O
low	O
copy	O
number	O
.	O

This	O
study	O
provides	O
a	O
benchmark	O
for	O
metagenomic	O
sequencing	O
application	O
as	O
is	O
required	O
for	O
virus	O
detection	O
in	O
complex	O
food	O
matrices	O
using	O
a	O
culture	O
-independent	O
diagnostic	B-P
approach	I-P
.	O

A	O
new	O
angle	O
and	O
its	O
relationship	O
with	O
early	O
fixation	O
failure	O
of	O
femoral	O
neck	O
fractures	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
.	O

The	O
Pauwels	O
angle	O
has	O
been	O
used	O
widely	O
,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	O
is	O
difficult	O
because	O
of	O
deformity	O
of	O
the	O
affected	O
lower	O
extremity	O
.	O

Therefore	O
we	O
designed	O
a	O
new	O
measurement	O
of	O
the	O
orientation	O
of	O
femoral	O
neck	O
fracture	O
and	O
applied	O
this	O
in	O
a	O
retrospective	O
study	O
to	O
assess	O
:	O
(	O
1	O
)	O
its	O
reproducibility	O
,	O
(	O
2	O
)	O
its	O
advantages	O
compared	O
with	O
the	O
Pauwels	O
angle	O
,	O
(	O
3	O
)	O
its	O
relationship	O
with	O
the	O
short-term	O
prognosis	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
.	O

This	O
new	O
measurement	O
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	O
of	O
femoral	O
neck	O
fractures	O
.	O

Two	O
hundred	O
and	O
twenty-eight	O
patients	O
with	O
femoral	O
neck	O
fractures	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
were	O
retrospectively	O
analyzed	O
.	O

The	O
VN	O
angle	O
,	O
which	O
was	O
the	O
angle	O
between	O
the	O
fracture	O
line	O
and	O
the	O
vertical	O
of	O
the	O
neck	O
axis	O
,	O
and	O
the	O
Pauwels	O
angle	O
were	O
measured	O
respectively	O
.	O

The	O
method	O
of	O
ICC	O
was	O
performed	O
to	O
assess	O
the	O
reproducibility	O
of	O
the	O
two	O
angles	O
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre-operative	O
and	O
post-operative	O
radiographs	B-P
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	O
.	O

These	O
fractures	O
were	O
divided	O
into	O
four	O
groups	O
according	O
to	O
VN	O
angle	O
(	O
VN	O
<	O
0°	O
(	O
n=92	O
)	O
,	O
0°≤VN	O
<	O
10°	O
(	O
n=82	O
)	O
,	O
10°≤VN	O
<	O
15°	O
(	O
n=26	O
)	O
,	O
VN≥15°	O
(	O
n=28	O
)	O
)	O
,	O
and	O
the	O
short-term	O
(	O
within	O
6	O
months	O
)	O
fixation	O
results	O
of	O
radiographs	B-P
in	O
these	O
fractures	O
were	O
evaluated	O
.	O

The	O
ICC	O
of	O
the	O
VN	O
angle	O
and	O
the	O
Pauwels	O
angle	O
in	O
pre-operative	O
radiographs	B-P
were	O
0.937	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.922-0.950	O
)	O
and	O
0.942	O
respectively	O
(	O
95	O
%	O
CI	O
:	O
0.914-0.970	O
)	O
,	O
indicating	O
both	O
angles	O
had	O
a	O
good	O
inter-rater	O
reproducibility	O
.	O

However	O
,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
Pauwels	O
angle	O
in	O
pre-operative	O
and	O
post-operative	O
radiographs	B-P
(	O
P=0.037	O
)	O
,	O
the	O
absolute	O
difference	O
was	O
10.66±6.47	O
(	O
range	O
:	O
1.72-38.48	O
)	O
,	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
VN	O
angle	O
(	O
P=0.084	O
)	O
and	O
the	O
absolute	O
difference	O
was	O
2.20±1.63	O
(	O
range	O
:	O
0.05-7.56	O
)	O
.	O

The	O
overall	O
fixation	O
failure	O
rate	O
which	O
was	O
defined	O
as	O
screw	O
loosening	O
,	O
varus	O
collapse	O
,	O
obvious	O
fracture	O
displacement	O
or	O
femoral	O
neck	O
shortening	O
was	O
11.84	O
%	O
,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
VN	O
angles	O
were	O
respectively	O
0	O
%	O
,	O
3.24	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.64-4.84	O
)	O
,	O
22.69	O
%	O
(	O
95	O
%	O
CI	O
:	O
16.43-28.96	O
)	O
,	O
65.45	O
%	O
(	O
95	O
%	O
CI	O
:	O
59.36-71.53	O
)	O
.	O

The	O
mean	O
failure	O
rates	O
of	O
fractures	O
according	O
to	O
post-operative	O
Pauwels	O
angle	O
(	O
<	O
30°	O
,	O
30-50°	O
,	O
>	O
50°	O
)	O
were	O
respectively	O
0	O
%	O
,	O
1.46	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.42-1.50	O
)	O
and	O
36.24	O
%	O
(	O
95	O
%	O
CI	O
:	O
34.93-37.54	O
)	O
.	O

The	O
VN	O
angle	O
has	O
a	O
good	O
inter-rater	O
reproducibility	O
,	O
a	O
higher	O
reliability	O
than	O
the	O
Pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short-term	O
prognosis	O
of	O
femoral	O
neck	O
fractures	O
treated	O
with	O
cannulated	O
compression	O
screws	O
.	O

Level	O
IV	O
,	O
retrospective	O
diagnostic	O
study	O
.	O

Correlation	O
between	O
preoperative	O
physical	O
signs	O
and	O
functional	O
outcomes	O
after	O
laminoplasty	O
for	O
ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
.	O

Ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
(	O
OPLL	O
)	O
can	O
cause	O
myelopathy	O
that	O
is	O
often	O
managed	O
surgically	O
.	O

Knowledge	O
of	O
predictors	O
of	O
surgical	O
outcomes	O
can	O
provide	O
decision	O
support	O
to	O
surgeons	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
the	O
relationships	O
between	O
preoperative	O
physical	O
signs	O
and	O
postoperative	O
functional	O
outcomes	O
in	O
patients	O
with	O
OPLL	O
and	O
to	O
clarify	O
whether	O
physical	O
signs	O
could	O
predict	O
functional	O
outcomes	O
.	O

Fifty-five	O
patients	O
with	O
OPLL	O
who	O
had	O
undergone	O
cervical	O
laminoplasty	O
were	O
included	O
in	O
this	O
study	O
.	O

Six	O
physical	O
signs	O
including	O
hyperreflexia	O
,	O
Babinski	O
sign	O
,	O
sensory	O
disturbance	O
,	O
grip	O
strength	O
,	O
10-s	B-P
grip	I-P
and	I-P
release	I-P
test	I-P
,	O
and	O
bladder	O
dysfunction	O
,	O
and	O
four	O
other	O
factors	O
including	O
age	O
,	O
duration	O
of	O
symptoms	O
,	O
history	O
of	O
minor	O
trauma	O
and	O
preoperative	O
Japanese	O
Orthopaedic	O
Association	O
(	O
JOA	O
)	O
score	O
were	O
investigated	O
as	O
potential	O
predictive	O
prognostic	O
factors	O
using	O
both	O
univariate	O
and	O
multivariate	O
analyses	O
.	O

The	O
mean	O
recovery	O
rate	O
of	O
JOA	O
score	O
was	O
62.5	O
±	O
32.5	O
%	O
.	O

The	O
neurological	O
recovery	O
rate	O
was	O
negatively	O
associated	O
with	O
age	O
(	O
P	O
=	O
0.002	O
)	O
,	O
the	O
duration	O
of	O
symptoms	O
(	O
P	O
=	O
0.002	O
)	O
and	O
Babinski	O
sign	O
(	O
P	O
=	O
0.007	O
)	O
,	O
whereas	O
it	O
was	O
positively	O
correlated	O
with	O
grip	O
strength	O
(	O
P	O
=	O
0.011	O
)	O
.	O

Multiple	O
logistic	O
regression	O
analyses	O
revealed	O
that	O
age	O
(	O
Odds	O
ratio	O
:	O
0.89	O
,	O
95	O
%	O
CI	O
:	O
0.81-0.99	O
)	O
and	O
Babinski	O
sign	O
(	O
Odds	O
ratio	O
:	O
0.18	O
,	O
95	O
%	O
CI	O
:	O
0.04-0.89	O
)	O
were	O
factors	O
associated	O
with	O
functional	O
outcomes	O
.	O

Satisfactory	O
functional	O
outcomes	O
could	O
be	O
expected	O
for	O
patients	O
who	O
are	O
young	O
and	O
do	O
not	O
exhibit	O
the	O
Babinski	O
sign	O
,	O
showing	O
that	O
the	O
Babinski	O
sign	O
could	O
be	O
useful	O
as	O
an	O
indicator	O
of	O
the	O
window	O
of	O
opportunity	O
for	O
achieving	O
satisfactory	O
functional	O
outcomes	O
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	O
infection	O
or	O
complicated	O
urinary	O
tract	O
infection	O
in	O
phase	O
3	O
trials	O
of	O
ceftolozane/tazobactam	O
.	O

Diabetes	O
mellitus	O
and	O
hyperglycemia	O
are	O
associated	O
with	O
increased	O
susceptibility	O
to	O
bacterial	O
infections	O
and	O
poor	O
treatment	O
outcomes	O
.	O

This	O
post	O
hoc	O
evaluation	O
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	O
(	O
cIAI	O
)	O
and	O
complicated	O
urinary	O
tract	O
infections	O
(	O
cUTI	O
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane/tazobactam	O
and	O
comparators	O
.	O

Ceftolozane/tazobactam	O
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram-negative	O
pathogens	O
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
cIAI	O
(	O
with	O
metronidazole	O
)	O
and	O
cUTI	O
(	O
including	O
pyelonephritis	O
)	O
.	O

Patients	O
from	O
the	O
phase	O
3	O
ASPECT	O
studies	O
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	O
were	O
compared	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane/tazobactam	O
and	O
active	O
comparators	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
;	O
patients	O
with	O
diabetes	O
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	O
impairment	O
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	B-P
II	I-P
scores	I-P
≥10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

More	O
patients	O
with	O
diabetes	O
had	O
comorbidities	O
and	O
an	O
increased	O
incidence	O
of	O
complicating	O
factors	O
in	O
both	O
cIAI	O
and	O
cUTI	O
.	O

Clinical	O
cIAI	O
and	O
composite	O
cure	O
cUTI	O
rates	O
across	O
study	O
treatments	O
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
cIAI	O
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
cUTI	O
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane/tazobactam	O
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	O
with	O
ceftolozane/tazobactam	O
than	O
with	O
levofloxacin	O
in	O
patients	O
without	O
diabetes	O
with	O
cUTI	O
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

Significantly	O
higher	O
rates	O
of	O
adverse	O
events	O
observed	O
in	O
patients	O
with	O
diabetes	O
were	O
likely	O
due	O
to	O
comorbidities	O
because	O
treatment	O
-related	O
adverse	O
events	O
were	O
similar	O
between	O
groups	O
.	O

In	O
this	O
post	O
hoc	O
analysis	O
,	O
patients	O
with	O
diabetes	O
in	O
general	O
were	O
older	O
,	O
heavier	O
,	O
and	O
had	O
a	O
greater	O
number	O
of	O
complicating	O
comorbidities	O
.	O

Patients	O
with	O
diabetes	O
had	O
lower	O
cure	O
rates	O
and	O
a	O
significantly	O
higher	O
frequency	O
of	O
adverse	O
events	O
than	O
patients	O
without	O
diabetes	O
,	O
likely	O
because	O
of	O
the	O
higher	O
rates	O
of	O
medical	O
complications	O
in	O
this	O
subgroup	O
.	O

Ceftolozane/tazobactam	O
was	O
shown	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
comparators	O
in	O
treating	O
cUTI	O
and	O
cIAI	O
in	O
this	O
population	O
.	O

cIAI	O
,	O
NCT01445665	O
and	O
NCT01445678	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
September	O
26	O
,	O
2011	O
)	O
;	O
cUTI	O
,	O
NCT01345929	O
and	O
NCT01345955	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
April	O
28	O
,	O
2011	O
)	O
.	O

Global	O
Strategy	O
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
2017	O
Report	O
.	O

GOLD	O
Executive	O
Summary	O
.	O

This	O
Executive	O
Summary	O
of	O
the	O
Global	O
Strategy	O
for	O
the	O
Diagnosis	O
,	O
Management	O
,	O
and	O
Prevention	O
of	O
COPD	O
,	O
Global	O
Initiative	O
for	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
(	O
GOLD	O
)	O
2017	O
report	O
focuses	O
primarily	O
on	O
the	O
revised	O
and	O
novel	O
parts	O
of	O
the	O
document	O
.	O

The	O
most	O
significant	O
changes	O
include	O
:	O
(	O
1	O
)	O
the	O
assessment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
has	O
been	O
refined	O
to	O
separate	O
the	O
spirometric	B-P
assessment	I-P
from	O
symptom	O
evaluation	O
.	O

ABCD	O
groups	O
are	O
now	O
proposed	O
to	O
be	O
derived	O
exclusively	O
from	O
patient	O
symptoms	O
and	O
their	O
history	O
of	O
exacerbations	O
;	O
(	O
2	O
)	O
for	O
each	O
of	O
the	O
groups	O
A	O
to	O
D	O
,	O
escalation	O
strategies	O
for	O
pharmacologic	O
treatments	O
are	O
proposed	O
;	O
(	O
3	O
)	O
the	O
concept	O
of	O
deescalation	O
of	O
therapy	O
is	O
introduced	O
in	O
the	O
treatment	O
assessment	O
scheme	O
;	O
(	O
4	O
)	O
nonpharmacologic	O
therapies	O
are	O
comprehensively	O
presented	O
;	O
and	O
(	O
5	O
)	O
the	O
importance	O
of	O
comorbid	O
conditions	O
in	O
managing	O
chronic	O
obstructive	O
pulmonary	O
disease	O
is	O
reviewed	O
.	O

Gender	O
and	O
Direction	O
of	O
Effect	O
of	O
Alcohol	O
Problems	O
and	O
Internalizing	O
Symptoms	O
in	O
a	O
Longitudinal	O
Sample	O
of	O
College	O
Students	O
.	O

Alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
are	O
consistently	O
found	O
to	O
be	O
associated	O
but	O
how	O
they	O
relate	O
to	O
each	O
other	O
is	O
unclear	O
.	O

The	O
present	O
study	O
aimed	O
to	O
address	O
limitations	O
in	O
the	O
literature	O
of	O
comorbidity	O
of	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
by	O
investigating	O
the	O
direction	O
of	O
effect	O
between	O
the	O
phenotypes	O
and	O
possible	O
gender	O
differences	O
in	O
college	O
students	O
.	O

We	O
utilized	O
data	O
from	O
a	O
large	O
longitudinal	O
study	O
of	O
college	O
students	O
from	O
the	O
United	O
States	O
(	O
N	O
=	O
2607	O
)	O
.	O

Three	O
waves	O
of	O
questionnaire-based	O
data	O
were	O
collected	O
over	O
the	O
first	O
two	O
years	O
of	O
college	O
(	O
in	O
2011-2013	O
)	O
.	O

Cross-lagged	O
models	O
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	O
of	O
effect	O
of	O
internalizing	O
symptoms	O
and	O
alcohol	O
problems	O
.	O

Possible	O
effects	O
of	O
gender	O
were	O
investigated	O
using	O
multigroup	O
modeling	O
.	O

There	O
were	O
significant	O
correlations	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
.	O

A	O
direction	O
of	O
effect	O
was	O
found	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
but	O
differed	O
between	O
genders	O
.	O

A	O
unidirectional	O
relationship	O
varying	O
with	O
age	O
was	O
identified	O
for	O
males	O
where	O
alcohol	O
problems	O
initially	O
predicted	O
internalizing	O
symptoms	O
followed	O
by	O
internalizing	O
symptoms	O
predicting	O
alcohol	O
problems	O
.	O

For	O
females	O
,	O
a	O
unidirectional	O
relationship	O
existed	O
wherein	O
alcohol	O
problems	O
predicted	O
internalizing	O
symptoms	O
.	O

Conclusions/Importance	O
:	O
We	O
conclude	O
that	O
the	O
relationship	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
is	O
complex	O
and	O
differ	O
between	O
genders	O
.	O

In	O
males	O
,	O
both	O
phenotypes	O
are	O
predictive	O
of	O
each	O
other	O
,	O
while	O
in	O
females	O
the	O
relationship	O
is	O
driven	O
by	O
alcohol	O
problems	O
.	O

Importantly	O
,	O
our	O
study	O
examines	O
a	O
population-based	O
sample	O
,	O
revealing	O
that	O
the	O
observed	O
relationships	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
are	O
not	O
limited	O
to	O
individuals	O
with	O
clinically	B-P
diagnosed	I-P
mental	O
health	O
or	O
substance	O
use	O
problems	O
.	O

Low-intensity	O
pulsed	O
ultrasound	O
reduces	O
periodontal	O
atrophy	O
in	O
occlusal	O
hypofunctional	O
teeth	O
.	O

To	O
clarify	O
whether	O
low-intensity	O
pulsed	O
ultrasound	O
(	O
LIPUS	O
)	O
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	O
periodontal	O
ligament	O
(	O
PDL	O
)	O
and	O
interradicular	O
alveolar	O
bone	O
(	O
IRAB	O
)	O
.	O

Twelve-	O
week	O
-old	O
male	O
Sprague-Dawley	O
rats	O
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
5	O
each	O
)	O
:	O
a	O
normal	O
occlusion	O
(	O
C	O
)	O
group	O
,	O
an	O
occlusal	O
hypofunction	O
(	O
H	O
)	O
group	O
,	O
and	O
an	O
occlusal	O
hypofunction	O
group	O
subjected	O
to	O
LIPUS	O
(	O
HL	O
)	O
treatment	O
.	O

Hypofunctional	O
occlusion	O
of	O
the	O
maxillary	O
first	O
molar	O
(	O
M1	O
)	O
of	O
the	O
H	O
and	O
HL	O
groups	O
was	O
induced	O
by	O
the	O
bite-raising	O
technique	O
.	O

Only	O
the	O
HL	O
group	O
was	O
irradiated	O
with	O
LIPUS	O
for	O
5	O
days	O
.	O

The	O
IRAB	O
and	O
PDL	O
of	O
M1	O
were	O
examined	O
by	O
microcomputed	B-P
tomography	I-P
(	O
micro-CT	B-P
)	O
analysis	O
.	O

To	O
quantify	O
mRNA	O
expression	O
of	O
cytokines	O
involved	O
in	O
PDL	O
proliferation	O
and	O
development	O
,	O
real-time	O
reverse	O
transcription	O
quantitative	O
PCR	O
(	O
qRT-PCR	O
)	O
was	O
performed	O
for	O
twist	O
family	O
bHLH	O
transcription	O
factor	O
1	O
(	O
Twist1	O
)	O
,	O
periostin	O
,	O
and	O
connective	O
tissue	O
growth	O
factor	O
(	O
CTGF	O
)	O
in	O
the	O
PDL	O
samples	O
.	O

Micro-CT	B-P
analysis	O
showed	O
that	O
the	O
PDL	O
volume	O
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
of	O
the	O
C	O
and	O
HL	O
groups	O
.	O

Both	O
bone	O
volume	O
per	O
tissue	O
volume	O
(	O
BV	O
/	O
TV	O
)	O
of	O
IRAB	O
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
in	O
the	O
C	O
group	O
.	O

LIPUS	O
exposure	O
restored	O
BV	O
/	O
TV	O
in	O
the	O
IRAB	O
of	O
the	O
HL	O
group	O
.	O

qRT-PCR	O
analysis	O
showed	O
that	O
Twist1	O
,	O
periostin	O
,	O
and	O
CTGF	O
mRNA	O
levels	O
were	O
decreased	O
in	O
the	O
H	O
group	O
and	O
increased	O
in	O
the	O
HL	O
group	O
.	O

LIPUS	O
exposure	O
reduced	O
the	O
atrophic	O
changes	O
of	O
alveolar	O
bone	O
by	O
inducing	O
the	O
upregulation	O
of	O
periostin	O
and	O
CTGF	O
expression	O
to	O
promote	O
PDL	O
healing	O
after	O
induction	O
of	O
occlusal	O
hypofunction	O
.	O

Risk	O
of	O
advanced	O
lesions	O
at	O
the	O
first	O
follow-up	O
colonoscopy	B-P
after	O
polypectomy	O
of	O
diminutive	O
versus	O
small	O
adenomatous	O
polyps	O
of	O
low-grade	O
dysplasia	O
.	O

The	O
current	O
guidelines	O
for	O
surveillance	O
after	O
polypectomy	O
do	O
not	O
distinguish	O
between	O
diminutive	O
(	O
1-5	O
mm	O
)	O
and	O
small	O
(	O
6-9	O
mm	O
)	O
polyps	O
with	O
low-grade	O
dysplasia	O
(	O
LGD	O
)	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
risk	O
for	O
advanced	O
neoplasia	O
on	O
follow-up	O
colonoscopy	B-P
.	O

We	O
retrospectively	O
analyzed	O
443	O
patients	O
whose	O
worst	O
finding	O
at	O
index	O
colonoscopy	O
was	O
polypectomy	O
of	O
1	O
to	O
5	O
or	O
6	O
to	O
9	O
mm	O
polyps	O
with	O
LGD	O
and	O
those	O
who	O
underwent	O
a	O
follow-up	O
colonoscopy	B-P
.	O

During	O
a	O
mean	O
follow-up	O
of	O
32.0	O
months	O
(	O
interquartile	O
range	O
13-48	O
months	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
26	O
patients	O
(	O
5.9	O
%	O
)	O
.	O

Among	O
all	O
included	O
patients	O
(	O
n	O
=	O
443	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
13	O
of	O
310	O
patients	O
(	O
4.2	O
%	O
)	O
of	O
the	O
1-	O
to	O
5-mm	O
group	O
versus	O
13	O
of	O
133	O
patients	O
(	O
9.8	O
%	O
)	O
of	O
the	O
6-	O
to	O
9-mm	O
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
3.49	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.6-7.6	O
)	O
.	O

Among	O
the	O
patients	O
with	O
1	O
to	O
2	O
polyps	O
resected	O
(	O
n	O
=	O
313	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
8	O
of	O
231	O
patients	O
(	O
3.5	O
%	O
)	O
of	O
the	O
1-	O
to	O
5-mm	O
group	O
versus	O
8	O
of	O
82	O
patients	O
(	O
9.8	O
%	O
)	O
of	O
the	O
6-	O
to	O
9-mm	O
group	O
(	O
HR	O
3.97	O
;	O
95	O
%	O
CI	O
,	O
1.47-10.7	O
)	O
.	O

Among	O
the	O
patients	O
with	O
≥3	O
polyps	O
resected	O
(	O
n	O
=	O
130	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
5	O
of	O
79	O
patients	O
(	O
6.3	O
%	O
)	O
of	O
the	O
1-	O
to	O
5-mm	O
group	O
versus	O
5	O
of	O
51	O
patients	O
(	O
9.8	O
%	O
)	O
of	O
the	O
6-	O
to	O
9-mm	O
group	O
(	O
HR	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
0.7-8.36	O
)	O
.	O

Fair	O
bowel	O
preparation	O
also	O
was	O
associated	O
with	O
the	O
risk	O
for	O
advanced	O
neoplasia	O
at	O
follow-up	O
(	O
HR	O
3.87	O
,	O
95	O
%	O
CI	O
,	O
1.70-8.82	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
among	O
patients	O
with	O
up	O
to	O
9-mm	O
adenomatous	O
polyps	O
,	O
a	O
polyp	O
size	O
of	O
6	O
to	O
9	O
mm	O
,	O
>	O
2	O
polyps	O
,	O
and	O
fair	O
bowel	O
preparation	O
are	O
associated	O
with	O
advanced	O
neoplasia	O
.	O

Demonstration	O
and	O
validation	O
of	O
a	O
new	O
pressure	O
-based	O
MRI	O
-safe	O
pain	O
tolerance	O
device	O
.	O

One	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	O
and	O
emotional	O
effects	O
of	O
pain	O
using	O
functional	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
(	O
fMRI	B-P
)	O
is	O
the	O
absence	O
of	O
a	O
commercially	O
available	O
,	O
MRI	O
-	O
compatible	O
,	O
pressure	O
-based	O
algometer	O
to	O
elicit	O
pain	O
.	O

The	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
MRI	O
-safe	O
apparatus	O
capable	O
of	O
delivering	O
incremental	O
,	O
measurable	O
amounts	O
of	O
pressure	O
inside	O
a	O
scanning	O
bore	O
.	O

We	O
introduced	O
an	O
MR-safe	O
device	O
used	O
to	O
administer	O
pressure	O
-based	O
pain	O
.	O

To	O
test	O
against	O
a	O
commercially	O
available	O
,	O
MRI	O
-	O
incompatible	O
algometer	O
(	O
AlgoMed	O
)	O
,	O
199	O
participants	O
reported	O
their	O
pain	O
tolerance	O
for	O
both	O
devices	O
.	O

A	O
second	O
experiment	O
tested	O
the	O
validity	O
of	O
pressure	O
-based	O
pain	O
in	O
an	O
MRI	O
environment	O
by	O
comparing	O
brain	O
activation	O
with	O
established	O
neural	O
networks	O
for	O
pain	O
.	O

10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	O
for	O
pain	O
tolerance	O
while	O
being	O
scanned	B-P
in	O
a	O
7T	O
MRI	O
scanner	O
.	O

Results	O
support	O
the	O
validity	O
and	O
reliability	O
of	O
our	O
novel	O
device	O
.	O

In	O
Study	O
1	O
,	O
pain	O
tolerance	O
with	O
this	O
device	O
was	O
strongly	O
correlated	O
with	O
pain	O
tolerance	O
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	O
(	O
r=0.78	O
)	O
.	O

In	O
Study	O
2	O
,	O
this	O
device	O
yielded	O
BOLD	O
activation	O
within	O
the	O
insula	O
(	O
BA	O
13	O
)	O
and	O
anterior	O
cingulate	O
gyrus	O
(	O
BA	O
24	O
)	O
;	O
as	O
pressure	O
increased	O
,	O
activation	O
in	O
these	O
areas	O
parametrically	O
increased	O
.	O

These	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	O
,	O
electrical	O
,	O
or	O
mechanical	O
pain	O
applications	O
.	O

Behavioral	O
and	O
functional	O
data	O
demonstrate	O
that	O
this	O
new	O
device	O
is	O
a	O
valid	O
method	O
of	O
administering	O
pressure	O
-related	O
pain	O
in	O
MRI	O
environments	O
.	O

Our	O
novel	O
MRI	O
-safe	O
device	O
is	O
a	O
valid	O
instrument	O
to	O
measure	O
and	O
administer	O
pressure	O
-based	O
pain	O
.	O

Evaluation	O
of	O
Soft	O
Tissue	O
Sarcoma	O
Response	O
to	O
Preoperative	O
Chemoradiotherapy	O
Using	O
Dynamic	B-P
Contrast-Enhanced	I-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
.	O

This	O
study	O
aims	O
to	O
assess	O
the	O
utility	O
of	O
quantitative	B-P
dynamic	I-P
contrast-enhanced	I-P
(	I-P
DCE	I-P
)	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	I-P
MRI	I-P
)	I-P
parameters	O
in	O
comparison	O
with	O
imaging	B-P
tumor	O
size	O
for	O
early	O
prediction	O
and	O
evaluation	O
of	O
soft	O
tissue	O
sarcoma	O
response	O
to	O
preoperative	O
chemoradiotherapy	O
.	O

In	O
total	O
,	O
20	O
patients	O
with	O
intermediate-	O
to	O
high-grade	O
soft	O
tissue	O
sarcomas	O
received	O
either	O
a	O
phase	O
I	O
trial	O
regimen	O
of	O
sorafenib	O
+	O
chemoradiotherapy	O
(	O
n	O
=	O
8	O
)	O
or	O
chemoradiotherapy	O
only	O
(	O
n	O
=	O
12	O
)	O
,	O
and	O
underwent	O
DCE-MRI	B-P
at	O
baseline	O
,	O
after	O
2	O
weeks	O
of	O
treatment	O
with	O
sorafenib	O
or	O
after	O
the	O
first	O
chemotherapy	O
cycle	O
,	O
and	O
after	O
therapy	O
completion	O
.	O

MRI	B-P
tumor	O
size	O
in	O
the	O
longest	O
diameter	O
(	O
LD	O
)	O
was	O
measured	O
according	O
to	O
the	O
RECIST	O
(	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumors	O
)	O
guidelines	O
.	O

Pharmacokinetic	O
analyses	O
of	O
DCE-MRI	B-P
data	O
were	O
performed	O
using	O
the	O
Shutter-Speed	O
model	O
.	O

After	O
only	O
2	O
weeks	O
of	O
treatment	O
with	O
sorafenib	O
or	O
after	O
1	O
chemotherapy	O
cycle	O
,	O
K	O
(	O
trans	O
)	O
(	O
rate	O
constant	O
for	O
plasma	O
/	O
interstitium	O
contrast	O
agent	O
transfer	O
)	O
and	O
its	O
percent	O
change	O
were	O
good	O
early	O
predictors	O
of	O
optimal	O
versus	O
suboptimal	O
pathological	O
response	O
with	O
univariate	O
logistic	O
regression	O
C	O
statistics	O
values	O
of	O
0.90	O
and	O
0.80	O
,	O
respectively	O
,	O
whereas	O
RECIST	O
LD	O
percent	O
change	O
was	O
only	O
a	O
fair	O
predictor	O
(	O
C	O
=	O
0.72	O
)	O
.	O

Post-therapy	O
K	O
(	O
trans	O
)	O
,	O
ve	O
(	O
extravascular	O
and	O
extracellular	O
volume	O
fraction	O
)	O
,	O
and	O
kep	O
(	O
intravasation	O
rate	O
constant	O
)	O
,	O
not	O
RECIST	O
LD	O
,	O
were	O
excellent	O
(	O
C	O
>	O
0.90	O
)	O
markers	O
of	O
therapy	O
response	O
.	O

Several	O
DCE-MRI	B-P
parameters	O
before	O
,	O
during	O
,	O
and	O
after	O
therapy	O
showed	O
significant	O
(	O
P	O
<	O
.05	O
)	O
correlations	O
with	O
percent	O
necrosis	O
of	O
resected	O
tumor	O
specimens	O
.	O

In	O
conclusion	O
,	O
absolute	O
values	O
and	O
percent	O
changes	O
of	O
quantitative	O
DCE-MRI	B-P
parameters	O
provide	O
better	O
early	O
prediction	O
and	O
evaluation	O
of	O
the	O
pathological	O
response	O
of	O
soft	O
tissue	O
sarcoma	O
to	O
preoperative	O
chemoradiotherapy	O
than	O
the	O
conventional	O
measurement	O
of	O
imaging	B-P
tumor	O
size	O
change	O
.	O

Dominant	O
and	O
Non-	O
Dominant	O
Frequency	O
Structure	O
of	O
Evoked	O
Ventricular	O
Fibrillation	O
in	O
Dogs	O
with	O
Myocardial	O
Ischemia	O
.	O

The	O
first	O
10	O
min	O
of	O
electrically	O
provoked	O
ventricular	O
fibrillation	O
in	O
dogs	O
with	O
ischemic	O
heart	O
disease	O
were	O
characterized	O
by	O
organized	O
myocardial	O
activity	O
evidenced	O
by	O
the	O
dominant	O
ECG	O
frequency	O
structure	O
.	O

During	O
the	O
first	O
2	O
min	O
of	O
ventricular	O
fibrillation	O
,	O
low-frequency	O
oscillations	O
(	O
4-7	O
Hz	O
)	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	O
,	O
the	O
dominant	O
frequencies	O
were	O
low	O
and	O
medium	O
(	O
4-12	O
Hz	O
)	O
.	O

After	O
10-min	O
fibrillation	O
,	O
the	O
oscillations	O
became	O
non-	O
dominant	O
.	O

Thus	O
,	O
ischemic	O
myocardium	O
maintains	O
the	O
organized	O
structure	O
of	O
ventricular	O
fibrillation	O
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	O
of	O
automatic	B-P
diagnostics	I-P
of	O
abnormal	O
cardiac	O
activity	O
in	O
humans	O
.	O

Mapping	O
mitochondrial	O
heteroplasmy	O
in	O
a	O
Leydig	O
tumor	O
by	O
laser	O
capture	O
micro-dissection	O
and	O
cycling	O
temperature	O
capillary	O
electrophoresis	O
.	O

The	O
growth	O
of	O
tumor	O
cells	O
is	O
accompanied	O
by	O
mutations	O
in	O
nuclear	O
and	O
mitochondrial	O
genomes	O
creating	O
marked	O
genetic	O
heterogeneity	O
.	O

Tumors	O
also	O
contain	O
non-tumor	O
cells	O
of	O
various	O
origins	O
.	O

An	O
observed	O
somatic	O
mitochondrial	O
mutation	O
would	O
have	O
occurred	O
in	O
a	O
founding	O
cell	O
and	O
spread	O
through	O
cell	O
division	O
.	O

Micro-anatomical	O
dissection	O
of	O
a	O
tumor	O
coupled	O
with	O
assays	O
for	O
mitochondrial	O
point	O
mutations	O
permits	O
new	O
insights	O
into	O
this	O
growth	O
process	O
.	O

More	O
generally	O
,	O
the	O
ability	O
to	O
detect	O
and	O
trace	O
,	O
at	O
a	O
histological	O
level	O
,	O
somatic	O
mitochondrial	O
mutations	O
in	O
human	O
tissues	O
and	O
tumors	O
,	O
makes	O
these	O
mutations	O
into	O
markers	O
for	O
lineage	O
tracing	O
.	O

A	O
tumor	O
was	O
first	O
sampled	B-P
by	O
a	O
large	O
punch	B-P
biopsy	I-P
and	O
scanned	B-P
for	O
any	O
significant	O
degree	O
of	O
heteroplasmy	O
in	O
a	O
set	O
of	O
sequences	O
containing	O
known	O
mutational	O
hotspots	O
of	O
the	O
mitochondrial	O
genome	O
.	O

A	O
heteroplasmic	O
tumor	O
was	O
sliced	O
at	O
a	O
12	O
μm	O
thickness	O
and	O
placed	O
on	O
membranes	O
.	O

Laser	O
capture	O
micro-dissection	O
was	O
used	O
to	O
take	O
25000	O
μm	O
(	O
2	O
)	O
subsamples	O
or	O
spots	O
.	O

After	O
DNA	O
amplification	O
,	O
cycling	O
temperature	O
capillary	O
electrophoresis	O
(	O
CTCE	O
)	O
was	O
used	O
on	O
the	O
laser	O
captured	O
samples	O
to	O
quantify	O
mitochondrial	O
mutant	O
fractions	O
.	O

Of	O
six	O
testicular	O
tumors	O
studied	O
,	O
one	O
,	O
a	O
Leydig	O
tumor	O
,	O
was	O
discovered	O
to	O
carry	O
a	O
detectable	O
degree	O
of	O
heteroplasmy	O
for	O
two	O
separate	O
point	O
mutations	O
:	O
a	O
C	O
→	O
T	O
mutation	O
at	O
bp	O
64	O
and	O
a	O
T	O
→	O
C	O
mutation	O
found	O
at	O
bp	O
152	O
.	O

From	O
this	O
tumor	O
,	O
381	O
spots	O
were	O
sampled	B-P
with	O
laser	O
capture	O
micro-dissection	O
.	O

The	O
ordered	O
distribution	O
of	O
spots	O
exhibited	O
a	O
wide	O
range	O
of	O
fractions	O
of	O
the	O
mutant	O
sequences	O
from	O
0	O
to	O
100	O
%	O
mutant	O
copies	O
.	O

The	O
two	O
mutations	O
co-distributed	O
in	O
the	O
growing	O
tumor	O
indicating	O
they	O
were	O
present	O
on	O
the	O
same	O
genome	O
copies	O
in	O
the	O
founding	O
cell	O
.	O

Laser	O
capture	O
micro-dissection	O
of	O
sliced	O
tumor	O
samples	O
coupled	O
with	O
CTCE	O
-based	O
point	O
mutation	O
assays	O
provides	O
an	O
effective	O
and	O
practical	O
means	O
to	O
obtain	O
maps	O
of	O
mitochondrial	O
mutational	O
heteroplasmy	O
within	O
human	O
tumors	O
.	O

